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Abstract 
 
Epidermal growth factor (EGF) receptor belongs to the broad family of enzymatic 
receptors called receptor tyrosine kinases (RTKs). Generally, the binding of a ligand 
to these receptors leads to activation of their intracellular kinase activity that sets in 
motion a cascade of signaling events. In order to ensure appropriate responses to 
physiological stimuli, the cell is endowed with the ability to regulate signal 
transduction via numerous mechanisms such as dephosphorylation of the RTK and its 
substrates as well as downregulation of the RTK.  
Activation of EGFR is a potent mitogenic (proliferative) and motogenic (cell motility) 
signal that plays crucial roles during embryonic development and maintenance of 
adult tissue. EGFR signaling is primarily regulated by ligand-induced receptor 
internalization with subsequent degradation in lysosomes. While the complex of 
proteins that are recruited to EGFR after its activation is well understood, proteins that 
interact with the receptor in the absence of ligand binding are still not systematically 
studied. 
With the goal of identifying novel binding partners of non-activated EGFR, a 
membrane based yeast-two hybrid screen (MYTH) was conducted.  MYTH is based 
on the principle of in vivo reconstitution of the N-terminus (Nub) and C-terminus 
(Cub) halves of ubiquitin once brought into close proximity. A chimeric protein 
consisting of EGFR fused to Cub and a transcription factor was used as a bait to 
screen Nub-tagged cDNA library. Analysis of resultant yeast transformants revealed a 
total of 87 proteins to interact with EGFR. Of these only 11 were previously shown to 
bind to EGFR. A majority of the other proteins were shown to interact with the 
receptor by yeast retransformation. Fifteen were confirmed to bind to EGFR by co-
immunoprecipitation assays in mammalian cells.  
One of the novel EGFR interactors identified in the screen was histone deacetylase 6 
(HDAC6). This deacetylase is localized in the cytoplasm and known to deacetylate -
tubulin, HSP90 and cortactin. The juxtamembrane region of EGFR binds to the C-
terminus of HDAC6. Functionally, overexpression of wild type HDAC6 stabilized 
ligand-induced degradation of the receptor. On the other hand, deacetylase deficient 
or EGFR binding compromised mutants of HDAC6 were able to stabilize EGFR only 
partially. Downmodulation of HDAC6 expression by RNAi markedly accelerated  
Abstract
 
  3 
degradation of the receptor. Taken together, HDAC6 is a negative regulator of EGFR 
downregulation that is dependent on its deacetylase activity and ability to bind to the 
receptor. 
Imaging studies revealed that HDAC6 does not affect internalization of EGFR from 
the plasma membrane but rather influences the post-endocytic trafficking of the 
receptor-ligand complex to lysosomes. Pulse-chase experiments using fluorophore-
tagged EGF showed that EGFR is transported faster towards the peri-nuclear region 
and delivered to late endosomes rapidly in HDAC6 depleted cells.  
HDAC6 is demonstrated to act, at least partly, by regulating the acetylation of -
tubulin. Upon EGFR activation, acetylation of -tubulin on lysine 40 is progressively 
increased as shown by mass spectrometry and immunoblotting. Forced expression of 
a dominant negative mutant of -tubulin, but not wild type -tubulin, led to reduced 
speed and processive movement of early endosomes in GFP-Rab5 expressing cells. In 
a surprising twist, EGFR is able to phosphorylate HDAC6 on Tyr570. 
Phosphorylation of Tyr570 and Ser568 leads to inactivation of the deacetylase 
function of HDAC6 as shown by in vivo and in vitro assays. In summary, HDAC6 
diminishes EGFR downregulation by slowing the transport of intracellular vesicles. 
The inhibitory effect is removed once HDAC6 is phosphorylated on key residues.  
In line with these findings, two recent reports have shown that hyper-acetylation of -
tubulin induced by inhibition of HDAC6 increases the transport of brain derived 
neurotrophic factor and JNK interacting protein-1 in different cell systems. Acetylated 
microtubules are more efficient in recruiting motor proteins like kinesin-1 and dynein.  
These findings indicate that HDAC6 plays an important regulatory role in 
intracellular trafficking pathways. However, several outstanding issues still remain 
unresolved. How does acetylation of microtubules influence vesicular trafficking? In 
this regard, the temporal and spatial dynamics of -tubulin acetylation following 
EGFR activation should be studied. Furthermore, whether HDAC6 affects the 
trafficking of other endocytic cargos and additional organelles is an interesting 
question to address. 
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Zusammenfassung 

Einleitung 
Der epidermale Wachstumsfaktor-Rezeptor (EGFR) gehört zu der umfassenden 
Familie enzymatisch aktiver Rezeptoren, die als Rezeptortyrosinkinasen (RTKs) 
bezeichnet werden. RTKs stellen eine große Gruppe der Zelloberflächenrezeptoren 
dar, die eine intrinsische Tyrosinkinaseaktivität aufweisen. Sie katalysieren infolge 
extrazellulärer Stimuli den Transfer der gamma-Phosphatgruppe eines ATP-Moleküls 
auf Hydroxylgruppen von Tyrosinresten
3. Die allgemeine Struktur von RTKs lässt 
sich in eine extrazelluläre Ligandenbindedomäne, eine einzige Transmembrandomäne 
und eine zytoplasmatische, katalytisch aktive Region gliedern, auf die der für die 
Regulation der Signalweiterleitung verantwortliche C-Terminus folgt. 
Die Bindung eines Liganden an diese Rezeptoren führt im allgemeinen zur 
Aktivierung ihrer intrazellulären Kinaseaktivität, die eine Kaskade von 
Signalvorgängen in Gang setzt. Im Fall des EGFR bindet der Ligand (EGF) als 
Monomer an den Rezeptor in einem Verhältnis von 2:2 und induziert 
Konformationsänderungen, die zur Dimerisierung des Rezeptors führen. Daraufhin 
werden Signalwege innerhalb der Zelle eingeleitet, indem Proteine, die eine 
Phosphotyrosinbindedomäne aufweisen, an phosporylierte Tyrosinreste im C-
terminalen Bereich des Rezeptors binden. Die Aktivität des EGFR sowie anderer 
RTKs ist streng reguliert, um eine angemessene und physiologische Antwort auf 
einen Stimulus zu generieren. 
Mehrere Mechanismen wie die Dephosphorylierung des Rezeptors und weiterer 
Komponenten des Signalweges stellen sicher, dass die Signalweiterleitung 
entsprechend beendet wird. Der wichtigste Mechanismus, um die Weiterleitung des 
Signals herunterzuregulieren, besteht jedoch in der schnellen Endozytose und dem 
anschließendem Abbau sowohl des Rezeptors als auch des Liganden. Die Aktivierung 
infolge der Bindung eines Liganden führt zur Anhäufung des Rezeptors in von 
Clathrin überzogenen Einstülpungen (CCPs) auf der Plasmamembran, die sich 
anschließend durch Bildung von „Clathrin bedeckten Vesikeln“ (CCVs) abschnüren. 
Der EGFR wird über CCVs, frühe Endosomen und multivesikuläre Körper schließlich 
zum Abbau ins Lysosom gebracht. Das Schicksal der Fracht entscheidet sich auf der 
Ebene des frühen Endosoms: entweder kommt es zur Rückführung an die 
Plasmamembran oder zum Abbau im Lysosom. Welcher Weg eingeschlagen wird,  
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hängt von der Ubiquitinierung der Fracht ab, die von einem Proteinkomplex 
(endosomal-sorting complex required for transport (ESCRT)) erkannt wird. 
Mikrotubuli und die an diese assoziierten Motorproteine wie Dynein sind für den 
Transport früher Endosomen zu späten Endosomen essentiell und somit auch für den 
Abbau der Fracht. 
In der vorliegenden Doktorarbeit wurde ein modifizierter membrane yeast two-hybrid 
screen (MYTH) durchgeführt, um neue Interaktionspartner des Liganden-unbesetzten, 
inaktiven EGFR zu identifizieren. Das Prinzip des MYTH besteht auf dem split-
ubiquitin System, wobei ein “quasi natives Ubiquitinmolekül” rekonstituiert wird, 
wenn die N-terminale und C-terminale Hälfte des Ubiquitinmoleküls (Nub bzw. Cub) 
in einer Zelle separat exprimiert werden. Ein Transmembranprotein, an das Cub 
fusioniert ist, kann dabei als Köder benutzt werden, um eine cDNA library, die an 
Nub gekoppelt vorliegt, auf neue Bindungspartner hin zu untersuchen. Einer der in 
dem Screen neu identifizierten EGFR-Bindungspartner ist die Histondeacetylase 6 
(HDAC6). HDAC6 ist eine einzigartige Deacetylase, die aus zwei katalytischen 
Domänen und einer Ubiquitin-bindenden Zinkfingerdomäne besteht und fast 
ausschließlich im Zytoplasma lokalisiert ist. Dadurch, dass sie  -Tubulin deacetyliert, 
spielt HDAC6 u. a. eine wichtige Rolle bei der chemotaktisch induzierten 
Zellmotilität, der Fusion des HIV-1 Viruspartikels mit der Zellmembran sowie der 
Bildung von Immunsynapsen. HDAC6 sorgt auch für die Aufrechterhaltung des 
richtigen Acetylierungsgrades von HSP90, der für die Interaktion mit seinen Ko-
Chaperonen und weiteren Assoziationspartnern benötigt wird. Unabhängig von ihrer 
Deacetylaseaktivität dient HDAC6 durch Bindung an polyubiquitinierte Proteine 
einerseits und Dynein andererseits als Adaptorprotein. Diese Rolle von HDAC6 ist für 
die Beseitigung falsch gefalteter Proteine und Aggresomen von Bedeutung. 
Das Hauptziel dieser Doktorarbeit ist die Identifizierung neuer EGFR 
Bindungspartner, die an den inaktiven Rezeptor gebunden sind, sowie die funktionelle 
Charakterisierung putativer Interaktionspartner. 
 
Ergebnisse und Diskussion 
Zunächst wurde ein geeigneter EGFR-Köder für die Verwendung im MYTH 
generiert, indem das Signalpeptid des menschlichen EGFR (bestehend aus den 
Aminosäuren 1-24) durch die ersten 85 Aminosäuren des -Mating Faktors (MF),  
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die Cub und einem Transkriptionsfaktor (MF-EGFR-C-T) ersetzt wurde. 
Fraktionierung der zellulären Komponenten und Immunblots, hefegenetische und 
bildgebende Methoden wurden angewandt, um die Transformation, Expression und 
Lokalisation des Köderproteins in der Plasmamembran der Hefe sicherzustellen. Zur 
Identifizierung von EGFR-Interaktionspartnern wurde das MF-EGFR-C-T-
Konstrukt als Köderprotein für einen im großen Maßstab durchgeführten MYTH 
Screen eingesetzt; die verwendete Nub-gekoppelte cDNA library entstammte fötalem 
Hirngewebe. Der Screen offenbarte insgeamt 87 Proteine, die mit EGFR interagieren. 
Die Proteine, die das EGFR-MYTH Interaktom ausmachen, gliedern sich nach 
GeneOntology in mehrere funktionelle Gruppen, die unter anderem eine Rolle bei der 
zellulären Organisation, dem Stoffwechsel und dem Abbau von Proteinen spielen. 
Vierzehn der identifizierten EGFR-Bindungspartner stellen entweder ausgewiesene 
integrale oder membranassoziierte Proteine dar; dies unterstreicht, dass zur 
Identifizierung von Membranproteinen der MYTH geeignet ist. Nur von 11 der 87 
gefundenen Proteine war die Interaktion mit EGFR durch Proteomanalysen oder 
biochemischen Methoden schon gezeigt worden. Erwartungsgemäß wurden 
phosphotyrosinabhängige Interaktionen, die den Großteil der Bindungspartner des 
aktiven EGFR ausmachen, nicht beobachtet. Die Interaktion einiger vermeintlicher 
Bindungspartner mit dem EGFR in Säugerzellem wurde mittels Ko-
Immunpräzipitation endogener sowie überexprimierter Proteine bestätigt. Darüber 
hinaus deuteten weitere bioinformatische Analysen auf die hohe Qualität des Screens 
hin. Zusammengefasst zeigt die erfolgreiche Anwendung dieses Screens, dass mit 
einem geeigneten Köderkonstrukt der MYTH eine sehr gute Methode darstellt, um 
Membranproteine zu analysieren. 
Einer der in dem Screen neu identifizierten EGFR-Bindungspartner war die 
Histondeacetylase 6 (HDAC6). Diese Deacetylase befindet sich im Zytoplasma und 
entfernt Acetylgruppen von -Tubulin, HSP90 und Cortactin. Zunächst wurde 
gezeigt, dass HDAC6 den endogenen EGFR ligandenunabhängig 
koimmunpräzipitieren kann. Durch Versuche in Säuger- und Hefezellen wurden die 
Bindedomänen identifiziert, wodurch festgestellt wurde, dass die intrazelluläre, der 
Transmembrandomäne folgende Region des EGFR den C-Terminus von HDAC6 
bindet. Des Weiteren zeigten fluoreszensmikroskopische Methoden, dass HDAC6 und 
EGFR sowohl im Bereich der Plasmamembran als auch an intrazellulären Vesikeln  
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nach der Internalisierung des Rezeptors kolokalisieren. Kürzlich konnte gezeigt 
werden, dass die intrazelluläre, der Transmembrandomäne folgende Region des 
EGFR für die Aktivierung der Kinasedomäne essentiell ist; vor diesem Hintergrund 
wäre es interessant zu untersuchen, ob die Interaktion mit HDAC6 irgendeinen 
Einfluss auf die Kinaseaktvität hat. Darüber hinaus würde eine dreidimensionale 
Struktur von HDAC6 im Komplex mit EGFR wertvolle Informationen über die 
Konformation und die Beziehung der Kinase- und der Deacetylasedomäne liefern.  
Überexpression von Wildtyp HDAC6 führt zur Stabilisierung des Liganden-
induzierten Abbaus des Rezeptors, während eine enzymatisch inaktive oder eine 
EGFR nicht-bindende Variante von HDAC6 den Rezeptor nur teilweise stabilisieren 
konnten. Die Herunterregulierung der Expression von HDAC6 mittels RNAi 
beschleunigte den Abbau des Rezeptors deutlich. Es ist von Bedeutung anzumerken, 
dass die Überexpression von HDAC6 einen viel geringeren Effekt zeigt als die 
Depletion mittels RNAi von endogenem HDAC6. Dies liegt wahrscheinlich an der 
hohen Expression von HDAC6, wobei die Depletion eine größere Wirkung zeigen 
kann als die Überxpression, da die zelluläre Maschine, deren Bestandteil HDAC6 ist, 
schon gesättigt sein könnte.  
Um die zeitliche und räumliche Kinetik von Endosomen, die EGFR tragen, zu 
untersuchen, wurden „pulse-chase“ Experimente durchgeführt für welche EGF-
Moleküle verwendet wurden, die durch Fluorophore markiert worden waren. Die 
Analyse erfolgte indem die Vesikel zunächst identifiziert und die Bewegungungen 
anschließend mit, für Untersuchungen an Vesikeln spezifischen Algorithmen 
berechnet wurden. Dabei wurde festgestellt, dass HDAC6 nicht die Internaliesierung 
des EGFR von der Plasma beeinflusst, sondern eine Rolle beim postendozytotischen 
Transport des Rezeptor-Liganden-Komplexes zu den Lysosomen spielt. In Zellen die 
kein oder kaum HDAC6 exprimieren wird der EGFR sehr schnell zu den späten 
Endosomen transportiert und wird auch schneller zur perinukleären Region gebracht. 
Die Kombination aus verbesserter Mikroskopie, der Markierung von Intrazellulären 
Komponenten und speziellen Algorithmen hat wichtige Auswirkungen auf unser 
Verständnis der hochdynamischen Vorgänge in Zellen. Die Anwendung dieser 
Methoden in der vorliegenden Studie ermöglichte eine quantitative Beschreibung der 
Prozesse die Ablaufen, nachdem der EGFR internalisiert wurde. Die bei HDAC6 
beobachteten Effekte erinnern an die Effekte von KIF16B, einem Mitglied der  
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Kinesinfamilie, bei der es sich um Motorproteine handelt. KIF16B ist ein 
Motorprotein das zum Plusende der Mikrotubuli, also richtung Plasmamebran, 
wandert und das bei Überexpression dazu führt, dass frühe Endosomen zum 
Zellkortex gebracht werden. Wichtig hierbei ist, dass dies den ligandenabhängigen 
Abbau des EGFR inhibiert. Im Gegensatz dazu führt das Ausschalten von KIF16B 
durch siRNA zum schnelleren Transport von frühen Endosomen zum perinukleären 
Bereich und beschleunigt dessen Abbau. 
Es ist bekannt, dass HDAC6 zumindest teilweise den Acetylierungsstatus von -
Tubulin reguliert. Eine umfassende Suche nach anderen Zielproteinen von HDAC6, 
die eine Rolle beim Vorgang der Endozytose spielen, offenbarte keine weiteren 
Substrate, wobei solche nicht definitiv ausgeschlossen werden können. Nach 
Aktivierung des EGFR nimmt der Acetylierungsgrad des Lysinrestes 40 von -
Tubulin stark zu; dies wurde sowohl mittels massenspektrometrischer 
Proteinsequenzierung als auch Immunblots gezeigt. Die Auswirkung dieses Anstiegs 
der Acetylierung von -Tubulin auf den Vesikeltransport wurde mit Hilfe von „Live 
Cell Imaging“ untersucht, wobei die Dynamik der Lokalisation GFP-Rab5 markierter 
früher Endosomen unter Zuhilfenahme computergestützer Auswertungsverfahren 
analysiert wurde. Dazu wurde -Tubulin (Wildtyp) oder einer dominant-negativen 
Mutante (K40A), die nicht acetyliert, aber nichtsdestotrotz in Mikrotubuli (MT) 
eingebaut werden kann, überexprimiert. Der Einbau der K40A Mutante von -
Tubulin führte zur einer Verringerung der Geschwindigkeit sowie der prozessiven 
Bewegungen früher Endosomen; dies weist auf die Bedeutung von 
Acetylierungsvorgängen bei der effizienten Fortbewegung von Endosomen hin. 
Interessanterweise führt die Inhibierung der enzymatischen Aktivität von HDAC6 in 
Neuronen in Abhängigkeit des Acteylierungsgrades der MT zu einer beschleunigten 
Sekretion des brain derived neurotrophic factor (BDNF). Ein denkbarer 
Mechanismus stellt die gesteigerte Rekrutierung von Motorproteinen wie z.B. 
Kinesin-1 an hyperacetylierte MT dar. Zusammenfassend lässt sich sagen, dass die 
Acteylierung von -Tubulin einen wichtigen Mechanismus darstellt, um die Kinetik 
intrazellulärer Transportvorgänge zu regulieren. 
Interessanterweise ist bekannt, dass der EGFR Tyrosinreste von HDAC6 in vitro 
phosphoryliert. In Zellen führt die Stimulierung mit EGF zu vermehrter 
Phosporylierung von HDAC6 an Tyrosinresten. Mit Hilfe der Massenspektrometrie  
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wurden folgende Phosporylierungstellen identifiziert: Tyr570 und Ser568. Um deren 
funktionelle Bedeutung hinsichtlich der Deacetylaseaktivität von HDAC6 genauer zu 
untersuchen, wurden Punktmutanten generiert, die an diesen Stellen entweder einen 
Glutamat- oder einen Phenylalanin- bzw. Alaninrest aufweisen; erstgenannte 
Mutation imitiert phosphorylierte Tyrosin- bzw. Serinreste, wohingegen letztgenannte 
nicht-phosphorylierbare Varianten von HDAC6 darstellen. Die Phosphorylierung von 
Tyr570 und Ser658 führte zur Inaktivierung der Deacetylasefunktion von HDAC6. 
Des Weiteren wies HDAC6, das in vitro mit Phosphatase behandelt wurde, eine 
höhere Deacetylaseaktivität auf; demnach beeinflußt die Phosphorylierung die 
enzymatische Aktivität von HDAC6 negativ. Andere HDACs werden ebenfalls durch 
Phosphorylierungen reguliert; so inaktiviert z. B. die Phosporylierung des Serinrests 
39 von HDAC8 durch die Proteinkinase A (PKA) dessen Aktivität beinahe 
vollständig. Die Auswirkung hinsichtlich HDAC6 kann auch an EGFR-Signalwegen 
beobachtet werden. In Zellen, deren HDAC6 Proteinlevel verringert war, zeigte sich 
eine leicht verminderte Aktivierung von ERK1/2 sowie eine erhöhte Akt Aktivität. 
Zellen, in denen HDAC6 mittels RNAi herunterreguliert ist, reagieren weniger stark 
auf EGFR; dies zeigte sich u. a. daran, dass sich A549 Zellen nach Stimulation mit 
EGF nicht abrundeten und eine geringere Proliferationsrate aufwiesen. 
Zusammenfassend lässt sich sagen, dass HDAC6 die Herunterregulierung des EGFR 
dadurch verringert, dass der Transport intrazellulärer Vesikel zum Lysosom 
verlangsamt abläuft und dieser inhibitorische Effekt aufgehoben ist, sobald HDAC6 
an spezifischen Aminosäureresten phosphoryliert wird.  
 
Ausblick 
Während diese Ergebnisse interessant sind, geben sie aber auch Anlass zu einer 
Anzahl von Fragen, die beantwortet werden müssen. Die Funktion der Bindung von 
HDAC6 an den ligandenunbesetzten Rezeptor bleibt weiterhin unklar. Es ist möglich, 
dass HDAC6 Einfluss auf die Aktivierung des Rezeptors nimmt. Darüber hinaus wäre 
es von Interesse zu untersuchen, ob HDAC6 bei der Regulation weiterer RTKs und 
dem Transport anderer intrazellulärer Organellen eine Rolle spielt. Des Weiteren ist 
es nötig, ein besseres Verständnis des molekularen Mechanismus zu erhalten, welcher 
der Regulation intrazellulärer Transportvorgänge durch Acetylierung von MTs in vivo 
zu Grunde liegt. Zum Beispiel würde eine Komplementationsexperiment, wobei  
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endogenes Tubulin depletiert und durch Wildtyp oder entsprechende Mutanten (eine 
nicht-acetylierbare K40A, eine ladungs-erhaltende K40R sowie eine acetylgruppe-
imitierende K40Q Mutante) ersetzt ist, wichtige Informationen über die Bedeutung 
der Acetylierung von -Tubulin  in vivo liefern. Ein idealer Modellorganismus in 
dieser Hinsicht ist das Wimperntierchen Tetrahymena thermophila, da in dessen 
Genom -Tubulin nur in einfacher Kopie vorliegt. Die Substitution von Wildtyp -
Tubulin mit Mutationsvarianten ist in diesem Organismus bereits mit Erfolg gelungen 
und kann verwendet werden, um die Rolle von Acetylierungsvorgängen beim 
Vesikeltransport zu untersuchen. Schließlich sollten vergleichende Struktur-
untersuchungen von acetylierten versus nicht-acetylierten MTs Einblicke in die 
biophysikalische Basis des Einflusses der Acetylierung auf den durch Motorproteine 
vermittelten Transport geben. 
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1. INTRODUCTION 
 
1.1 Epidermal growth factor receptor (EGFR) 
 
1.1.1 Growth factors and their cognate receptors 
 
The first cellular growth factors were discovered through a combination of serendipity 
and keen observation. Stanley Cohen, working with Rita-Montalcini in 1959, used 
crude extracts from mouse salivary glands to stimulate growth of nerve fibers in mice 
and stumbled upon not only nerve growth factor (NGF) but also epidermal growth 
factor (EGF)
1. Subsequently, a 170KDa protein was identified to be the receptor for 
EGF in an affinity chromatography experiment
2. Currently, EGFR is known to be a 
member of the ErbB receptor family that in turn is part of the super family of receptor 
tyrosine kinases (RTKs) in mammalian cells.  
RTKs are a large group of cell surface receptors possessing an intrinsic tyrosine 
kinase activity. They catalyze the transfer of gamma phosphate of ATP to hydroxyl 
groups of tyrosine residues in response to external stimuli
3.  The general protein 
architecture consists of a ligand binding extracellular domain, a single-pass 
transmembrane stretch, a cytoplasmic catalytic domain followed by a 
regulatory/signaling C-terminal tail
4. 
Based on mode of activation, RTKs can be broadly classified into three classes. Class 
I RTKs exist as inactive monomers at the plasma membrane that form active dimers 
upon the simultaneous binding of a bi-valent monomeric ligand to two receptor 
monomers. Typical members of this class include growth hormone receptor (GHR) 
and erythropoietin receptor (EPOR). Class II receptors (e.g. insulin receptor) exist as 
disulfide-bridged inactive dimers, which are activated by undergoing conformational 
change upon ligand binding. A broad group falls under Class III, in which the binding 
of a homodimer ligand to inactive monomers induces the formation of dimers and 
receptor activation
4, 5. Vascular endothelial growth factor receptor (VEGFR) and 
platelet derived growth factor receptor (PDGFR) are typical representatives of this 
group. Activation of the intrinsic tyrosine kinase activity of RTKs usually leads to 
auto- and trans-phosphorylation on C- terminal tyrosine residues, which triggers a 
cascade of signal transduction in the cell.   
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1.1.2 ErbB family receptors 
 
EGFR belongs to the ErbB family of receptors. The name ErbB was coined as a result 
of homology of these proteins to avian erythroblastoma viral gene product v-erbB. 
The ErbB family consists of four receptors: EGFR (or ErbB1) as the founding 
member, ErbB2/Her2/Neu, ErbB3/HER3 and ErbB4/HER4.  The receptors form 
homo- as well as hetero-dimers for signaling
6, 7. These dimers bind to 13 polypeptide 
ligands, except for the ErbB2 homodimer, that currently has no known ligand. Based 
on ligand-receptor affinity measurements, EGFR binds to TGF-, EGF, -cellulin and 
amphiregulin whereas EGFR-ErbB4 heterodimer binds epiregulin and HB-EGF. 
Neuregulin 1 acts as ErbB3-ErbB4 heterodimer ligand whereas neuregulins 2, 3 and 4 
bind to ErbB4 homodimer. It is interesting to note that the ErbB2-ErbB4 heterodimer 
binds all ligands with moderate to high affinity
8. All of these ligands are synthesized 
as transmembrane proteins containing the EGF module. This module comprises of 40 
amino acids and contains six cysteine residues in conserved spacing which interacts 
with the ligand binding domain of their respective receptors
9. 
 
1.1.3 Mechanism of activation of EGFR 
 
EGFR is an 1186 amino acids glycosylated protein comprising of an extracellular 
domain, a transmembrane segment, a juxtamembrane part, a kinase domain and a C-
terminal tail. In broad terms, a monomeric ligand like EGF binds to the extracellular 
ligand binding EGF module that results in activation of the tyrosine kinase activity. 
Following full activation, several tyrosine residues are phosphorylated in the C-
terminal tail of EGFR acting as docking points for phospho-tyrosine binding domains. 
As a prototypical RTK, EGFR has been extensively studied for close to three decades. 
However, the precise molecular mechanism of how ligand binding induces receptor 
activation is still debated. The main obstacle for the lack of complete understanding is 
the absence of a high-resolution X-ray structure of the full-length receptor bound to 
its ligand. Recently, there has been some success in determining structures of isolated 
domains and particularly of the extracellular ligand-binding domain in complex with 
its ligand
10.  
Compared to other models of monomeric ligand-RTK binding that occurs in a 1:2 
ratio, EGFR follows a unique mechanism. The monomeric ligand (EGF) binds to  
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EGFR in a 2:2 ratio
11. Structural studies show that the extracellular domain of the 
inactive receptor exists in an auto-inhibited conformation. Binding of a ligand to each 
EGFR monomer triggers conformational changes abolishing the auto-inhibition which 
results in a strictly receptor-only mediated dimerization (i.e. no “cross-linker” 
ligand)
10-12 (Fig. 1A). 
The cytoplasmic EGFR kinase domain adopts a unique structure. The kinase domain 
is intrinsically auto-inhibited and an intermolecular interaction facilitates its 
activation. Actually, the structure of active EGFR kinase domains resembles that of 
cyclin dependent kinases (CDKs) and not other RTKs. Activation results from 
formation of an asymmetric dimer in which the C-terminal lobe of one kinase (the 
donor) acts like cyclins on CDKs in allosterically activating the other kinase (the 
acceptor)
12-14. This EGFR structure also explains why the activation loop of EGFR 
kinase domain does not need to be phosphorylated, unlike other RTK kinase domains. 
In a remarkable structure-function interplay, an activating mutation of EGFR 
identified in lung cancer patients (V665M) can now be explained as being disruptive 
of this auto-inhibition and thus leading to constitutively active kinase
14. 
 
1.1.4 Signaling through EGFR 
 
1.1.4.1 Principles of signal transduction downstream of RTKs 
 
Signal propagation through EGFR and other RTKs can be seen as a product of the 
kinase activity and the scaffolding/docking platform function of the receptor. Work 
form the late 70`s and early 80`s with transforming viruses (e.g. Rous sarcoma virus) 
has facilitated the understanding of the mechanism of downstream signaling that leads 
to changes in cellular phenotype
15. The demonstration of the tyrosine kinase activity 
of the oncogenic v-Src gene product, and the subsequent identification of the cellular 
homolog c-Src and the presence of similar domains in RTKs were influential in the 
early study of signaling
16, 17. Three principles for activation of effector proteins 
downstream of RTK signaling have been proposed. The first effect is the direct 
phosphorylation of target proteins by the kinase domains of RTKs. The second is 
recruitment of phosphorylated tyrosine binding proteins to the receptor. The third  
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principle is the change in cellular localization of effectors by translocation to the 
membrane
5, 6, 17.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Activation and signaling by EGFR (A) Proposed mechanism of activation of EGFR. Based 
on recent crystal structures the mode of activation of EGFR appears to be unique compared to other 
RTKs. In the absence of ligand binding, the extracellular domains of EGFR exist in a compact 
conformation. Ligand binding induces the formation of an extended conformation. This removes the 
inhibition on the intrinsic ability of the transmembrane and cytoplasmic domains to dimerize. Rather 
than phosphorylation, the formation of an “asymmetric dimer” and allosteric activation of the 
“receiver” kinase by the “activator” is the major driving force for full activation of the receptor. This 
leads to phosphorylation of tyrosines in the C-terminal tail. (B) Major signaling pathways activated by 
EGFR.  A common theme in RTK signaling is the recruitment of target or adaptor proteins to 
phosphorylated tyrosines. Grb2/Sos recruitment activates Ras which inturn activates the first kinase in 
the MAP kinase cascade (upper left). The activation of the lipid kinase PI3K leads to formation of PIP3 
that acts as platform for recruitment of PH domain containing proteins like Akt, which get activated by 
phophorylation on key serine and threonine residues (upper right).The cleavage of PIP2 by PLC gives 
rise to two classical second messengers, DAG and IP3. These activate PKC and facilitate release of  
Ca
2+ from intracellular stores respectively. 
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Modular protein domains play central roles in these processes. The phosphotyrosine-
binding domain (PTB) and Src homology domain (SH2) that interact with 
phosphorylated tyrosines are found in many of the signaling proteins
18, 19. Other 
domains commonly found in signaling molecules include the SH3 domain that binds 
peptides containing proline in the motif PXXP
20 and the plekstrin homology (PH) 
domain that interacts with membrane bound phosphorylated phosphatidyl inositol 
molecules
21. 
 
1.1.4.2 Signaling pathways activated by EGFR  
 
The RAS/MAP kinase signaling cascade  
Active EGFR stimulates the exchange of GTP for GDP on the small G protein Ras 
through the guanine nucleotide exchange factor (GEF), Sos. The adaptor protein Grb-
2, directly or via another adaptor Shc, plays an important role in this process 
(represented in Fig. 1B). It forms a complex with Sos via its SH3 domain and with 
EGFR on phosphorylated Tyr1068 (or Tyr1148 and Tyr1173 for Shc) via its SH2 
domain. This facilitates the localization of Sos closer to the plasma membrane where 
Ras resides
5. Once Ras is bound to GTP, it undergoes a conformational change that 
favors binding to potent effector kinases like Raf and PI-3 kinase
22. Activated Raf 
phosphorylates mitogen-activated-protein kinase (MAP)-kinase-kinase (MEK) on key 
Ser residues in the activation loop. MEK subsequently phosphorylates and activates 
the MAP kinase, extracellular signal-regulated kinase (ERK) on both threonine and 
tyrosine residues leading to its activation. ERK diversifies the signal by 
phosphorylating a large group of downstream effectors in the cytoplasm. 
Additionally, ERK rapidly translocates to the nucleus and phosphorylates a variety of 
transcription factors like Elk1 that increase transcription of response genes involved 
in cellular growth and proliferation
23, 24. 
Phosphoinositol signaling 
The prime activator of phosphoinositol metabolism, phospholipase C  (PLC), is 
recruited through its SH2 domain to phosphorylated Tyr992 in EGFR (Fig. 1B). PLC 
subsequently hydrolyzes its substrate phosphatidylinositol bisphosphate, 
PtdIns(4,5)P2, to form diacyl glycerol (DAG) and inositol trisphosphate, Ins(1,4,5)P3.  
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Ins(1,4,5)P3 stimulates the release of Ca
2+ from intracellular stores which activates 
Ca
2+/calmodulin-dependent protein kinases and together with DAG activates protein 
kinase C(PKC)
25. The phospholipid kinase PI3-kinase is the other prominent signaling 
molecule activated by EGFR. By phosphorylating membrane phospholipds it creates 
docking sites for PH domain containing Ser/Thr kinases PDK1 and PKB/Akt. These 
in turn activate major cellular survival and growth responses
26, 27. Additionally, PI3K 
and PLC through the small GTPases Rho/Rac mediate the reorganization of the actin 
cytoskeleton that leads to formation of membrane ruffles, filopodia and lamellipodia. 
These changes are central to EGF induced cell motility
28-30.  
Signal transduction and activators of transcription (STATs) signaling 
STAT proteins get activated upon recruitment to phosphorylated tyrosines on EGFR 
leading to formation of STAT homo- or hetero-dimers. The dimers translocate to the 
nucleus and act as transcription co-activators of select target genes. Alternatively, c-
Src mediated phosphorylation of EGFR at Tyr845 acts as a docking site for STAT5 
that is subsequently activated. This pathway is central in promoting cell cycle 
progression, proliferation and survival
31.  
It is of paramount importance to note that in response to EGF stimulation, most cells 
either proliferate or migrate but not both. This so-called proliferation-migration 
dichotomy is due to selective activation of MAP kinase/STAT5/c-Src (proliferation) 
and PI3K/PLC (migration) pathways. The precise mechanism how this occurs is still 
not clear
32. 
 
1.1.5 Physiological functions of EGFR signaling 
 
Prokaryotes do not have any homologues of EGFR or other RTKs. EGFR 
homologues first appeared in lower organisms, like the nematode Caenorhabditis 
elegans
33 and the fruitfly Drosophila melanogaster
34. In C. elegans, the EGFR 
homologue, LET-23 is expressed in the three vulval precursor cells and together with 
its diffusible ligand LIN-3 (EGF-like) is essential for cell fate determination and 
induction of vulval development. Loss of function of LET-23 results in death.   
Interestingly, the major downstream signaling components are conserved as 
exemplified by the existence and action of the Ras like protein, let-60ras  gene 
product
33.  
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 In D. melanogaster, there is one homologue of EGFR, DER, but four ligands: Spitz, 
Gurken, Keren and Vein and the negative regulator Argos
34, 35.  DER plays roles at 
many instances during D. melanogaster development such as in oogenesis, 
embryogenesis, and brain, wing and eye development
36. In mammals, EGFR and its 
ligands are important for embryonic development, tissue differentiation and cellular 
functions. Knocking out EGFR in mice has severe consequences depending on 
genetic background. In CF-1 and 129/Sv backgrounds, EGFR ablation was embryonic 
lethal whereas in CD-1 background mice survived till the 3
rd week of life. In those 
pups that survived birth, defects were seen in multiple organs. There were major 
defects in the epidermis such as total lack of eyelids, low proliferation of gut 
epithelial cells and defective brain cortex
37. All this shows that EGFR plays essential 
roles in development. 
 
1.1.6 Pathological perturbations of EGFR and its signaling pathway 
 
Aberrant expression and activation of ErbB receptors and various downstream 
components are implicated in tumorigenesis. Gene amplifications leading to receptor 
overexpression, excessive autocrine or paracrine production of EGFR ligands, 
deletions and point mutations leading to constitutive activation occur in many solid 
tumors like glioblastoma, non-small cell lung cancer (NSCLC) and colorectal 
cancer
38. Point mutations are also reported granting the receptor resistance to tyrosine 
kinase inhibitors
39.  
Hence, strategies to inhibit signaling through ErbB receptors have been developed and 
used with promising results. Humanized monoclonal antibodies can block binding of 
ligand to the receptor, induce receptor endocytosis or activate a type of antibody 
dependent cellular cytotoxicity (e.g. cetuximab).  The other strategy, which is already 
approved to treat patients with colorectal and NSCLC, is the use of small molecule 
inhibitors of the EGFR kinase (e.g. gefitinib and erlotinib). Novel antibodies, 
antibody-chemotherapy conjugates and inhibitors with improved pharmacokinetic 
properties are now in clinical development
38, 40. It is of interest to note that patients 
receiving EGFR tyrosine kinase inhibitors suffer from side effects that are directly 
related to the physiological function of EGFR in adults. These include acneiform  
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eruptions and other proliferative disorders of the epidermis where EGFR is highly 
active
41. 
 
1.1.7   Mechanisms of EGFR signal attenuation 
Activity of RTKs is tightly regulated to mount an appropriate and physiological 
response to a stimulus. In Drosophila, an antagonistic EGF-like ligand called Argos 
competes away a positive signaling ligand. In a classic negative feedback mechanism, 
gene expression of negative regulators like Argos is induced upon DER activation
42. 
So far, however, no EGFR antagonist ligand has been reported in vertebrates. 
Phosphorylation of EGFR is generally activating, however phosphorylation on Ser 
and Thr residues in the juxtamembrane domain by protein kinase C (PKC) results in 
inhibition of its catalytic activity
43. A major negative modulator of EGFR signaling is 
dephosphorylation of activated receptor and downstream effectors by protein tyrosine 
phosphatases (PTP). Several phosphatases have been implicated in dephosphorylating 
EGFR after ligand stimulation such as receptor-type protein-tyrosine phosphatase 
kappa (RPTP)
44.  
However, the most important way of signal attenuation is by rapid endocytosis and 
degradation of both the receptor and the ligand. Ligand binding and activation induces 
clustering of the receptor in primarily clathrin-coated pits (CCPs) on the plasma 
membrane that pinch of to form clathrin-coated vesicles (CCVs). EGFR is trafficked 
through CCVs, early endosomes and multivesicular bodies and eventually degraded 
by lysosomal enzymes
45-47. 
 
1.2  EGFR trafficking 
 
1.2.1 Endocytosis 
 
Endocytosis can be defined as the formation of internal membranes from the lipid 
bilayer of the plasma membrane leading to full internalization of membrane lipids, 
proteins and extracellular fluid. It can be considered the opposite of exocytosis where 
internal membranes fuse with the plasma membrane
48. As imaging techniques 
improved, understanding of the process has come a long way from the initial 
description by Elie Metchnikoff that cells could phagocytose (literally “eat”) foreign  
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particles
49. Based on morphological and molecular characteristics of the endocytic 
structures and cargos transported, different pathways have been described. 
Classically, clathrin-mediated endocytosis (CME) has been the most extensively 
characterized. However, several clathrin independent endocytic pathways are now 
known to exist (depicted in Fig. 2).  
 
1.2.1.1 Clathrin-mediated endocytosis (CME) 
 
The defining feature of CME is the recruitment of soluble clathrin to the plasma 
membrane where it is assembled into pentagonal and hexagonal lattices that curve 
around membrane invaginations forming coated-pits (CCPs)
50. The presence of 
clathrin alone is not enough for deforming and stabilizing the membrane fold. 
Adaptor proteins such as amphiphysin and endophilin that contain uniquely curved 
domains called BAR domain (Bin/Amphyphysin/Rvs) are important in bending the 
plasma membrane
51. Additionally, cargo specific and non-specific adaptor proteins 
like AP2 (adaptor protein 2) link the cargo to the clathrin and aid in recruiting the 
GTPase dynamin
52. Dynamin releases the CCP from the plasma membrane by 
scission of the neck region to form clathrin-coated vesicles (CCVs). Short linear 
stretches of amino acids in the cytoplasmic tail of receptors acts as sorting signals into 
early endosomes or lysosomes. These signals are tyrosine based as in NPXY or 
dileucine based as in DExxxLL. The AP-2 adaptor recognizes tyrosine based 
sequences whereas GGAs (Golgi localized gamma ear containing ARF binding 
proteins) recognize dileucine-based signals. Classic examples of receptors containing 
NPxY motif are EGFR and low density lipoprotein receptor (LDLR) whereas CD3 
and the glucose transporter GLUT4 contain DExxxLL motif
53.  
Importantly, the membrane in these vesicles is far from being an inert media. 
Phospholipids like phosphatidylinositol-4.5-bisphosphate facilitate vesicle formation 
and budding by binding to adaptors. Subsequently, CCVs undergo uncoating to form 
naked vesicles that fuse with early endosomes (EEs). EEs are enriched in 
phosphatidylinositol-3-phosphate and FYVE (Fab1, YOTB, Vac1, EEA1) domain 
containing proteins that bind cargo and determine its destination. Hence, EEs are 
important molecular sorting stations. From here on, cargo can be directed into two  
Introduction
 
  20 
separate compartments, recycling endosomes (REs) or multivesicular endosomes 
(MVEs)
48, 49, 54. 
  A hotly debated area is how all of this change/transition of vesicular structures 
occurs. Basically, two schools of thought exist. In the “pre-formed compartment” 
model, vesicles transport cargo between two distinct and stable compartments. 
Endosomal carrier vesicles pinch of from early endosomes and fuse with late 
endosomes. Additionally, vesicles from the Golgi complex containing newly 
synthesized lysosomal enzymes fuse with this compartment converting it slowly to a 
lysosome. There is “vesicle shuttling” that denotes vesicles move in both directions to 
compensate for progressive membrane loss
55-58. On the contrary, the  “endosome 
maturation” model argues that there is gradual change in composition of a cargo 
containing vesicle
59, 60.  
 New imaging and fluorescent tagging of key proteins involved in assembly of these 
endocytic compartments is shedding light on their biogenesis and favors the 
maturation model. The GTPases Rab5 and Rab7 are key organizers of early and late 
endosomes respectively and act as compartmental identity markers. Dynamics of red 
fluorescent protein-Rab5 (RFP-Rab5) labeled single early endosomes were examined 
in real time. Images acquired by fast live-cell imaging were analyzed by a newly 
developed image analyses algorithm that is able to track single vesicles. Early 
endosomes progressively lost RFP-Rab5 signal and acquired GFP-Rab7. Remarkably, 
this Rab conversion coincided with changes in vesicle morphology (getting bigger), 
cargo content (getting brighter) and localization (coming closer to peri-nuclear area) 
which are all general features of late endosome formation. The other fundamental 
observation has been the visualization of the high dynamicity of the Rab5 machinery 
ranging from stable maintenance of identity to rapid loss of early endosomal 
identity
61.  
The fate of cargo is decided at the level of early endosomes where cargo is destined 
either to be recycled back to the plasma membrane or to be degraded in lysosomes. 
Nutrient receptors such as the transferrin receptor and LDL receptor are uniformly 
recycled back to the membrane where as most RTKs are sorted for degradation
62. 
Cargo destined for degradation ends up in late endosomes or multivesicular bodies 
(MVBs). Morphologically, MVBs have a characteristic appearance with accumulation 
of intraluminal vesicles (ILVs) containing cargo to be degraded
55, 60. Sorting and ILV  
Introduction
 
  21 
formation proceed hand in hand and are dependent on sorting signals and machinery. 
Cargo Ubiquitylation is the major sorting signal
63. Endosomal sorting complex 
required for transport (ESCRT) is a complex multi-protein sorting machinery on the 
limiting membrane of MVBs that recognizes this sorting signal and facilitates 
intraluminal budding of vesicles
64-66.  
Additionally, phosphatidyl inositol 3- phosphate (PtdIns3P) and FYVE domain 
proteins are intimately involved in the formation of ILVs. PtdIns (3)P is found in 
early endosomes whereas PtdIns(3,5)P and the unconventional lipid 
lysobisphosphatidic acid (LBPA) are localized in late endosomes. These 
phospholipids are crucial components of the sorting machinery and function by 
recruiting the protein components of the sorting apparatus.  
Hepatocyte growth factor regulated tyrosine kinase substrate protein (HRS) is the best 
characterized of the FYVE domain proteins involved in MVBs biogenesis. HRS is 
recruited by PtdIns3P and it in turn recruits clathrin. HRS also binds ubiquitylated 
cargo proteins through its ubiquitin interacting motif (UIM)
67, 68.  
Polyubiquitylation through Lys-48 is a signal for proteasomal degradation. On the 
contrary, multiple monoubiquitylation and Lys-63 polyubiquitylation serve as signals 
for lysosomal protein degradation
69, 70. In the endosomal membrane the ESCRT 
machinery recognizes the ubiquitylated cargo. Detailed genetic and biochemical 
analysis in the yeast Saccharomyces cerevisiae has led to the elucidation of 
components of this machinery that is conserved from yeast to humans. This complex 
apparatus consists of four complexes, ESCRT-0, I, II and III and several accessory 
components. ESCRT-0 consists of Hrs and STAM which function as the initial 
ubiquitin sensing subunits and help to concentrate cargo that will be sequentially 
passed onto the other complexes. ESCRT I and II also bind ubiquitin but primarily 
function to deform the endosomal membrane and recruit ESCRT III. ESCRT III 
causes prominent invagination and forms a circular array around the invagination to 
cause abscission that completes the formation of ILVs. ESCRT III also  recruits 
deubiquitinating enzymes to recycle ubiquitin. Vps4 (vacuolar protein sorting 4) 
hydrolyses ATP to drive the disassembly of the ESCRT III complex and generation of 
individual subunits
62, 65, 66. 
Subsequently, MVBs fuse with lysosomes in such a way that ILVs end up in the 
lumen that contains hydrolytic enzymes whereas the limiting membrane remains  
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intact.  The ILV membrane is degraded by lipases and the cargo proteins are degraded 
by lysosomal proteases
71, 72. Mechanistically late endosomes and lysosomes either 
permanently fuse to create a hybrid organelle or transiently fuse (kiss-and-run). Like 
other vesicular fusions, fusion occurs in three steps; tethering of the two vesicles via 
Rab7-recruited fusion complex, trans-SNARE (soluble N-ethylmaleimide sensitve 
factor [NSF] attachment protein receptor) complex formation between the opposing 
membranes and the final phospholipid bilayer fusion
73.  
 
 
Figure 2.  Entry into the cell. The simplistic rendition of major internalization pathways includes 
clathrin mediated (CME) and  caveolin dependent (CDE) pathways that require the GTPase dynamin 
for the release of vesicles. The less well characterized clathrin and caveolin independent pathways may 
or may not require dynamin. Large particles are engulfed by phagocytosis, whereas fluid is taken up by 
macropinocytosis. These two routes involve extensive cytoskeletal rearrangement and encompass large 
areas of the cell membrane. Most pathways eventually lead to early endosomes, either through coated 
vesicles (clathrin  or caveolin) or through clathrin and dynamin independent carriers (CLICS). In some 
cases of CDE, cargo may end up in caveosomes. Phagocytosed particles are usually terminated by 
fusion with lysosomes. 
 
1.2.1.1 Clathrin independent endocytosis (CIE) 

The existence of clathrin-independent modes of endocytosis is currently well 
established. The advent of novel techniques and markers has unraveled diverse  
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pathways of endocytosis
74, 75. However, precise distinctions between some routes are 
still lacking. A recurring theme in clathrin independent endocytosis is the involvement 
of specialized microdomains of the plasma membrane called “lipid rafts”. Lipid rafts 
are highly enriched in cholesterol and sphingolipid. Biochemically, they are isolated 
in low buoyant density and detergent–resistant membrane fractions 
76, 77. Their 
existence was once debated, as their specific composition seemed to defer widely 
depending on the type of detergent used for extraction. Currently though, research is 
focused on analysis of their biogenesis, size, stability, and lipid and protein 
composition
78. 
 
1.2.1.1.1 Caveolin mediated endocytosis 
 
Caveolae (literally “small caves”) are flask-shaped invaginations in the plasma 
membrane enriched with the lipid raft resident protein caveolin-1. Furthermore, they 
contain high proportion of cholesterol and sphingolipids 
79, 80. Like CME, caveolae-
mediated endocytosis requires scission by the GTPase dynamin. Caveolin is able to 
form oligomers and organizes caveolae by binding to cholesterol and fatty acids
81. It 
is also able to bind to other components of “lipid rafts” such as the glycosphinoglipid 
GM1 and Gb3. Cargo in caveolae is endocytosed into caveosomes, which are large 
neutral pH vesicles, can end up in classical early endosomes
82 or can fuse with the 
Golgi complex
83, 84. The number of markers shown to be endocytosed through 
caveolae is relatively few. These include simian virus 40 (SV40) and some 
glycosylphosphatdiylinositol (GPI)-anchored proteins. The best characterized is 
transport of cargo across endothelial barriers, so called transcytosis
85, 86.  
Another obscure dynamin dependent CIE endocytic pathway is responsible for the 
endocytosis of interleukin-2 receptor  chain (IL-2R-). IL-2R- segregates into 
detergent-resistant membranes, like in other CIE pathways, and is dependent on both 
dynamin and the small GTPase RhoA for its internalization
87.  
 
1.2.1.1.2  Dynamin-independent cdc42 regulated endocytosis 
 
Unlike most other forms of endocytosis, one class of CIE endocytosis is also dynamin 
independent. Rather, this pathway requires the small GTPase cdc42. The primary  
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vesicles that bud from the membrane, also called clathrin and dynamin independent 
carriers (CLICs), have long and wide surface invaginations
88, 89. CLICs end up in 
specialized endosomes known as glycosyl-phosphatidylinositol–anchored protein 
(GPI-AP) enriched early endosomal compartments (GEECs)
74, 88. So far, no clear 
sorting signal or specialized adaptor proteins have been identified for this pathway.  It 
is recently hypothesized that the nano-scale clustering of GPI-APs (at most four 
molecules per cluster), which is dependent on cholesterol might act as a sorting 
signal
90, 91. Cholera toxin B, GPI-anchored receptors and fluid phase markers like 
dextran are transported through this pathway
92. 
 
1.2.1.1.3 Internalization of large volumes of membrane – macropinocytosis and 
phagocytosis 
 
Macropinocytosis is a large-scale internalization of fluids and membrane that involves 
transient plasma membrane protrusions. The eventual fusion of these membranes with 
themselves or the plasma membrane results in the uptake of extracellular particles 
caught between the protrusions. One of the classical upstream activators of this route 
of endocytosis is growth factor signaling that activates PI3K
93. This process is rac1 
and actin dependent
94. Morphologically, macropinocytosis is similar to dorsal 
membrane ruffle formation after growth factor stimulation.  Rac1 directly binds and 
activates p21-activated kinase-1 (PAK1) that is central to subsequent morphological 
alterations of the cytoskeleton and plasma membrane by phosphorylating several 
effectors
95. The other role of rac1 is the recruitment of the actin polymerization 
complex Arp2/3 and N-WASP. The growth of actin polymer is the main driving force 
behind the membrane protrusions
96. Macropinocytosis is also dependent on 
cholesterol that is involved in recruitment of active rac1
97.  
Phagocytosis denotes the engulfment of particles that are larger than 0.5μm in 
diameter by specialized phagocytic cells like macrophages. Targets for phagocytosis 
could be invading pathogens, apoptotic cells or even inert foreign particles like 
beads
98. Actin-driven protrusions of the plasma membrane, called pseudopods, engulf 
the target by repeated receptor-ligand interactions. This very much proceeds in a 
zippering mechanism. Phagocytosis leads to massive reorganization of the actin 
cytoskeleton by activating multiple signaling pathways that end up with the formation  
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of the phagosome. The primary purpose of the phagosome is to degrade the cargo and 
hence fuses with lysosomes to form a hybrid organelle, the phagolysosome
98, 99. 
 
1.2.1.1.4 Pathogens and the endocytic pathway 
 
Endosomes help in fighting infections through several ways. In the innate immune 
response, pattern recognition proteins of the Toll-like receptor (TLR) family sense the 
presence of pathogens and trigger inflammatory responses by activation of 
transcription factors such as nuclear factor (NF)-kB. Some of the TLRs, namely 
TLR3, TLR7 and TLR9, signal from endosomes
100. Endosomes are also important for 
adaptive immune response. Antigen presenting cells take up and process extracellular 
antigens into peptides that are loaded onto major histocompatibility (MHC) class II 
complexes. These are sorted from the Golgi to the internal membranes of endosomes 
and the peptide-loaded complex is delivered by back fusion to the limiting membrane 
of the endosome. From here it is eventually delivered to the plasma membrane
101. 
Endosomes are also actively involved in pathogen killing. After phagocytosis of 
microorganisms, the phagosome undergoes a series of maturation events to be 
competent in cell killing and digestion. This mature phagosome, also known as 
phagolysosome, contains lysosomal hydrolases and an active NADPH oxidase 
complex in a highly acid pH that are crucial for its microbicidal activity.  
Intracellular pathogens, or their products, traverse through the plasma membrane 
mainly through the cell’s pre-existing internalizing pathways (CME, phagocytosis or 
macropinocytosis). These opportunistic organisms have developed ingenious ways of 
avoiding entrapment in pathways that could lead to their degradation.  
Anthrax toxin (AT) and enveloped vesicular stomatitis virus (VSV) are prototypic in 
using endocytosis to reach the cytoplasm. They are transported down the endocytic 
pathway, sorted into the intraluminal vesicles (ILVs) in MVBs and are finally 
released into the cytoplasm as the ILVs back-fuse with the limiting membrane
102, 103. 
Bacteria such as Listeria monocytogenes, Salmonella enerica and Shigella flexneri are 
particularly good at manipulating normally non-phagocytic cells to take them up
104. 
Bacteria not only use endocytosis to get into cells but have also come up with 
strategies to exit when necessary. Listeria, through its toxin listeriolysin O, forms  
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transmembrane pores that perforate the phagosome facilitating the bacteria’s escape 
into the cytoplasm
105.  
Another highly pathogenic organism, M.tuberculosis prevents the full maturation of 
the phagosome into a phagolysosome. It produces a highly glycosylated 
phosphatidylinositol (PtdIns) analogue, lipoarabinomannan and a PtdIns(3)P-
phosphatase, SapM. These prevent the PtdIns(3)P-dependent recruitment of lysosomal 
enzymes and v-ATPases; hence the bacteria can persist in the early endosomal-like 
compartment of macrophages for extended durations
106-108.   
 
1.2.3 EGFR endocytosis 
 
At steady state conditions the majority of EGFR is localized to the plasma membrane 
with a minor pool in endosomes. This is achieved by the interplay between 
constitutive internalization at a slow rate that is comparable to basal rate of membrane 
recycling (rate constant Ke ~0.02-0.05 min
-1) and a much faster recycling rate (rate 
constant Kr  0.2 min
-1)
109-111. Upon ligand binding, EGFR is internalized at a much 
faster rate (Ke ~0.2-0.4 min
-1), which incidentally is similar to internalization rate of 
transferrin receptors through clathrin-coated pits (CCPs)
112. In addition to this finding, 
various experiments have conclusively shown that EGFR is primarily internalized 
through clathrin-mediated endocytosis. These include localization of EGF/EGFR in 
CCPs
113, 114 and inhibition of EGFR internalization either by expression of dominant-
negative mutant of dynamin
115 or RNA interference mediated knockdown of clathrin 
heavy chain or dynamin
116. Interestingly, it is reported that EGFR internalization 
through CCPs occurs only at low EGF concentration (1-2ng/ml). At higher EGF 
concentrations (100ng/ml) EGFR is internalized via clathrin independent and lipid-
raft dependent pathway
114. However in cells expressing low to moderate amount of 
EGFR, the receptor is primarily internalized through CME even at high ligand 
concentrations
112, 117. In cells expressing very high amount of EGFR, like the human 
epidermoid carcinoma cell line A431, EGF stimulation leads to internalization of the 
receptor also through macropinocytosis
118.  
Kinase activity is important for internalization of EGFR as shown by inhibition of 
endocytosis in a kinase-dead mutant and by small molecule kinase inhibitors
119-121. 
Phosphorylation of several tyrosine residues in EGFR is also required for efficient  
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internalization. Tyr1068 and Tyr1086, which bind to Grb2 adaptor protein, are 
particularly important for CME
120. Additional evidences such as severe inhibition of 
endocytosis by Grb2 siRNA knockdown and localization of Grb2-EGFR complex in 
CCPs point to the possibility of EGFR being primarily internalized via Grb2 
dependent endocytosis
122, 123. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Salient features of EGFR trafficking. The binding of ligand, EGF,  to its cognate receptor, 
EGFR, activates not only signaling pathways but also negative regulators of EGFR signaling. Ligand-
induced internalization of EGFR occurs primarily through clathrin coated pits. Recruitment of  the E3 
ubiquitin ligase, cbl, to  phosphorylated EGFR leads to multiple monoubiquitylation of the receptor.  
Ubiquitin is recognized by ubiquitin interacting motif containing proteins like HRS or epsin. In a 
process orchestrated by the ESCRT complex, ubiquitylation acts as the sorting signal to degradation. 
This proceeds via pinching off of  small  vesicles containing cargo from the limiting membrane of the 
late endosomes into the intravesicular space creating intraluminal vesicles (ILVs). This effectively 
terminates signaling from the C-terminus of the receptor. Finally, fusion of these multivesicular 
bodies/late endosomes with lysosomes results in both ligand and receptor degradation by proteolysis.  
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One of the major interactors of Grb2 is the Cbl family of E3-ubiquitin ligases. 
Additionally, all three members of Cbl family, c-Cbl, Cbl-b and Cbl-3, bind to EGFR 
directly via Tyr1045
124. Cbl proteins are able to ubiquitylate EGFR; however, whether 
this ubiquitylation of EGFR is essential for internalization is still an unresolved issue. 
Knockdown of c-Cbl and Cbl-b or expression of dominant negative mutants leads to 
partial inhibition of EGFR internalization
70, 125, 126. Importance of homologues of Cbl 
proteins in EGFR internalization and signaling is also shown by genetic studies in 
Drosophila
127 and C.elegans
128. It is possible that Cbl proteins ubiquitylate other 
proteins in the endocytic pathway to mediate their effect on internalization of EGFR.  
Subsequent to internalization through CCPs, EGFR containing vesicles rapidly 
(within a few minutes) shed their clathrin coat and fuse with early endosomes (Fig 3). 
Even though the pH of early endosomes is mildly acidic (6.0-6.5), EGF-EGFR 
complex is not dissociated and is still phosphorylated and signaling competent
129. 
Interestingly, as opposed to earlier thoughts, early endosomes act not only as down-
modulators but also function as platforms for activating downstream signaling 
pathways like ERK/MAPK
130.  
As early endosomes mature, the vast majority of EGF-EGFR complex begins to 
accumulate in ILVs of MVBs
131. At this junction, a “point of no return” is reached. 
Unlike nutrient receptors (like transferrin receptor) that are constitutively endocytosed 
and recycled, the fate of ligand bound EGFR is degradation. The crucial determinant 
in the sorting of the ligand-receptor complex is the ubiquitylation of the receptor by 
E3 ubiquitin ligases like c-Cbl and recognition of this ubiquitin moiety by adaptor 
proteins in the ESCRT complex
132. In contrast to poly-ubiquitin chain formation in 
proteasomal degradation, mono-ubiquitylation (single or multiple) is the predominant 
degradation signal in endosomes
69. Ubiquitin interacting motif containing proteins 
like HRS or STAM1/2 recruit ubiquitylated EGFR. This starts the cascade of ESCRT 
machinery leading to formation of ILVs within MVBs that end up in lysosomes
133, 134.  
A number of proteins fine-tune the downregulation of EGFR, primarily by acting on 
Cbl activity. For instance, Sprouty 2 binds to Cbl and inhibits its ubiquitin ligase 
activity
135. In contrast CIN85 (Cbl-interacting protein of 85kDa) is postulated to form 
multimeric protein complexes that enhance receptor internalization
136, 137.  
In summary, ubiquitylation of EGFR by c-Cbl is a primary sorting signal for the 
lysosomal degradation of the receptor. Ubiquitylation targets lysine residues on its  
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substrate proteins. Another posttranslational modification that targets lysine residues 
is acetylation. This raises an interesting question. Can acetylation act competitively on 
the same lysine residues that are targeted by ubiquitylation? 
 
1.3  HDAC6 and protein acetylation 
 
1.3.1 Lysine acetylation as a post-translational modification 
 
The study of protein lysine acetylation has come a long way from the first 
demonstration of correlation between acetylation of histones and RNA synthesis
138.  
Two types of protein acetylation can be distinguished: a co-translational acetylation of 
N-terminal residues of most proteins and post-translational acetylation of the epsilon 
amino group of lysine residues
139, 140. The description that follows is focused 
exclusively on lysine acetylation as a post-translational modification. Histones are 
generally acetylated on lysine residues of their N-terminal tails in a site-specific 
manner in transcriptionally active chromatin. The primary result of this acetylation is 
charge neutralization, which is hypothesized to weaken histone to DNA interactions 
and also change histone to histone interaction between close nucleosomes
141. 
Modulating this acetylation are two groups of enzymes with opposing activities: 
acetyltransferases (HATs) and deacetylases (HDACs). Histone acetyltransferases 
transfer acetyl groups from acetyl coenzyme A (acetyl-CoA) onto the -amino groups 
of lysines whereas deacetylases remove this acetyl group
142, 143.  
 Based on domain architecture, HATs can be classified into GNAT (Gcn5-related N-
acetyltransferase), MYST (named after the founding members MOZ, Ybf2, Sas2 and 
Tip60) and p300/CBP families. They all share a common HAT domain containing 
binding site for acetyl-CoA but differ in other domains. Most of these HATs have 
been discovered as transcriptional co-activators
142.  Even though acetyltransferases 
are generally termed as histone acetyltransferase, their substrates are by no means 
limited to histones.  
Currently, the list of acetylated proteins is rapidly increasing. Acetylation appears to 
occur predominantly in the nucleus where transcriptional co-activators and 
transcription factors are abundantly acetylated. Some of these include p53, estrogen 
receptor-, nuclear factor-B, c-Myb, androgen receptor and HMG (high mobility  
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group) proteins
140. Interestingly, the number of reports of acetylated cytoplasmic 
proteins is also increasing. -Tubulin is the quintessential cytoplasmic protein known 
to be acetylated
144, 145. Moreover, functionally relevant acetylations of HSP90
146, 
cortactin
147, and STAT3
148 have been reported.  
How does acetylation affect the function of proteins? Acetylation of transcription 
factors such as p53 and E2F1 increases binding to DNA where as acetylation of 
HMGI transcription factor abolishes DNA binding
140. Furthermore, acetylation also 
influences protein-protein interactions, either positively or negatively. For instance 
acetylation of HSP90 increases its interaction with its client protein glucocorticoid 
receptor
146. It is also important to note that there is a highly conserved domain of 60 
amino acids that specifically recognizes acetylated lysines, the bromodomain. Located 
in various transcription factors, co-activators and co-repressors the bromodomain is 
involved in building large transcriptional and chromatin remodeling complexes
149. So 
far no cytoplasmic acetyllysine binding domain/motif has been described. Acetylation 
also regulates stability of proteins; acetylated E2F1 is for example more stable than 
it’s non-acetylated form
150. Interestingly, acetylation of Smad7 by p300 competes 
against ubiquitylation on the same lysine residue and rescues it from degradation
151.  
 
1.3.2 Deacetylases 
 
Lysine deacetylases are highly conserved proteins found from yeast to higher 
mammals. As the first deacetylases to be described are from the yeast Sacharomyces 
cerevisiae,  deacetylases are generally classified into three classes based on their 
similarities to the yeast HDACs. Class I HDACs (HDAC1, 2, 3, 8 and 11) are related 
to yeast RPD3
143, 152 whereas Class II HDACs (HDAC 4, 5, 6, 7, 9 and 10) share more 
similarities to yeast Hda1
153. The third class known as SIR2 (sir2 yeast founder 
protein) family of NAD
+- dependent HDACs are very distinct from the previous two 
classes of HDACs in sequence and catalytic mechanism
154.   
Class I HDACs are exclusively localized in the nucleus and their physiological targets 
are histones and transcription factors. They are classical transcriptional repressors and 
are active only in large chromatin remodeling complexes, hence the catalytic 
inactivity of recombinantly produced proteins. Phosphorylation slightly increases  
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their enzymatic activity but are primarily regulated by interactions with co-
repressors
155 .  
Class II HDACs are able to shuttle between the nucleus and the cytoplasm. However, 
HDAC6 is almost exclusively localized in the cytoplasm
156. HDACs 4, 5, and 7 are 
important in fine-tuning repression of gene expression as they readily respond to 
signaling cues by changing their sub-cellular localization via binding to 14-3-3 
proteins. Furthermore they are phosphorylated and depend on other co-repressors
157.  
The enzymatic action of these two classes of HDACs is similar. The catalytic 
deacetylase domain is composed of about 390 amino acids.  The active site is a 
tubular pocket comprising of two aspartate-histidine charge-relay systems that 
activate a water molecule. This water molecule launches a nucleophilic attack on the 
carbonyl carbon of the acetyllysine that is polarized by the critical zinc ion. An 
additional tyrosine residue is required to stabilize the intermediate, which yields 
acetate and lysine
158. There are various structural groups of HDAC inhibitors but act 
in related fashion by chelating the zinc, removing the water molecule and closing the 
entrance to the active site pocket. The most potent of HDAC inhibitors belongs to the 
hydroxamic acids such as the fungal fermentation product trichostatin A (TSA) while 
short chain fatty acids like sodium butyrate and valproic acid are weak inhibitors
143.  
The SIR2 family of deacetylases is completely resistant to all the above HDAC 
inhibitors due to their unique catalytic mechanism. They deacetylate lysines by 
consuming nicotinamide adenine dinucleotide (NAD
+) to generate 2`-O-Acetyl-ADP-
ribose, nicotinamide and the deacetylated substrate. They deacetylate histones and 
transcription factors involved in metabolism, stress response and survival
154, 159.  
Recently, SIR2 deacetyases have garnered immense interest, as they appear to be 
major regulators of life span of organisms.  Their activation leads to longer and 
healthier life in model organisms, in a manner remarkably similar to caloric 
restriction
160, 161.  
 
1.3.3 Histone deacetylase 6 (HDAC6) 
 
HDAC6 is a unique deacetylase as it is the only deacetylase with two catalytic 
domains
153. It contains ubiquitin binding zinc-finger domain of the type Zn-UBP
162, 
and is almost exclusively localized in the cytoplasm
163. HDAC6 was initially cloned  
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by searching the GenBank/expressed sequence tag database for homologues of the 
yeast deactylase Hda1
153. A single 5kb transcript was highly expressed in heart, liver, 
kidney, brain, pancreas and testis. Overexpressed and immunoprecipitated HDAC6 is 
capable of deacetylating histones in vitro. Both deacetylase domains are functional 
and can act independently of each other, at least in vitro. Like the other class II 
HDACs, HDAC6 shares sequence similarity to yeast Hda1 only in the deacetylase 
domain. However, in higher eukaryotes from C.elegans to humans these HDACs are 
well conserved
153. The discovery of -tubulin as an in vivo and in vitro substrate of 
HDAC6 established it as the first full-fledged cytoplasmic lysine deacetylase
156, 164. 
Interestingly, HDAC6 can not deacetylate free /-tubulin dimers but only 
polymerized microtubules
156.   HDAC6 binds to -tubulin through its deacetylase 
domains and deacetylates -tubulin on lysine-40
164.  
The generation of HDAC6 null mice by targeted ablation confirmed that HDAC6 is 
the physiological deacetylase of -tubulin. Even though these mice are viable and 
lack gross defects, they show massively increased acetylation of -tubulin in various 
tissues
165. 
What are the cellular functions of HDAC6 then? The major cellular roles of HDAC6 
for which reliable evidence has been provided are outlined in Figure 4. HDAC6 
mediated deacetylation of -tubulin enhances chemotactic motility towards serum. 
Acetylated microtubules are known to be highly stable and are absent from leading 
edge of motile cells where the cytoskeleton is very dynamic. It is hypothesized that 
HDAC6 increases fibroblast motility by destabilizing microtubules
156.  
Shortly after this finding, numerous substrates of HDAC6 have been identified. 
HDAC6 interacts with the F-actin binding protein cortactin. Cortactin is multiply 
acetylated on the F-actin binding site. Acetylated cortactin is not able to bind to actin 
and is not recruited to the cell periphery where active actin polymerization is taking 
place. In a Rac1 dependent fashion, HDAC6 deacetylates cortactin enabling it to 
translocate to the cell periphery, interact with actin and the actin polymerizing 
machinery. Thus deacetylated cortactin facilitates actin polymerization that is 
associated with ruffle formation and cell movement
147. Heat shock protein 90 
(HSP90) is involved in maturation of various signaling molecules like the 
glucocorticoid receptor. HSP90 is acetylated on a single lysine, K294, which is 
important in client protein and co-chaperone binding
166.   
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HDAC6 down modulation, either by inhibitor or siRNA, results in hyperacetylation of 
HSP90. This leads to the dissociation of HSP90 from the co-chaperone p23 and the 
client protein glucocorticoid receptor that in turn inhibits proper nuclear receptor 
maturation and signaling
146, 167.  
 
 
 
Figure 4.  Domain architecture and functions of HDAC6.  (A) HDAC6 is unique among all 
deacetylases in having two active deacetylase domains. It also contains a ZnF-UBP domain capable of 
binding to the C-terminal diglycine motif of ubiquitin. So far no  3-D structure of HDAC6 has been 
solved. Even isolated domains have proven to be  poorly suited to structural studies. (B)  Major 
substrates and biological functions of HDAC6. Deactylation of  -tubulin is important for  chemotactic 
cell motility, HIV-1 viral fusion to cell membrane and formation of immune synapse. Effect on the 
actin cytoseleton is mediated via cortactin, actin polymerization nucealtion protein. Cortactin needs to 
be  deacetylated  for its function. Proper level of acetylation of HSP90 needs to be maintained for 
functional interaction to its cochaperone and client proteins. TSA inhibition of HDAC6 abolishes these 
functions. On the other hand, HDAC6 also functions as an adaptor. It binds to free mono-ubiquitin with 
high affinity and can regulate cellular pool of free ubiquitin. The other well described role of HDAC6 
is its interaction with polyubiquitylated misfolded proteins (via ZnF-UBP domain) and dynein. This 
helps in the clearance of misfolded proteins and aggressomes. 
 
Interestingly, HDAC6 also has cellular functions independent of its enzymatic 
activity. This is primarily by acting as an adaptor protein by virtue of its ability to 
bind to ubiquitin
162 and the motor protein dynein
168.  Upon misfolded protein stress,  
Introduction
 
  34 
HDAC6 simultaneously binds polyubiquitylated proteins through its ubiquitin binding 
zinc finger and dynein through a short stretch of amino acids adjacent to the second 
catalytic domain. It thus participates in the transport of cytotoxic aggregates to a 
single prominent juxtanuclear storage structure termed the aggresome
168. Additionally 
it is known that inhibition of the ubiquitin proteasome system (UPS) leads to the 
induction of an alternative degradative pathway called autophagy that removes protein 
aggregates. In an elegant fly model of neurodegeneration, in which UPS is inhibited, 
the induction of autophagy was demonstrated to be HDAC6 dependent. In fact, 
ectopic expression of HDAC6 alone was sufficient to prevent retinal degeneration in 
flies with impaired UPS
169. 
 Intriguingly, a recent report using microtubules (MTs) purified from Tetrahymena 
thermophila showed that the recruitment of the molecular motor kinesin-1 to MTs is 
dependent on acetylation of -tubulin K40. Acetylation of MTs also increased the 
motility of kinesin-1 on a lawn of MTs as measured by in vitro gliding assays.  This 
was found to be replicated also in vivo where acetylation induced by HDAC 
inhibition increased the proportion of neurites receiving the cargo through MT 
dependent transport
170.  These findings were further extended when acetylated MTs 
were shown to bind dynein more efficiently by Dompierre et al
171. Furthermore, it 
was demonstrated that acetylation stimulates anterograde transport of brain-derived 
neurotrophic factor (BDNF) containing vesicles in cortical neurons for secretion into 
the striatum. Using dual color live-cell imaging, GFP-BDNF is trafficked more slowly 
in cells expressing a non-acetylatable mCherry-tubulin K40R mutant compared to 
mCherry-tubulin wt.  Interestingly, postmortem staining of brains from patients who 
suffered from Huntington disease showed a dramatic decrease in acetylated MTs. It is 
important to note that MT based trafficking is known to be impaired in Huntington 
disease
172.  
 
1.4  Microtubule dependent intracellular trafficking 
 
Microtubules are long filamentous entities that are important for organelle trafficking 
and localization, cell motility, segregation of chromosomes during cell division and 
cytokinesis. Movement on MTs is relatively faster than on actin, and can occur over 
longer distances. The role of MTs in the endocytic pathway is well established. MTs  
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are essential for trafficking from early endosomes to late endosomes and hence for 
degradation of cargo
173-175. Importantly, the early internalization events are largely 
independent of MTs but are rather orchestrated by the actin cytoskeleton whereby 
small vesicles are propelled by a “comet tail” of F-actin
176, 177.  
The driving forces behind these cytoskeleton-based movements are the various 
molecular motor proteins. The three classes of motors - myosin, kinesin, and dynein 
derive energy from ATP hydrolysis and undergo conformational changes that 
generate a `step` on the cytoskeleton track
178. In order to carry cargo over long 
distances, motor proteins need to move on their tracks without dissociating, a feature 
known as processivity.  Classical processive motor proteins achieve this by acting as 
dimers; the monomers keep the ATPase cycles out-of-phase and when one is attached 
to the track the other is stepping towards the next binding site
178. 
 In endocytic trafficking, motor proteins are able to interact with the membrane of the 
organelle through the transmembrane cargo protein either directly or via adaptor 
proteins. For instance, some motors can bind to membrane lipids through their lipid 
binding plekstrin homology (PH) domains.  An example for the use of an adaptor 
protein is the dynein-dynactin complex that is the prime organizer for early to late 
endosome movement
179. 
An important property of motor proteins is directionality and the choice of 
cytoskeleton apparatus.  Myosins generally move along actin filaments whereas 
dyneins and kinesins use MTs
180. Although the picture is much more complicated 
than initially appeared, dyneins are generally credited for movement towards the 
slow-growing minus-end of MTs in the juxtanuclear microtubule-organizing center 
(MTOC). In contrast, members of the kinesin and myosin superfamilies can move to 
either the plus- or minus-end
178.  
 
1.5  Membrane based yeast two-hybrid screening (MYTH) 
 
Inspired by the revolution in molecular genetics of the last decades, understanding of 
the functions of proteins on a global scale, and not only as single molecules, is 
becoming a pressing issue. Similar to genomics, this nascent field of science (termed 
proteomics) owes its existence largely to advances in technology. Proteomics aims to 
systematically study protein expression, structure, modifications and protein-protein  
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interactions at a global level
181. The complexity of the study subject can encompass a 
signaling pathway, a macromolecular complex, a cellular organelle, a cell or even a 
whole tissue
182. Some of the tools in proteomics include mass spectrometry (MS), 
protein-protein interaction screening platforms and high throughput structural 
determinations
183. As expected, each technology has its own strength and limitation 
that must be taken into account when applying it to investigate a particular system.  
Protein-protein interaction studies have contributed immensely to the study of signal 
transduction pathways. One of the most versatile tools for this purpose is affinity 
purification followed by mass spectrometry. MS relies on the digestion of protein 
samples into peptides by sequence specific proteases such as trypsin followed by 
separation of these peptides by high-pressure liquid chromatography. Next, these 
peptides are injected into an ionizer forming highly charged peptides. The core of the 
MS, the mass analyzer then measures the mass to charge ratio, m/z and a detector 
determines the number of ions at each m/z value.  Further fragmentation by gas 
collision and measurement gives a tandem mass spectrum (MS/MS). The spectra 
generated are then matched against protein sequence database giving identity of the 
peptide and hence the proteins it is derived from
184.  
Other tools to study protein-protein interaction include array based formats like 
protein microarrays and yeast-two hybrid screens (YTH). YTH has been extensively 
used to screen protein-protein interactions since its development in 1989 by Stanley 
Fields and Ok-kyu Song
185. The investigators made use of GAL4, a yeast 
transcription factor (TF), whose DNA binding domain and transactivation domain can 
be separately fused to two independent proteins. A genetic readout is switched on 
only when these two proteins can locate to the nucleus, bind to each other and bring 
the two domains of GAL4 into such close proximity that they can activate expression 
of their target genes. Some of the important limitations of YTH are the high rate of 
false positives and the need for the interacting proteins-TF fusion to translocate to the 
nucleus to activate gene expression. Unfortunately, this precludes the use of a 
conventional YTH to identify interacting partners of integral membrane proteins. 
To circumvent this problem and study integral membrane proteins, a split-ubiquitin 
based modified membrane yeast two hybrid (MYTH) screening technique has been 
developed. The founding principle for this technique was one of the many seminal 
works of Alexander Varshavsky on ubiquitin
186. It was observed that ubiquitin can be  
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expressed in cells as two separate fragments, N-terminus (Nub, aa 1-34) and C-
terminus (Cub, aa 35-76), and that these fragments can spontaneously re-associate to 
form a “quasi-native ubiquitin”. Importantly, if Nub and Cub are fused to the C-
terminus of different proteins they can still associate with each other and this was 
sufficient for ubiquitin specific proteases to recognize the re-associated “ubiquitin” 
and cleave it off. However, when ubiquitin Ile13 was mutated to Gly in the Nub 
fragment (henceforth called NubG), NubG and Cub were not able to re-associate 
spontaneously. Importantly, when NubG and Cub were fused to proteins that interact 
with each other, the “quasi-native ubiquitin” entity was formed and can be cleaved 
off. Later on, Igor Stagljar and Stanley Fields developed a technique that could be 
used to screen for interaction partners of integral membrane proteins in the yeast 
Saccharomyces cerevisae
187.  
The central features of this technique are drawn in Figure  5. Cub and NubG were 
attached individually to two different transmembrane proteins and could validate that 
the two proteins interact with each other. The ubiquitin fragments need to be fused to 
the cytosolic part of the proteins as UBPs are exclusively found in the cytosol and not 
in the endoplasmic reticulum (ER) lumen. An artificial transcription factor (ATF) 
made up of a fusion of the bacterial LexA-DNA binding domain and the Herpes 
simplex VP16 transactivator domain was used. The cleaved ATF activates expression 
of HIS3 and LacZ reporter genes that incorporate LexA binding sequences in their 
promoters. HIS3 encoded expression of imidazoleglycerol-phosphate dehydratase (an 
enzyme involved in histidine synthesis) enables the yeast to grow in selective media 
lacking histidine while -galactosidase encoded by the LacZ gene gives the 
characteristics blue coloration upon exposure to the substrate X-Gal (5-bromo-4-
chloro--D-indolyl-galactopyranoside).  
It is important to note that at least one of the two interacting proteins should be 
anchored to a membrane to prevent translocation of the non-cleaved fusion protein to 
the nucleus and activation of reporter genes without any specific interaction. So far 
the MYTH has been used to screen for transmembrane proteins like ion channels, G-
protein coupled receptors, and membrane transporters
188-191.  
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Figure 5. Split-ubiquitin based membrane yeast--two-hybrid system. Membrane anchored bait 
protein is fused to Cub and LexA-VP16 artificial transcription factor. Prey could be either membrane 
bound or cytosolic fused to NubG. LexA operator sites in the promoter of reporter genes are 
unoccupied and no transcription is going on (left panel). If bait and prey interact in the extracellular, 
intra-membrane or cytoplasmic regions, NubG and Cub will get into enough proximity to permit 
reconstitution into “native “ ubiquitin. Ubiquitin specific proteases recognize this and cleave C-
terminus to it. The released transcription factor binds to LexA operator sites and activate expression of 
reporter genes like His3, ADE2 or lacZ (right panel). 
 
1.6  Related original work- a Cbl-CIN85 complex in EGFR endocytosis   

Before moving into the main topic of my thesis, I was involved in characterizing the 
formation of a complex of proteins necessary for the downregulation of EGFR. As 
described before, the ubiquitin ligase c-Cbl and its binding partner CIN85 are 
prominent regulators of the endocytosis of EGFR. The E3 ubiquitin ligase c-Cbl 
incorporates ubiquitin on select lysines in the cytoplasmic domain of EGFR. These 
ubiquitin moieties are recognized by ubiquitin binding domain containing proteins in 
the ESCRT complex
132. CIN85 is recruited to the EGFR complex after ligand induced 
activation by binding to c-Cbl. CIN85 is constitutively associated with the BAR 
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domain containing protein endophilin
192. Endophilin and closely related proteins like 
amphyphysin are important for bending of the plasma membrane
193. Hence, the 
complex initiated by c-Cbl acts at multiple levels of the downregulation of EGFR. c-
Cbl, through a proline rich region containing the PxxxPR motif interacts with the SH3 
domains of CIN85. CIN85 contains three SH3 domains, which are all capable of 
interacting with c-Cbl. It has thus been proposed that CIN85 can act as a scaffold to 
recruit c-Cbl molecules
124, 136.  
Together with our collaborators, Katrin Rittinger (London) and Jeronimo Bravo 
(Spain), we studied in detail the CIN85-Cbl interaction. In order to understand more 
about the complex formation between c-Cbl and CIN85, a peptide containing a 
PxxxPR motif of c-Cbl was co-crystallized with the first SH3 domain of CIN85. 
Interestingly, the Cbl peptide interacted simultaneously with two molecules of SH3 
domains. This was in sharp contrast to other PxxxP-SH3 domain interactions that 
occur in 1:1 ratio. The crystallographic observation was reproducible in solution. 
Additionally, the formation of a trimeric complex between two SH3 domains from 
CIN85 and Cbl was confirmed in vivo by using co-immunoprecipitation of 
differentially tagged SH3 domain and full length CIN85 with Cbl
137. In a similar 
fashion, a crystal structure of SH3 domain of a CIN85 related protein, CMS, was 
shown to interact with Cbl in a 2:1 stoichiometric ratio. Again, this was corroborated 
by in vivo work
194. The relevance of such a trimeric complex on downregulation of 
EGFR was analyzed by using Cbl mutants that selectively abolish formation of 
trimeric complex while keeping 1:1 binding. Both Cbl and CIN85 are able to homo-
dimerize.  
These two works identified crucial residues in Cbl that are involved in the formation 
of a large complex endocytic machinery that is important for efficient clearance of the 
receptor from the plasma membrane. In these two reports, I contributed to 
characterizing the interaction of Cbl and CIN85 or CMS in vivo. Taken together, the 
fact that Cbl can interact with two SH3 domains, and that CIN85 can bind more than 
one Cbl molecule via its three SH3 domains shows that a large complex of the two 
proteins can form. The precise composition of the complex in vivo is still not 
understood and should be investigated further.   
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1.7   Aims of the current study 
 
There are a number of proteomic investigations that described the list of proteins that 
interact with EGFR
195, 196. These studies have looked primarily at the activated 
receptor following ligand binding. However, to the best of our current knowledge, a 
systematic approach to identify proteins that bind to EGFR in the absence of ligand 
stimulation has not been reported. Interestingly there are isolated reports of proteins 
that interact with the inactive receptor. For instance, it is known that the zinc finger 
containing protein ZPR1 binds to EGFR in the absence of ligand but dissociates from 
the receptor and translocates to the nucleus upon ligand binding
197. 
Hence, one of the primary objectives of the current study is to identify the group of 
proteins that bind to EGFR in a ligand-independent manner using the MYTH 
screening system. Even though the MYTH has been used with success to study 
various transmembrane proteins, so far it has limited success with single pass TM 
proteins like RTKs. The lack of success is primarily due to problems with the proper 
folding of the bait receptor fusion protein and resulting degradation (unpublished 
personal communications with Igor Stagljar). 
Hence the first objective of the present study is to optimize the screening strategy. 
Next validation of putative interactors as true EGFR binders will be performed by 
one-to-one yeast retransformation, co-immunoprecipitation in mammalian cells and 
supporting bioinformatic analysis. Furthermore, this study also seeks to address the 
molecular functions of select binding partners on EGFR function. In as much as 
signaling by EGFR is important, its proper regulation is of paramount significance. 
Hence, the interplay between the putative interactor and EGFR will be studied in 
terms of effect on EGFR signaling, trafficking and degradation.  
Moreover, the influence of EGFR on the interactor will be investigated. This pertains 
primarily to the study of the phosphorylation status of the novel binder and to 
ascertain whether it is a target for the kinase activity of the receptor. 
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2. MATERIALS and METHODS 
2.1 MATERIALS 

2.1.1 Chemical compounds 
All chemicals were, unless otherwise stated, purchased from Roth (Karlsruhe, 
Germany), Sigma-Aldrich (Taufkirchen, Germany), Merck (Darmstadt, Germany) or 
Baker (Deventer, the Netherlands). 
Reagent Source 
Trichostatin A  Cell Signaling Technology (Beverly, MA 
USA) 
Cycloheximide  Sigma-Aldrich ((Taufkirchen, Germany) 
Taxol  Cytoskeleton Inc (Denver, CO, USA) 
Phenylmethylsulfonyl fluoride (PMSF)  Roth (Karlsruhe, Germany) 
Leupeptin  BioMol (Lörrach, Germany) 
Aprotinin Sigma-Aldrich 
Sodium vanadate  Sigma-Aldrich 
Bovine serum albumin (BSA)  Roth 
1,4-diazabicyclo (2,2,2) octan (DABCO)  Fluka (Neu-Ulm, Germany) 
Mounting medium  Biomeda (Foster city, CA, USA) 
Ampicillin Roth 
Kanamycin Roth 
 
2.1.2 Recombinant proteins and speciality reagents 
 
Reagent Source 
EGF (human, recombinant)  BD Biosciences  (Bedford, MA, 
USA) 
EGF-Alexa Fluor 488  Invitrogen (Karlsruhe, Germany) 
EGF-Alexa Fluor 555  Invitrogen 
GST-EGFR kinase domain (human, recombinant)  Abcam (Cambridge, UK) 
HDAC6 (human, recombinant)  BioMol  
Microtubules (bovine)  Cytoskeleton Inc.  
125I-EGF  (human,  recombinant)  Perkin Elmer  (Jügesheim,  
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Germany) 
Lyticase Sigma-Aldrich 
ProteinA- agarose beads  Santa Cruz Biotech (Santa Cruz, 
CA, USA) 
Mission shRNA lentivirus   Sigma-Aldrich 
Calf intestinal phosphatase  New England BioLabs (Ipswitch, 
MA, USA) 
Restriction enzymes  Fermentas (St.Leon-Rot, 
Germany) 
Pfu-Ultra polymerase  Roche (Mannheim, Germany) 
Pwo polymerase  Roche 
Precisionplus Dual stained protein marker  BioRad  (Richmond, CA, USA) 
 
Basic cell culture  
Reagent Source 
Dulbecco`s modified Eagle`s medium (DMEM)  Gibco, Invitrogen  
Fetal calf serum  PAA Laboratories (Austria 
Penicillin/Streptomycin Gibco, Invitrogen 
Trypsin Gibco, Invitrogen 
Puromycin Roth 
Geneticin Gibco, Invitrogen 
Lipofectamine Invitrogen 
FugeneHD Roche 
Effectene  Qiagen (Hilden, Germany) 
Kits  
Kit Source 
QIAfilter plasmid Mini kit  Qiagen  
QIAfilter plasmid MIDI kit  Qiagen 
QIAfilter plasmid MAXI kit  Qiagen 
Luminol chemiluminescence reagent  Santa Cruz Biotech (Santa Cruz, 
CA, USA) 
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2.1.3 Antibodies 
Primary antibodies 
Antibody Source 
species 
WB IP  IF  Supplier 
EGFR (RK2)  R  1:1000  1:100  -  Home-made 
EGFR (528)  M  -  1:100  1:50  Santa Cruz  
HDAC6 (227)  R  1:1000  1:100  1:100  Home-made 
HDAC6 (H-300)  R  1:1000  1:100  1:50  Santa Cruz  
Phospho-tyrosine (Py99)  R  1:1000  -  -  Santa Cruz  
Tubulin Acetyl-Lys40  M  1:1000  -  -  Sigma-Aldrich 
-tubulin M  1:1000  1:100  -  Sigma-Aldrich 
Acetyllysine M  1:1000  -  -  Cell  signalling 
technology 
Phospho-ERK1/2 M  1:500  -  -  Santa  Cruz   
ERK 1/2  R  1:1000  -  -  Santa Cruz  
Phospho-Akt-Ser473 R  1:500  -  -  Cell  signalling 
technology 
Akt R  1:1000  -  -  Cell  signalling 
technology 
Phospho-EGFR 
(Tyr1045) 
R 1:1000 -  -  Cell  signalling 
technology 
FLAG M2  M  1:10000  1:500  -  Sigma-Aldrich 
EEA1 R  -  -  1:100  Home-made 
LAMP1 M  -  -  1:100  Home-made 
Phospho-GSK3  Ser9 
 
 1:1000  - -  Cell  signalling 
technology 
Phospho-PTEN Ser380    1:1000  -  -  Cell signalling 
HA epitope tag  M  1:1000  1:100  -  Santa Cruz 
His epitope tag  R  1:2000  -  -  Santa Cruz 
MAP3K12 R  1:500  -  -  Abcam   
-adaptin M  1:1000  -  -  BD  Biosciences 
(San Diego, USA)  
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(M = mouse, R = rabbit, WB = Western blot, IF = Immunofluorescence, IP = 
Immunoprecipitation, HRP = horseradish peroxidase) 
 
Secondary antibodies 
Antibody Source 
species 
WB IF  Supplier 
Rabbit-HRP Goat  1:2000  -  Dako  (Glostrup, 
Denmark) 
Mouse-HRP Goat  1:5000  -  Dako 
Rabbit-Cy3 Goat  -  1:500  Jackson 
Immunoresearch 
(Suffolk, UK) 
Mouse-Cy5 Donkey  -  1:500  Jackson 
Immunoresearch  
Rabbit-FITC Goat  -  1:500  Jackson 
Immunoresearch  
 
2.1.4 Buffers, solutions and media for routine use 
 
Solution Composition 
SDS loading buffer  50mm TrisHcl, pH6.8,  
2% SDS,  
10% glycerol,  
0.1% bromophenolblue  
25mm DTT 
SDS running buffer  192mm glycine 
25mm Tris base 
0.1% SDS 
WB transfer buffer  192mM glycine 
25mM Tris 
20% methanol 
WB blocking solution  5%  BSA in 
1x TBS-Tween  
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TBS-Tween  10mM Tris, pH 7.4 
100mM NaCl 
0.05% Tween 20 
PBS 20mm  NaH2PO4, pH 7.4 
150mm NaCl 
Luria-Bertoni ( LB) media  10g/L tryptone 
5g/L yeast extract 
10g/L NaCl  
Z buffer (for X-gal test)  60mM Na2HPO4,  
40mM NaH2PO4, 
10mM KCl  
1mM MgSO4. 
 
Polyethyleneglycol (PEG)-lithium 
acetate master mix for yeast 
transformation per μg of DNA 
240μl 50% PEG-4000 
36μl 1M Lithium acetate 
50μl single strand DNA (2mg/ml) 
34μl ddH2O 
YPAD medium  20g/L peptone 
10g/L yeast extract 
18g/L agar (for plates) 
2% glucose 
Selective drop-out (SD) media   46.7g/L minimal SD agar base for plates 
or 46.7g/L minimal yeast nitrogen base + 
1.4g/L yeast synthetic drop-out media 
supplement (-His, -leu, -Trp,- Uracil as 
needed) 
 
2.1.5 Plasmids 
EGFR encoding plasmid in the pRK5 vector background was made in the lab of 
Joseph Schlessinger (Yale University, CT, USA). The plasmids, pcDNA3 FLAG-
HDAC6 wt and deletion mutants were kindly provided by Prof Tso-Pang Yao (Duke 
University, NC, USA). The yeast two-hybrid screen bait vector, MF pAMBV, and 
the prey library (human fetal brain cDNA) were from Dualsystems Biotech  
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(Schlieren, Switzerland). FKBP38-HA is a kind gift of Keiichi Nakayama (Kyushu 
University, Japan). mCherry-tubulin wt was received from Frederic Saudou (Institut 
Curie, Paris), under permission from the creator, Roger Tsien (University of 
California at San Diego, CA, USA).  
 
2.1.6 Oligonucleotides 
 
Primer name  Sequence 
MF pAMBV for  GCACAATATTTCAAGCTATACCAAGCATACAATCAA
CTCCAAGCAAAAATGAGATTTCCTTCAATTTTTACTG
CAG 
MF pAMBV rev  GCCACTGGTTCGGCCCGGGCGAGCGAGTTTGGCCTG
AATGGCCGGCTCTTTTATCCAAAGATACCCCTTCTTC 
HDAC6 S568E for 
 
AGTTCCAACTTTGACGAGATCTATATCTGCCCCAGT 
 
HDAC6 S568E rev 
 
ACTGGGGCAGATATAGATCTCGTCAAAGTTGGAACT 
 
HDAC6 S568A for 
 
AGTTCCAACTTTGACGCCATCTATATCTGCCCCAGT 
 
HDAC6 S568A rev 
 
ACTGGGGCAGATATAGATGGCGTCAAAGTTGGAACT 
 
HDAC6 Y570E for 
 
AACTTTGACTCCATCGAGATCTGCCCCAGTACC 
 
HDAC6 Y570E rev 
 
GGTACTGGGGCAGATCTCGATGGAGTCAAAGTT 
 
HDAC6 Y570F for 
 
AACTTTGACTCCATCTTTATCTGCCCCAGTACC 
 
HDAC6 Y570F rev 
 
GGTACTGGGGCAGATAAAGATGGAGTCAAAGTT 
 
 
2.1.7 Cell lines, bacterial and yeast strains 
The E.coli strain DH5 is from Invitrogen (Karlsruhe, Germany) and E.coli BL21 is 
from Promega (Madison, WI, USA). The S.cerevisea  strain  THY.AP40 is from 
Dualsystems Biotech (Schlieren, Switzerland). The cell lines used in the study, 
HEK293T, HeLa, A549 and A431 are derived from American Type Culture 
Collection (ATCC) in Rockville, MD, USA.  
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2.2 METHODS 
 
2.2.1 Basic molecular biology techniques 
 
2.2.1.1 Plasmid DNA transformation into E.coli 
Plasmid DNA was transformed into competent E.coli strain DH5 by heat-shock 
treatment. Basically, 1μl of a 0.1μg/μl solution of DNA was incubated with freshly 
thawed bacteria for 15 minutes on ice, heat-shocked at 42
oC for 45 seconds and 
chilled on ice for 2 minutes. 250μl of LB media added to the bacteria that were then 
incubated at 37
 oC for one hour and plated on LB+Agar plates containing respective 
antibiotic (100μg/ml Ampicillin or 25μg/ml kanamycin). Twelve to sixteen hours 
later, bacterial colonies were picked and inoculated into desired amount of LB media 
with antibiotic. 
 
2.2.1.2 Plasmid DNA extraction from bacteria 
Plasmid purifications were done using Qiagen Miniprep or Midiprep kits. For 
minipreps for instance, an overnight culture of DH5 was spun down at 4000g and 
resuspended in 250μl of resuspension buffer (50mM TrisHCl, pH 8.0, 10mM EDTA, 
100  μg/ml RNase A). Bacteria were then lysed in 250μl of lysis buffer (200mM 
NaOH, 1% SDS) and neutralized with 350μl of 3M potassium acetate at pH 5.5. 
Precipitate was removed by centrifugation at 13,000g and supernatant loaded onto 
DNA binding columns. Columns were washed with    and ethanol. Finally, DNA is 
eluted with 10mM TrisHCl, pH 8.0, 1mM EDTA). 
 
2.2.1.3 Plasmid DNA transformation into S.cerevisae using the lithium acetate 
method 
A single colony of yeast strain is inoculated into 5ml of YPAD media and grown 
overnight at 30
0C with shaking. Next day, the optical density was measured at 600nm 
(OD600) and diluted with appropriate amount of liquid YPAD media to reach final 
OD600 of 0.3. The yeast are then grown to an OD600 of 0.8, pelleted at 700g, then 
resuspended and washed in 10ml of sterile 1xTE, pH 8.0 (10mM Tris, 1mM EDTA). 
Yeast were pelleted again at 700g and resuspended in sterile H2O in such a volume 
that each transformation will utilize 2ml of culture. 300μl of PEG-lithium acetate  
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master mix is then added to each transformation mix. 50μl of yeast are added to the 
transformation mix and vortexed vigorously for 1 min. Yeast are then heat-shocked at 
42
0C for 15 min, pelleted at 700g, resuspended in 100μl H2O and plated onto SD-Leu 
plate (for bait transformation) or SD-Trp (for prey transformation). Plates are 
incubated for 2-4 days at 30
0C to monitor growth. 
 
2.2.1.4 Plasmid DNA extraction from yeast- the lyticase approach 
5ml of yeast grown in liquid SD-Leu or SD-Trp media are pelleted at 4000g and 
resuspended in 30μl lyticase solution (in 0.9M sorbitol, 10mM TrisHCl pH 8, 0.1mM 
EDTA, 4,5 units/μl) and incubated at 37
0C for 1hr. Then 200μl yeast lysis buffer (2% 
TritonX-100, 1%SDS, 100mM NaCl, 10mM TrisCl pH8 and 1mM EDTA) added. 
After 5min, mixture centrifuged 12,000gfor 15min and supernatant loaded onto DNA 
binding columns of Qiagen Miniprep. The rest done basically as described for 
plasmid DNA isolation from bacteria. 
 
2.2.1.5 Site-directed mutagenesis 
C-terminal deletion constructs of pcDNA3-FLAG-HDAC6 and other point mutations 
were generated by site-directed mutagenesis using the specific character of the 
restriction enzyme DpnI to cleave only the methylated template DNA produced in 
bacteria. Basically, an oligonucleotide pair containing the desired nucleotide 
substitution is used as a primer set to amplify the template plasmid in a 50μl reaction 
volume with the high-fidelity polymerase, Ultra-Pfu. Later, the reaction mixture is 
incubated with 1μl of the enzyme DpnI and 10μl was transformed into competent 
DH5 bacteria. Colonies surviving on plates with appropriate antibiotics were used to 
purify plasmids that were sequenced to confirm the successful introduction of the 
desired mutations. 
 
2.2.1.6 PCR amplification and restriction digestion of DNA  
PCR reactions for amplification of cDNAs were performed in a Biometra 
thermocycler using Pfu or Pwo DNA polymerases. Typical conditions include 15ng of 
template, 10pmol of sense and antisense primers with 1μl of dNTPs, 5μl of PCR 
reaction buffer, 0.5μl enzyme to a final volume of 50μl. Restriction digestion of  
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plasmid DNA was performed in 25μl volume using diluted DNA with buffer and 
temperature as suggested by the manufacturer. 
 
2.2.1.7 Preparation of MF-EGFR-C-T construct  
MF-EGFR-C-T construct was generated by in vivo recombination in yeast. Briefly, 
cDNA encoding human EGFR was amplified by PCR with 60-mer primers having 5` 
ends (40 nucleotides) that are identical to the vector, thus allowing cloning into the 
vector by homologous recombination in yeast, and 3` 20 nucleotides specific to 
EGFR. Primers were designed in such a way that they amplify EGFR starting only 
from amino acid 25, and thus exclude the signal peptide. The PCR product and an 
empty and HindIII linearized MF pAMBV vector were then transformed into the 
yeast strain THY.AP40. The yeast directs the homologous recombination and gap 
repair, resulting in the MF-EGFR-C-T bait construct that imparts growth in selective 
media lacking leucine. Further confirmation of successful generation of bait construct 
was tested by colony PCR, where a loop full of yeast colony was boiled in PCR 
reaction solution and amplified with primers recognizing vector and bait.  
 
2.2.2 Membrane-based yeast two-hybrid screen 
 For this screen the yeast reporter strain THY.AP40 (MATa trp1 leu2 his3 
LYS2::lexA-HIS3
 URA3::lexA-lacZ)  was used. This strain has its trp, leu and his 
genes deleted and substituted with LYS2,  HIS3 and lacZ under control of lexA 
responsive promoter elements. For the large-scale screen, THY.AP40 was 
transformed with 1.5μg of the plasmid construct MF-EGFR-C-T bait using the 
lithium
  acetate protocol to generate the bait-strain. Later, this bait strain was 
transformed with 28 μg of prey library using the above mentioned transformation 
protocol. The prey library was derived from fetal brain cDNA library and is fused C-
terminally to NubG (NubG-X orientation).  
Yeast were streaked on 30, 15cm plates containing highly selective media (SD Leu
-
Trp
-His
-Ade
-) with 5 mM 3-aminotriazole
  (3-AT). Transformation efficiency was 
measured by streaking serially diluted amounts on SD Leu
-Trp
-  medium and was 
about 3 x 10
6 TRP
+ LEU
+ transformants.
 After 5 days of growth at 30
0C a total of 300 
colonies were picked and transferred to SD Leu
-Trp
-His
-Ade
- and
 SD Leu
-Trp
- plates. 
The yeast growing on SD Leu
-Trp
-  plates were tested for activation of the lacZ  
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reporter (-galactosidase) by X-gal filter lift-off assay. A 3MM Whatmann filter 
paper is layed on top of yeast growing on a plate. Yeast are “lifted-off” onto the filter 
paper which is briefly immersed in liquid nitrogen. The filter paper is then put in a 
plate and carefully covered with X-gal substrate solution. This is composed of Z-
buffer, 0.3mg/ml X-Gal (20mg/ml stock diluted in Dimethylformamide) and 0.27% -
mercaptoethanol. Development of blue colour on the Whatmann paper up to 8 hrs was 
scored as positive. 
Of the 300 colonies picked, 295 turned positive on X-gal test and also grew on SD 
Leu
-Trp
-His
-Ade
-. Plasmid DNA was extracted from all “positives” using the lyticase 
method. As plasmid DNA isolated from these yeast is of low quality and quantity, one 
more round of amplification was done by transforming into E. coli DH5  using 
standard protocols.  
These library plasmids
 were individually retransformed into THY.AP40 expressing 
EGFR-C-T, TFRC-C-T or empty bait vector for the so-called “one-to-one” test. The 
transformants were again analysed for the activation of the lacZ reporter by X-gal 
filter lift-off assay and growth on SD Leu
-Trp
-His
-Ade
- plates. Plasmids that activated 
the
 HIS3 and lacZ reporters in combination with the EGFR-C-T bait were selected
 for 
sequencing and further studies. 
 
2.2.3 Cell culture methods 
 
2.2.3.1 Cultivation of mammalian cells 
Mammalian cells were grown in an incubator (Heraeus) with 5% CO2, 95% humidity 
at 37
0C. All the cells used in the study were grown in Dulbecco`s Modified Eagle 
Medium (DMEM) with 4.5g/l glucose, supplemented with 10% fetal calf serum, 5μg/l 
penicillin and 5mg/l streptomycin. Cell passage was facilitated by trypsinization  (2-
3min, 37
0C) with 0.05% (w/v) trypsin, 0.53mM EDTA in PBS. Growth media for 
A549 cells stably expressing HDAC6 shRNA is supplemented with puromycin 
(3μg/ml) and A431 cells expressing GFP-Rab5 with G418. 
 
2.2.3.2 Transfection of mammalian cells 
The transfection reagents used are Lipofectamine (Invitrogen) for HEK293T cells, 
Effectene (Qiagene) for HeLa and FugeneHD (Roche) for A549 cells. Briefly,  
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3x10
5 cells were seeded in each well of a 6-well dish one day before transfection. 
Plasmid DNA (from 0.1μg to 1μg) was diluted in serum free DMEM and then mixed 
with recommended amount of transfection reagent. Generally, 3μl of Lipofectamine 
or FugeneHD and 8μl of Effectene enhancer with 15μl of Effectene were used 
per 1μg of DNA. After 20min incubation, the DNA/reagent complex was added drop-
wise onto cells. Adequate expression of desired protein was achieved within 24 hours. 
 
2.2.3.3 Lentivirus transduction and stable shRNA expression cell line generation 
Mission Lentivirus transduction particles expressing four different shRNA 
sequences targeting the coding sequence of human HDAC6 and one shRNA against 
the 3`untranslated region (UTR) in the vector bacbone of pLKO.1-PURO were 
purchased from Sigma. These sequences were selected by a proprietary algorithm 
developed by the supplier and detailed information is sadly unavailable. Viral 
particles with shRNA sequence non-existent in the human genome were used as 
negative control. A549 cells were seeded in 24-well format and 24 hours later 
hexadimethrine bromide added to final concentration of 8μg/ml to increase 
transduction efficiency. Viral particles were added at 5, 10 and 20 multiplicity of 
infection (MOI). 72 hours later cell lysates were analysed for expression of HDAC6. 
However this transient transduction resulted in only minor knockdown of HDAC6. 
Hence, the experiment was repeated and 48 hours after transduction, puromycin 
(3μg/ml) was added to select for stable clones. After two weeks of propagation in 
selective media, cell lysates were prepared and tested for expression of HDAC6 by 
immunoblotting. Only one shRNA sequence transduced at 20 MOI resulted in marked 
knockdown, two in moderate knockdown of HDAC6 whereas the two other sequences 
failed to suppress expression of HDAC6.  
 
2.2.3.4 Real time cell analysis (RTCA) 
The real time cell analysis (RTCA) from Roche was made possible by the xCelligence 
device that uses electrodes to detect minor perturbations in current flow caused by 
cells. A549 parental and knockdown cells were seeded in the provided gold coated 
96-wells at 1250, 2500, 5000, 10000 and 20000 cells per well in DMEM with only 
0.3% fetal calf serum. After 16 hours, EGF (100ng/ml) was added and cells were  
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continually monitored for change in cell index (representing cell attachment or 
number) for 72 hours.  
 
2.2.4 Biochemical assays 
 
2.2.4.1 SDS-PAGE and Western blot 

Separation of proteins in one dimension by electrophoresis was performed essentially 
according to standard protocols in 5-15% SDS polyacrylamid gels with 1mm 
thickness. Vertical mini-Protean system (BioRad, Munich) was used in running 
buffer (25mM Tris, 250mM glycine pH 8.3, 0.1% SDS), at low constant 80V 
(initially, for the stacking gel) and 120V (for separation gel). Gels were then either 
stained with Comassie brillian blue R250/G250 or electroblotted using the wet system 
onto nitrocellulose membranes (0.45μm pore-size). Transfer was done at 200mA 
constant current for 60 to 120 min in transfer buffer (25mM Tris, 192mM glycine, 
20% methanol, freshly added). Nitrocellulose membranes were stained with Ponceau 
S to assess transfer quality and blocked in blocking buffer (5% BSA in TBS-Tween) 
for 2 hours at room temperature or overnight at 4
0C. Blots were incubated with 
primary antibody in 5% BSA for 1 hour room temperature or overnight at 4
0C and 
then washed four times in TBS-Tween or Tx100, 10 min each. Afterwards, species-
specific Horseradish peroxidase (HRP) conjugated secondary antibody was added in 
5% milk in TBS-Tween for 40 min at room temperature. Blots were again washed 
four times in TBS-Tween or TBS-Tx100. Bound antibody was visualized by 
chemiluminescence using Western Blotting Luminol reagent (Santa Cruz), whereby 
an iridescent light is emitted during oxidation of luminol by HRP.  
When re-probing with additional set of antibodies is required, blots were stripped of 
primary and secondary antibodies by incubating in 0.2M NaOH solution for 10 min. 
 
2.2.4.2 Immunoprecipitation 
HEK293T cells were transfected with the needed constructs. After 24 to 48 hours, 
cells were lysed for 20 min on ice in lysis buffer (50 mM HEPES, 150 mM NaCl, 1 
mM EDTA, 1 mM EGTA, 10% glycerol, 1% Triton-X-100, 25 mM NaF, 10  M 
ZnCl2, pH 7.5) containing protease inhibitors (2μg/ml aprotinin, 1μg/ml leupeptin, 
and 1mM PMSF) and the phosphatase inhibitor sodium vanadate. Cell lysates were  
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collected, centrifuged for 15 min (13,000 x g) to remove the insoluble fraction. 
Supernatant was incubated with the respective antibodies for 2 to 4 h at +4 °C 
followed by 1 hr incubation with 20μl of ProtA-Sepharose beads. The sepharose 
matrix was then washed three times either with RIPA buffer (50 mM TrisCl pH 7.4, 
150 mM NaCl, 2 mM EDTA, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS plus 
inhibitors) or with lysis buffer depending on downstream application. The final wash 
was removed via insulin needle to minimize loss of beads, which were then boiled in 
SDS loading buffer. The immunoprecipitated proteins were analysed by SDS-PAGE 
and immunoblotting using antibodies against other proteins to determine co-
immunoprecipitation or with the antibody used for immunoprecipitation. 
To detect acetylation, cells were treated with trichostatin A (TSA, 1μM) for 2-4 hrs to 
inhibit deacetylases, lysed, and immunoprecipitation was performed with the antibody 
against the protein of interest followed by immunoblotting with acetyllysine specific 
antibody.  
 
2.2.4.3 GST-GATE16 purification and GST pull down assay 
GST-GATE16 expressing plasmid was transformed into E.coli BL21 strain which 
were inoculated into 20 ml starter LB media with ampicillin overnight. Next day, the 
starter culture was used to inoculate 500ml media, and bacteria were induced at OD of 
0.4 with 0.5mM IPTG. After 4 hours of growth, bacteria were spun down, washed in 
chilled PBS and frozen in -20
0C. They were thawed in buffer 1 (20mM Tris-HCl, pH 
7.5, 10mM EDTA, 5mM EGTA, 150mM NaCl, 1mM PMSF, 0.1% -
mercaptoethanol), and broken by sonication. After centrifugation at 10,000g, 
supernatant was incubated with 500μl glutathione beads for 90 min at 4
0C. The beads 
were then washed with buffer 2 (buffer 1 plus 0.05% triton X100) to remove unbound 
proteins and resuspended in buffer 3 (20mM Tris-HCl, pH 7.5, 0.1% NaN3). Purity 
was assessed by running 5 to 10μl of sample on SDS-PAGE and staining with 
Comassie. 10μl of beads bound to GST-GATE16 or GST were incubated with A431 
cell lysates and washed in cell lysis buffer. Beads were boiled in SDS loading buffer, 
loaded on SDS-PAGE and Western probing done with EGFR antibody to detect if 
EGFR is pulled down specifically by GST-GATE16. 
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2.2.4.4 In vitro kinase assay 
Recombinant full length human HDAC6 expressed and purified from Sf9 insect cells 
and GST-EGFR kinase domain were purchased from Biomol and Abcam 
respectively. An in vitro kinase assay was setup in kinase assay buffer (8mM MOPS, 
pH 7.0, 0.2mM EDTA, 10mM MnCl2, 0.8M ammonium sulfate). Typical reactions 
(total volume 50μl) included 4μM of HDAC6, 2 to 20nM of EGFR kinase domain, 
100μM ATP, incubated for 30 min at 30
0C. Control reactions were set up by 
eliminating ATP, EGFR or HDAC6. Reaction was stopped by boiling in SDS loading 
buffer and run on SDS-PAGE. Immunoblotting using phosphotyrosine (Py99, Santa 
Cruz) was used to detect presence of phosphorylated tyrosine residues. 
 
2.2.4.5 Deacetylase assay 
2x10
6 HEK293T cells were seed into 10cm plates and transfected with 5FLAG-
HDAC6. A day later, cells were lysed in 1ml of mammalian cell lysis buffer. FLAG-
HDAC6 was immunoprecipitated by 4  M2-FLAG antibody followed by 
stringent washing in lysis buffer. While HDAC6 was still bound to ProteinA-
sepharose beads, calf interstinal phosphatase was added in PIPES buffer (5mM PIPES 
pH 8.0, 85mM KCl), and washed away after incubation for 1 hr at 37
oC. Taxol 
stabilized microtubules (50 g) were then added to the beads in 10 mM Tris-HCl, pH 
8, 10 mM NaCl buffer and incubated for 2 h at 37
oC and chilled for 15 min on ice. 
Subsequently, the reaction mixtures were spun down, beads and supernatant 
separated, boiled in SDS loading buffer and subjected to western blot. Probing is done 
with HDAC6 antibody for the bead fraction and with acetyllysine antibody against the 
supernatant where free  and -tubulin dimers are located. 
 
2.2.4.6 Ligand induced EGFR degradation 
3x10
5 A549 cells were seeded in each well of a 6-well dish. 24 hours later, they were 
transfected with 1μg of FLAG-HDAC6, deacetylase dead HDAC6 or HDAC6 
deltaHEBD constructs. A day later, serum starvation started by growing the cells in 
DMEM supplemented with 0.3% fetal calf serum. After 16 hours, cells were pre-
treated with cycloheximide (40g/ml) for two hours and then stimulated with EGF 
(100ng/ml) for 0, 20, 40, 60, 120 or 180 minutes. Cells were lysed and centrifuged.  
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Total protein concentration of the supernatant was measured by a nano-
spectrophotometer (Implen) at 280nm wavelength, and 30μg of protein loaded per 
lane in an SDS-PAGE. Total cellular levels of EGFR were then probed by EGFR 
antibody. 
 
2.2.4.7 EGFR internalization assay using 
125I-labelled EGF 
 as performed and described by Mirko Schmidt, Edinger Institute of Neurology, 
Goethe universitaet Frankfurt 
 Chinese hamster ovary (CHO) cells were transiently transfected with EGFR together 
with wt or deacetylase dead HDAC6 constructs or with GFP vector as a negative 
control. Forty-eight hours later, 50 ng/ml EGF was added to induce receptor 
trafficking at 37°C for 10, 20, 30 and 60 min and transferred on ice. Subsequently, the 
amount of EGFR molecules still left at the cell surface was determined by removal of 
receptor bound EGF by mild acidic treatment and incubation with 1ng/ml 
125I-labelled 
EGF for 1.5 hours. Following vigorous washing, cells were lysed and samples 
analyzed with a gamma-counter (1470 Wizard, Perkin Elmer). The percentage of 
surface receptor was calculated by comparison to samples challenged with EGF on ice 
only. 
 
2.2.4.8 Mass spectrometry sample preparation 
1x10
7 A549 cells were grown in 15cm dishes, serum starved for 16 hours and left 
untreated or stimulated with EGF (100ng/ml) for 30 min. Cells were lysed and 
immunoprecipitation done using -tubulin antibody. Samples were run on SDS-
PAGE, Comassie stained and a band corresponding to tubulin was cut out. Similarly, 
FLAG-HDAC6 was transfected in HeLa cells, immunoprecipitated from lysates, run 
on an SDS-PAGE, Comassie stained and bands corresponding to estimated size were 
cut of of the gel and subjected to mass spectrometry to identify phosphorylated 
residues.  
(Mass spectrometric analysis - as performed and described by Blagoy Blagoev, 
University of Southern Denmark, Odense, Denmark)- Tubulin containing gel bands 
were cut out from the SDS-PAGE and subjected to reduction and alkylation with 10 
mM dithiothreitol and 55 mM iodoacetamide (Sigma–Aldrich), respectively. Bands 
were subsequently washed with 50 mM ammonium bicarbonate and in-gel digested  
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with endoproteinase Asp-N (Roche, Penzberg, Germany) for 16 h at 37°C. Samples 
were analyzed by online C18-reverse-phase nanoscale liquid chromatography tandem 
mass spectrometry essentially as described. Briefly, analysis were preformed on an 
Agilent 1200 nanoflow system (Agilent Technologies, Boeblingen, Germany) 
connected to a LTQ-Oribitrap XL (ThermoFisher, Bremen, Germany) equipped with 
a nanoelectrospray ion source (Proxeon Biosystems, Odense, Denmark). The MS/MS 
spectra were centroided and searched with Mascot (MatrixScience, London, UK) 
against the human IPI protein database. Search parameters included mass tolerance of 
6 ppm for peptides and 0.6 Da for fragments, Carbamidomethyl (C) as fixed 
modification and Oxidation (M) and Acetyl (K) as variable modifications. The 
intensities of the acetylated Lys40-containing peptide derived from the non-stimulated 
and EGF stimulated cells were used to calculate a ratio reflecting the relative levels of 
Lys40 acetylation between the two samples. The intensity ratios of seven distinct non-
modified Tubulin peptides were used for normalization. 
 
2.2.5 Cell imaging studies 
 
2.2.5.1 Immunofluorescence microscopy 
1x10
5A549 cells (parental and HDAC6 knockdown) were grown on cover slips for 
one day before starting starvation by changing media to DMEM with only 0.3% 
serum. After 16 hours, cells were pulsed with Alexa488-EGF (100 μg/ml) for 30 sec 
and chased for 0, 1, 2, 3, 5, 7, 10, 20, 30, and 60 min with unlabelled EGF. Cells were 
fixed with 4% paraformaldehyde for 15 minutes and permeabilised for 10 minutes in 
permeabilization and blocking buffer (0.1% saponin w/v, 0.2% gelatin w/v, 0.02% 
sodium azide, 5mg/ml BSA). Cells were then incubated with EEA1 and LAMP1 
primary antibodies in saponin/gelatin buffer (0.01% saponin w/v, 0.2% gelatin w/v, 
0.02% sodium azide) for one hour. After three, five-minute washes with PBS; 
secondary antibodies (Cy3 anti-rabbit, Cy5 anti-mouse) in saponin/gelatin buffer were 
added and incubated in the dark for one hour. Following washing steps as above, 
DAPI (1:1000) was added and coverslips were mounted in Dabco/Moviol mounting 
media. Four channel images (EGF- channel 488, EEA1- channel 563, LAMP1- 
channel 668, Nucleus- UV channel) with Z-stacks were taken by Carl-Zeiss 510 UV 
confocal microscope. All cover slips were imaged at the same laser output and in a  
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single batch to minimize laser fluctuations, with at least 10 representative fields 
having a minimum of 10 cells per experimental point. After image acquisition, with 
the help of manual inspection parameters and cut-off points for MotionTracker® 
program were determined. All images were then analysed by the software for 
position, size, signal intensity and overlap. The data generated was fed into the 
Supercomputer service at the Technical University of Dresden for data crunching. 
Afterwards, desired parameters were statistically analysed and graphed by the in-built 
application in MotionTracker®. 
 
2.2.5.2 Live cell imaging 
1x10
5A431 cells stably expressing GFP-Rab5 were seeded in glass bottom dishes. 
One day later, they were transfected with 100ng of plasmid encoding mCherry-tubulin 
wt or the dominant negative mCherry-tubulin K40A. 24 hours later, cells were imaged 
in a live cell chamber (CO2 and temperature regulated). Imaging was done using a 
custom assembled microscope at the Max-Planck-Institute for Cell Biology and 
Genetics in Dresden, Germany. The microscope uses spinning-disc technology for 
laser beam focusing and connected with a high-speed camera for image acquisition. 
Cells were imaged for 5 minutes (4 images per Z-stack, 2 stacks per second). Z stacks 
were collapsed by maximum projection and minimum of 10 cells were followed for 
each experimental condition. Individual endosomes were identified and tracked for 
the duration of the imaging. Fluorescence tracing with intensity were quantified for 
individual GFP-Rab5 endosomes by MotionTrack® software. Statistical analysis was 
done to arrive at cumulative average speed and processive movement of vesicles 
essentially as in Rink et al. 
 
2.2.6 Bioinformatic analyses  
(detailed analysis by Igor Jurisica, University of Toronto, Toronto, Canada) 
All proteins from MYTH screen were mapped into SwissProt identifiers, and 
integrated with protein-protein interactions (PPIs) in Interologous Interaction 
Database (I
2D) version 1.71 (http://ophid.utoronto.ca/i2d).  Mapping was done using 
the source databases: the International Protein Index version 3.36 (IPI, 
http://www.ebi.ac.uk/IPI/), SwissProt version 51.5, Unigene Hs.208, and Entrez Gene 
2007-02-08.  Interactions in I
2D integrate interactions from human curated sources, 
high-throughput mammalian experiments, and predicted PPIs using orthologs from  
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model organism protein interaction data sets, as previously described 
198, 199. 
Computational evidence provided support to the experimentally-derived PPIs using 
the following procedure, performed essentially as previously described 
198.  First, a 
domain-domain co-occurrence matrix was constructed by extracting all InterPro 
domains from UniProt version 9.5, and enumerating the number of times each domain 
pair occurs between proteins known to interact, or those that have not been 
experimentally demonstrated to interact.  Domain pairs that occur more frequently 
between interacting proteins were identified using the hypergeometric distribution 
with a Bonferroni-corrected alpha level of 0.05.  The resulting domain-domain co-
occurrence set included 10,391 domain pairs significantly enriched in known human 
PPIs.  Second, gene co-expression was calculated using the Pearson correlation 
between genes encoding the interacting proteins from the GeneAtlas expression 
compendium 
200, which profiles gene expression on 79 human tissues.  Finally, 
functional similarity was computed for all PPIs using Gene Ontology (GO) 
annotations 
201.  Briefly, GO terms were retrieved from the UniProt database (version 
9.5) for each of the interacting proteins, and the semantic similarity 
202 was computed.   
  In order to establish a threshold above which the aforementioned evidence was 
statistically significant, 65,535 random protein pairs were selected from the set of 
proteins that comprise the known human interactome.  Each evidence type was 
computed for every random protein pair, and the threshold for statistical significance 
was derived from the 95% confidence interval of the resulting distributions. 
Protein-protein interaction network was visualized using NaViGATor ver. 2.02 
(http://ophid.utoronto.ca/navigator).  
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3. RESULTS 
 
3.1  MYTH based screening of ligand-unoccupied EGFR. 
 
3.1.1 Generation of bait EGFR-Cub-TF construct 
 
The first step in any yeast two-hybrid screen is the generation of a suitable bait 
construct expressing the desired protein fused in-frame with the appropriate 
transcription factor. For this study the full length human EGFR was initially fused to 
the Cub-TF moiety that comprises of the C-terminus of ubiquitin plus an artificial 
transcription factor composed of the DNA binding domain of LexA and the 
transactivation domain of VP16. Unfortunately, expression of this fusion protein in 
yeast caused a strong self-activation phenotype and the protein was markedly 
degraded in vivo (Fig. 6B and 6C) rendering it unsuitable for screening purposes. 
Therefore, a modification was necessary. In order to facilitate insertion of the 
heterologous human protein into yeast membrane, the signal peptide of human EGFR 
(comprising aa 1-24) was deleted and substituted with the first 85 amino acids of the 
yeast mating factor  (MF) pheromone followed by the Cub-TF fragment (Fig. 6A). 
Subsequently, various experiments were undertaken to verify transformation, 
expression and localization of the bait protein in yeast.  
Immunoblotting analysis using crude protein extracts from the yeast strains showed 
that a major single band representing the MF-EGFR-C-T fusion protein at 
approximately 180 kDa is seen (Fig. 6B, lane 3), but not in the case of the full length 
receptor fusion protein, EGFR-C-T (Fig 6B, lane 2) showing it is a stable protein. 
Next a genetic assay was done to ensure that the MF-EGFR-C-T bait protein is 
properly inserted into the membrane (the so-called NubI test) and not self-activated 
(NubG test) 
188, 189. For this purpose, the MF-EGFR-C-T bait was analyzed in the 
presence of two non-interacting yeast integral membrane proteins, the ER membrane 
protein Ost1p and the plasma membrane protein Fur4p, fused to either NubI (Ost1-
NubI and Fur4-NubI) or NubG (Ost1-NubG and Fur4-NubG) (Fig. 7A). The 
constructs Ost1-NubI and Fur4-NubI are designed to activate the yeast reporter 
system constitutively (positive controls) because of the high affinity of NubI to 
associate with Cub into active ubiquitin irrespective of a protein-protein interaction
187.   
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Figure 6. MF-EGFR-C-T is a stable and  non-self-activating bait for use in MYTH screens.  
(A) Design of the EGFR bait construct for MYTH screening. The EGFR-C-T construct encodes its 
endogenous signal sequence and the full-length EGFR protein (aa 1-1195) fused at the C-terminus to 
Cub-TF (C-T). The second construct, MF-EGFR-C-T, was modified to include the yeast mating 
factor  pheromone precursor (MF) signal sequence (aa 1-85) and amino acids 25 through 1195 of 
the EGFR protein fused at the C-terminus to C-T. (B) Western blot of total protein of yeast THY.AP4 
cells transformed with empty bait vector (pMF-AMBV.4, lane 1), the EGFR-C-T construct (lane 2), 
or the MF-EGFR-C-T construct (lane 3), probed with an -VP16 polyclonal antibody. (*) in lanes 1-3 
indicate the presence of unspecific proteins. (C)  Self-activation test for the EGFR bait constructs. 
THY.AP4 cells were transformed with a positive control vector (pLexA-VP16) and the two EGFR bait 
constructs, EGFR-C-T and MF-EGFR-C-T. Yeast were grown on SD-Leu and Xgal plates. MF-
EGFR-C-T construct is not self-activating.  
 
 
The MF-EGFR-C-T bait protein showed a positive signal in the presence of both 
NubI membrane protein fusions, indicating that it is properly inserted into the ER and 
plasma membranes. On the other hand, expression of the MF-EGFR-C-T bait fusion 
with the non interacting Ost1-NubG and Fur4-NubG protein fusions (negative 
controls) did not lead to activation of the reporter system, showing that the MF-
EGFR-C-T bait is not self-activating (Fig. 7A).   
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Furthermore, membrane targeting of the MF-EGFR-C-T bait was analyzed in yeast 
lysates after sequential high-speed centrifugations. The endogenous yeast ER 
membrane protein Wbp1p and a cytosolic Gpd1p were included in this assay to 
validate the cell fractionation procedure. As shown in the Fig. 7B, the MF-EGFR-C-
T bait was found exclusively in the membrane and not in the cytosolic fraction of 
yeast lysates. Another important parameter checked was whether the expressed MF-
EGFR-C-T is phosphorylated on tyrosine residues and thus activated. By using anti-
phosphotyrosine antibodies, the EGFR or other yeast proteins were not detected to be 
tyrosine phosphorylated in yeast lysates expressing MF-EGFR-C-T bait (Fig. 7C). 
In summary, the results of these biochemical and genetic experiments strongly 
suggest that the above-mentioned N-terminal modification of the human EGFR yields 
a non-phosphorylated EGFR-C-T bait protein that is properly inserted into the yeast 
membrane, thereby minimizing its self-activation problems. Furthermore, MF-
EGFR-C-T bait localization was analyzed by immunofluorescence and was found 
predominantly in the plasma membrane of yeast cells (Fig. 7D).  
 
3.1.2 MYTH screening using MF-EGFR-C-T 
To identify EGFR-interacting partners, the MF-EGFR-C-T construct was used as a 
bait protein in large-scale MYTH screens. A cDNA library derived from human fetal 
brain tissue fused to NubG in the orientation NubG-X was used as the prey library. 
From approximately 3 x 10
6 yeast transformants tested in total, 300 grew in selective 
media lacking histidine and adenine. Further X-Gal test narrowed down the positives 
to 295 colonies. Subsequently, the specificity of these interactions was evaluated 
through the bait-dependency test.  This test is designed to rule out false positive prey 
clones by retransforming each prey cDNA into yeast together with either the bait, a 
negative control protein that is known to have distinctly different localization or the 
empty vector. This is particularly helpful if the prey clone has a propensity to non-
specifically bind to parts of the fusion protein like the transcription factor or simply 
self-activates the expression of reporter genes. 
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Figure 7.  MF-EGFR-C-T is properly inserted into membranes and is not tyrosine 
phosphorylated. (A) NubG/NubI assay. THY.AP4 cells were co-transformed with the bait construct, 
MF-EGFR-C-T, and the testing vectors as listed (Fur4-NubG/I and Ost1NubG/I). Growth was 
assayed by spotting three independent transformants on SD-Trp-Leu-Ade-His and X-gal plates with 
two different yeast integral membrane proteins fused to NubG confirms that MF-EGFR-C-T is not 
self-activating. Growth on the same plates with NubI constructs indicates that the modified construct is 
expressed and the protein is properly inserted into the membrane. (B) Western blot of yeast lysates 
harboring either an empty vector (lanes 1 and 3) or the MF-EGFR-C-T bait construct (lanes 2 and 4) 
were subjected to two consecutive ultracentrifugations to segregate the cytosolic (lanes 3 and 4) from 
the detergent-soluble membrane fractions (lanes 1 and 2). Bait protein was detected by a -VP16 
polyclonal antibody. Controls used are the endogenous yeast ER membrane protein Wbp1p and the 
cytosolic Gpd1p. (C) MF-EGFR-C-T bait protein is not phosphorylated in yeast. Lysates from yeast 
transformed with either an empty vector (lane 1) or MF-EGFR-C-T bait construct (lane 2) were 
subjected to Western blotting and probed with phospho-EGFR 1045 to determine if the receptor is 
phosphorylated in yeast. Gpd1p antibody was used as a loading control. 
 (D) Fluorescence images were taken by confocal microscopy exhibiting the localization of the MF-
EGFR-C-T bait in yeast. Yeast cells expressing bait or empty vector were fixed, and acetone-treated 
spheroblasts were probed with rabbit anti-VP16 antibody and visualized by Cy3-conjugated anti-rabbit 
antibody (red). DAPI staining (blue) located the nucleus of yeast cells.  
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Figure 8. Application of a modified MYTH system to the human EGFR. 
 (A) EGFR-interactome identified using a modified MYTH. All proteins from MYTH screen were 
mapped into SwissProt identifiers, and integrated with interactions in I
2D version 1.71 
(http://ophid.utoronto.ca/i2d). The interactions identified are rendered using NAViGaTor 2.02 
(http://ophid.utoronto.ca/navigator). Node color corresponds to the GeneOntology, as shown in the 
legend. Diamond nodes represent membrane-associated and integral membrane proteins. Edge color 
corresponds to source of interaction; green represents MYTH interactions, while red corresponds to I
2D 
interactions. Thicker edges signify multiple sources for a given interaction. 
(B) Venn diagram showing the intersection of 402 EGFR interactions from the three main sources – 
two published reports (5, 6) known interactions from I
2D version 1.71 (http://ophid.utoronto.ca/i2d), 
and MYTH.   
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In this case, using human transferrin receptor (TFRC) as a negative control, it was 
ensured that the prey proteins interacted specifically with EGFR due to their affinity 
for the original bait (MFa-EGFR-C-T).  The bait dependency screen refined the 
number of EGFR-interacting proteins to 87 that were further evaluated by 
bioinformatics, biochemical and functional tests. 
  The proteins comprising the EGFR-MYTH-interactome fall into multiple 
GeneOntology biological function groups as depicted in Fig 8A. These include those 
that play a role in cell fate and organization (green nodes), metabolism (yellow and 
green nodes), protein degradation (light blue nodes) and proteins with yet undefined 
functions (white nodes). Fourteen of the EGFR-interacting partners are annotated as 
either integral membrane or membrane-associated proteins thus clearly demonstrating 
the utility of the modified MYTH system for the identification of membrane proteins 
as EGFR binding partners.  To see how this screen fares in relation to other 
approaches, the data was compared with data from other studies. The venn diagram in 
Fig 8B shows the comparison of the MYTH isolated proteins with previous proteomic 
studies on EGFR
195, 196. There were only 3 common proteins between these two 
studies and the MYTH where as 8 more overlapping interactions were documented in 
the manually curated protein-protein interaction database.  
To further annotate and support observed protein interactions, computational tools 
were used. With the help of the bioinformatician Igor Jurisca (University of Toronto, 
Canada), significant domain-domain co-occurrences, gene co-expressions, and 
computed functional similarity of interacting protein pairs were identified. 
The proteins from the MYTH screen were compared with protein-protein interactions 
described in protein binding databases that represent experimentally verified 
interactions (both low- and high-throughput assays in mammalian and other 
organisms)omputations yield more support for the validity of the screen. 
First, domain pairs that occur in proteins that interact were compared to domains that 
occur in non-interacting proteins creating the so-called domain-domain co-occurrence 
matrix
198. Application of this matrix to the MYTH result supported 34 of the 
interactions identified (Fig. 9). Secondly, functional similarity was computed for all 
protein-protein interactions using Gene Ontology (GO) annotations 
201 by taking 
about 65000 random protein pairs from the human genome. Of the novel interactions   
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identified, 62 fall within the 95% confidence interval of the resulting distribution. 
Take together, the above investigations in yeast and in silico provide more support for 
the validity of the MYTH. However, in order to see if the results are relevant in the 
context of mammalian cells, further assays were done.  
 
 
 
 
Figure 9. Flow chart of bioinformatic analysis of putative MYTH interactors. Domain pairs that 
occur more frequently between interacting proteins were identified by generating domain-domain co-
occurrence matrix. This was done by taking all reported protein-protein interactions (PPIs) and for 
every interacting
 protein pair, each domain from protein A was connected to the
 domains in protein B. 
The frequency of these domain pairs was
 determined for all interacting protein pairs (n = 16 107), as
 
well as all non-interacting pairs (i.e. all proteins not reported
 to interact in PPI databases; n = 1.8 x 10
7). 
Statistical analyses was used to determine which domain
 pairs were enriched in interacting protein pairs 
compared to
  the non-interacting pairs. Finally, a search was done for these domain pairs between 
EGFR and MYTH clones. 
 
 
3.1.3 Biochemical validation of putative interactions  
To demonstrate specific binding of the MYTH clones to EGFR in mammalian cells 
several approaches were used. To assess whether the isolated clones are found in  
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complex with EGFR and whether this association was in any way affected by ligand 
binding A431 cells were used. This cell line is derived from human epidermoid 
carcinoma, expresses sufficient amount of EGFR and has been used extensively in 
studying EGFR signalling
203. Cells were grown in normal growth medium for 24 
hours followed by 24 hours of serum starvation. Subsequently cells were stimulated 
with EGF (100ng/ml) for 5, 15, 60 minutes or left unstimulated. Cell lysates were 
subjected to immunoprecipitation with antibody to EGFR. Resulting blots were 
probed with antibodies to the respective proteins identified in the screen. It is 
important to note that the lack of good antibodies for many of the less characterized 
proteins hampered the effort to study most of them.  
Nonetheless, several putative interactors were validated for their ability to bind to 
EGFR in these cells. Histone deacetylase 6 (HDAC6), -adaptin, HSP70, and 
MAP3K12 were co-immunoprecipitated with endogenous EGFR in non-stimulated 
cells (Fig. 10A). The results showed that HDAC6 is constitutively bound to the 
receptor before and after ligand stimulation. On the contrary, the interaction with  -
adaptin was progressively increased upon receptor stimulation, whereas that of 
MAP3K12 and HSP70 transiently increased after five minutes only to decline to the 
basal level after one hour.  
For those proteins whose endogenous study was not successful, overexpression and 
co-immunoprecipitation was done. EGFR, along with 14-3-3-His or FKBP38-HA, 
was expressed in HEK293T cells. 14-3-3 is co-immunoprecipitated by EGFR 
antibody (Fig 10B, right panel). Similarly, immunoprecipitation with either EGFR or 
HA antibody showed that FKBP38 and EGFR can associate together (Fig. 10B, lower 
panel). In a different approach, the bacterially expressed and purified GST-GATE-16 
fusion protein efficiently pulled down EGFR whereas GST alone did not (Fig. 10C).  
Taken together, it was possible to show that several of the novel putative EGFR 
interactors were indeed EGFR binders in mammalian cells. Furthermore, the 
combination of studies in yeast, cell culture and supporting bioinformatics strengthen 
the conviction in the quality of data generated from the membrane yeast two hybrid 
screen.  
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Figure 10. Several putative EGFR interactors identified by MYTH bind to the receptor in 
mammalian cells. (A) HDAC6, MAP3K12, -adaptin, HSP70 associate with endogenous EGFR. 
A431 cells were serum starved overnight and left non-stimulated or stimulated with EGF for 5, 15 or 
60 min. Immunoprecipitation (IP) was done using EGFR antibod and probed with indicated antibodies. 
Probe with EGFR antibody after stripping membrane shows equal efficiency of immunoprecipitation. 
(B)  14-3-3 and FKBP38 interact with EGFR. HEK293T cells were transfected with plasmids 
encoding EGFR and 14-3-3-His  (upper panel) and FKBP38-HA (lower panel). Cell lysates were 
subjected to IP by anti-His, anti-HA or EGFR antibody and probed as shown. Total cell lysates (TCL) 
indicate expression of each protein analysed. (*) indicates co-IPed proteins. (C) For GST- pulldown 
assay, GST-GATE16 fusion protein was purified from bacteria, coupled to Sepharose beads and 
incubated with lysate of A431 cells. Blot was probed using EGFR antibody. 
  
 
3.2 Interaction between the cytoplasmic deacetylase HDAC6 and EGFR 
 
One of the interesting proteins identified in the screen was histone deacetylase 6 
(HDAC6).  As its initial cloning was based on domain similarity search with already 
established yeast histone deacetylase
153, it is stuck with the rather misleading name of  
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“histone” deacetylase. However, its localization and so far described functions clearly 
show it to be a cytoplasmic lysine deacetylase
146, 156, 165.  
Hence, the identification of HDAC6 in the MYTH screen opened the door to a 
number of speculative thoughts. EGFR undergoes a number of post-translational 
modifications that regulate its function such as phosphorylation and ubiquitylation. In 
the same context, could acetylation be an additional modification in EGFR? Or is 
there another protein in complex with EGFR that is acetylated? These highly 
provocative ideas encouraged the rest of the work to be focused on the study of the 
interplay between HDAC6 and EGFR.  
 
3.2.1 HDAC6 binds to EGFR  
 
In order to confirm the initial observations from the screen, NubG-HDAC6 construct 
was transformed into yeast expressing MF-EGFR-C-T or transferrin receptor Cub-
transcription factor  (TFRC) as bait proteins. Strongly positive X-gal test and growth 
on highly selective media showed that HDAC6 interacts with MF-EGFR-C-T (Fig. 
11A, left panel) but not with TFRC (Fig. 11A, right panel). Positive interactions of 
both MF-EGFR-C-T and TFRC with the plasma membrane resident yeast protein 
(Fur4-NubI) show that they are properly expressed and inserted into the plasma 
membrane. In this assay, the known EGFR interactor glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) acted as positive control. Fur4-NubG and GABA11A are 
negative controls showing the specificity of EGFR-HDAC6 binding.  
To see if this apparent interaction is also evident in mammalian cells, FLAG-HDAC6 
and EGFR were overexpressed in HEK293T cells. Co-immunoprecipitation clearly 
showed that HDAC6-FLAG and EGFR are able to interact (Fig. 11B). Furthermore, 
similar observation can be reproduced at endogenous levels. Lysates from A431 cells 
growing at steady state (Fig. 11C) or starved and stimulated with EGF (Fig. 10A) 
were immunoprecipitated with HDAC6 or EGFR antibody. In both cases antibodies to 
EGFR and HDAC6, but not a rabbit pre-immune serum, were able to co-
immunoprecipitate HDAC6 and EGFR respectively. Interestingly, the interaction 
between HDAC6 and EGFR is not modulated by ligand stimulation to any discernible 
extent (Fig. 10A). Importantly, HDAC6 was able to co-immunoprecipitate  
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catalytically dead EGFR mutant, EGFR K721A (Fig. 11D), showing activation or 
tyrosine phosphorylation of EGFR is not required for efficient interaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. HDAC6 is a novel EGFR interactor.  (A)  Bait-dependency test. The isolated NubG-
HDAC6 prey plasmid was transformed into the THY.AP40 strain expressing MF-EGFR-C-T (left 
panel) and human transferrin receptor (T-C-TFRC fusion, right panel). Yeast growth was assayed on 
SD-Trp-Leu-Ade-His + 25 mM 3AT media, and for blue colour on X-gal plates.NubG-GAPDH was 
used as a positive control and NubG-GABA 1A as a negative control. Cells co-transformed with 
Fur4-NubI serve as a positive control for growth on selective plates. (B) EGFR overexpressed in 
HEK293T cells was IPed and blot probed with FLAG antibody to detect the co-expressed HDAC6-
FLAG. (C) Lysates of A431 cells was IPed with HDAC6 anitserum and blot probed with EGFR. 
Stripped blot was reprobed with HDAC6 antibody. (D)  Wt EGFR or EGFR K721A and FLAG-
HDAC6 were transfected in HEK293T cells, and IP done using FLAG antibody. Blots were probed 
with EGFR and later reprobed with  FLAG antibody.   
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3.2.2 Mapping of EGFR and HDAC6 binding regions 
 
In order to map the binding site of EGFR on HDAC6, FLAG-tagged HDAC6 wt, 
HDAC6 deacetylase dead (DD), HDAC6 N-terminal deletion (dN), HDAC6 lacking 
the ubiquitin binding domain (dBUZ) or HDAC6 with stop codon at residue 840 (1-
840) were co-expressed with EGFR in HEK293T cells (Fig. 12A). 
Immunoprecipitation using FLAG antibody showed that all constructs, except 
HDAC6 1-840, were able to efficient bring down EGFR, thus narrowing down the 
interaction surface on HDAC6 to the region between amino acid residues 840 and 
1132 (Fig. 12A). The minimal binding domain of HDAC6 was further defined using 
the MYTH system. Five prey constructs comprising of different C-terminal HDAC6 
fragments were generated and transformed in to yeast expressing MF-EGFR-C-T. 
As seen by growth on selective media and blue coloration on X-gal test, the 
interaction was maintained in the short fragment containing HDAC6 amino acids 
1010 to 1050, which denotes the minimal interaction domain between the two 
proteins (Fig. 12B).  
Further analyses to determine the binding surface of HDAC6 on EGFR and whether 
HDAC6 can also bind to other transmembrane receptors was done by Jasna Curak in 
the lab of Igor Stagljar on a collaborative basis. Since it is helpful for the discussion 
of the work presented here, these findings are briefly described below. 
Using the MYTH approach the HDAC6 binding surface of EGFR was determined. 
The deletion mutants reveal that the juxtamembrane region of EGFR (corresponding 
to amino acids 645-672 of mature EGFR) is responsible for its interaction with 
HDAC6.  
Furthermore, binding of HDAC6 to other ErbB family members was detected 
including binding to ErbB2, ErbB3, and ErbB4.  However, HDAC6 did not interact 
with a wide variety of mammalian integral membrane proteins such as the mouse 
transporters NHE3, NaPi-IIa, and MAP17, as well as the human ion channels SLC989 
and SLC22A4. This excludes the possibility that HDAC6 associates with any integral 
membrane protein that is internalized via clathrin-coated pits.  
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3.2.3 HDAC6 colocalizes with EGFR on the plasma 
To strengthen the above biochemical observations, the sub-cellular localizations of 
EGFR and HDAC6 were investigated. HeLa cells were grown in cover slips, serum 
starved and stimulated with fluorescent-labelled EGF (EGF-Alexa 555). The fixed 
cells were then stained with anti-HDAC6 antibody and confocal images were 
acquired. As expected, HDAC6 is primarily localized in the cytoplasm. However, a 
minor fraction is seen to partially co-localize with EGF/EGFR complex at the 
membrane (Fig. 13A  
Figure 12. Mapping of EGFR 
binding site on HDAC6. 
(A)  HEK293T cells were 
transfected with EGFR and 
FLAG-HDAC6 wild-type or 
deletion constructs containing 
the first 840 amino acids 
(HDAC6 1-840), lacking the N-
terminus (dN, 439-1215), 
lacking the zinc-finger domain 
(dBUZ, 1-1132), or a full-length 
HDAC6 lacking deacetylase 
activity (DD, HDAC6-
H216A/H611A). IP done using 
M2-FLAG antibody, followed 
by probing first with EGFR 
antibody and then with FLAG 
antibody. Total cell lysates 
(TCL) show comparable levels 
of expression of the proteins. 
(B) HDAC6 amino acid 
residues 1010 to 1050 bind to 
EGFR. 
Yeast THY.AP40 cells were co-
transformed with MF -EGFR-
Cub-TF and the various 
HDAC6 prey constructs as 
indicated. Three independent 
colonies from each co-
transformation were tested for 
growth on Trp
-Leu
-, Trp
-Leu
-
Ade
-His
-, and X-gal containing 
media. A non-interacting 
membrane protein, Ost1p, fused 
to NubG was used as a negative 
control and the same protein 
fused to NubI was used as a 
positive control.  Schematic 
representation of HDAC6 
domains and HEBD (HDAC6 
EGFR binding domain) shown. 
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Figure 13. HDAC6 partially colocalizes with EGFR 
(A)  HeLa cells were starved and pulsed with EGF-Alexa555 (red) for 45 seconds. Then were 
immediately fixed (0 min) or chased for 10 minutes. Cells were later immunostained with HDAC6 
antibody (green) and visualized by confocal microscopy. (B) HeLa cells transfected with Rab5 Q79L 
were starved, pulsed with EGF-Alexa555 and immunostained as in (A). Nucleus stained with DAPI 
and images in zoom shows a close up of representative vesicular signals.  
 
 
upper panel). After 10 minutes of stimulation, EGF/EGFR is internalized and located 
in intracellular vesicles. Importantly, HDAC6 was again seen to partially co-localize 
with EGFR in these vesicular structures (Fig. 13A lower panel). The extent of 
colocalization was however weaker than can be expected from the co- 
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immunoprecipitation experiments. This could be due to a rapid on-off interaction 
between the two proteins. Hence in order to unequivocally demonstrate that HDAC6 
is localized on endosomes carrying EGF/EGFR, the formation of enlarged early 
endosomes was induced by transfection of the GTPase-deficient mutant Rab5 Q79L. 
This mutant has the ability to increase the size of endosomes by facilitating 
homotypic fusions
204. As depicted in Fig. 13B, a remarkably enhanced co-localization 
of HDAC6 is observed in these endosomes together with EGFR showing HDAC6 can 
travel with the receptor from the plasma membrane along endocytic vesicles. 
 
3.3 HDAC6 regulates ligand-induced degradation of EGFR 
 
While studying the interaction between HDAC6 and EGFR it was noted that over-
expression of HDAC6 enhanced the levels of EGFR in HEK293T cells (Fig. 14A). As 
can be seen in lanes 2 and 4 the basal levels of the receptor are markedly enhanced 
upon transfection of HDAC6.  
On the other hand downmodulation of HDAC6, either pharmacologically using an 
inhibitor or genetically by shRNA mediated knock down has the opposite effect. The 
inhibition of deacetylase activity of HDAC6 by trichostatin A (TSA) in A549 cells led 
to reduced expression of EGFR (Fig 14B). But more prominently the knockdown of 
HDAC6 using shRNA in these cells resulted in much lower expression of EGFR (Fig 
13C). Degradation of EGFR in lysosomes, primarily due to ligand binding and to a 
lesser extent due to constitutive internalization, is a prominent regulatory 
mechanism
110, 112. Hence, the effect of HDAC6 on ligand-induced degradation of 
endogenous EGFR was investigated next. 
 
3.3.1 HDAC6 overexpression slows ligand-induced degradation of EGFR 
 
Experiments to assess ligand-induced degradation of EGFR were performed in A549 
cells. These cells, derived from human non-small cell lung carcinoma, are suitable for 
studying dynamics of ligand induced EGFR as they express decent amount of the 
receptor, are tightly adherent and amenable to plasmid or oligonucleotide transfection.   
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Cells grown in normal growth media were transfected with a control EGFP vector, 
FLAG-HDAC6 or a FLAG-HDAC6 mutant lacking deacetylase activity (HDAC6-
H216A/H611A). One day later, cells were serum starved for 16 hours and de  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Expression level of HDAC6 affects total cellular levels of EGFR. 
(A) HEK293T cells were transfected with 100ng (lanes 1 and 2) or 500ng (lanes 3 and 4) of a plasmid 
encoding EGFR, alone (lane 1 and 3) or with FLAG-HDAC6 (lane 2 and 4). Cell lysates were run on 
SDS-PAGE and immunoblotted with EGFR and FLAG antibodies. (B) A549 cells were treated with 
the inhibitor TSA (1μM) for 12 hours. TCL probed for EGFR. IPed tubulin shows increased 
acetylation, serving as control for efficienct inhibition of deacetylase activity. (C) A549 cells were 
transduced with Lentivirus expressing a scrambled or HDAC6 specific shRNA. Stable clones were 
established and tested for expression of EGFR and HDAC6. Tubulin blot show loading of comparable 
amount of cell lysates. 
 
 
novo protein synthesis was inhibited by cycloheximide treatment. The cells were then 
stimulated with EGF for 20 to 180 minutes and lysates were probed for levels of 
EGFR. Wt HDAC6, but not HDAC6-H216A/H611A or control EGFP, led to  
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stabilization of EGFR in non-stimulated and EGF stimulated cells (Fig. 15A).   
Whether this stabilization was dependent on the ability of HDAC6 to bind to the 
receptor was tested next by using an HDAC6 deletion mutant that does not bind to 
EGFR (termed HDAC6-DelHEBD). This mutant is still catalytically competent and 
able to bind ubiquitin (data not shown). A similar assay as above was done to 
compare the ligand-induced degradation of EGFR upon overexpression of wt HDAC6 
or HDAC6-DelHEBD. Importantly, HDAC6-DelHEBD had a weaker stabilization 
effect on ligand-induced EGFR degradation as compared to wild-type HDAC6 (Fig. 
15B).  It is worthwhile to notice that abolishing EGFR binding did not completely 
abrogate stabilization effect of HDAC6-DelHEBD, indicating the possibility of direct 
interaction independent effects of HDAC6 on EGFR. 
 
3.3.2 HDAC6 knockdown accelerated the degradation of EGFR 
 
In order to complement the above gain-of-function studies, a loss-of-function 
experiment using shRNA-mediated knockdown of HDAC6 was performed. For this 
purpose, A549 cells were transduced with lentiviruses encoding shRNA against 
HDAC6 and stable clones were established. A549 parental and knockdown cells were 
serum starved, EGF stimulated and lysates were subjected to Western blotting and 
probed with EGFR antibody. In control cells, receptor degradation was initiated 
slowly and progressively continued to 3 hours, whereas in HDAC6 knockdown cells, 
degradation of EGFR started much earlier and accelerated dramatically within the 
next hours (Fig. 15C).  Again, it is important to note that the knockdown of HDAC6 
caused a much more pronounced effect on EGFR degradation compared to the 
overexpression of HDAC6. This could very well be due to the high level of 
expression of endogenous HDAC6 in these cells whereby gain of function will have 
comparatively lower effect than loss-of-function as a result of near saturation of 
HDAC6-utilizing apparatus. 
 
3.4 HDAC6 modulates the kinetics of EGFR intracellular trafficking 
 
How is HDAC6 stabilizing the receptor from ligand-induced degradation? It is well 
established that the primary mechanism of EGFR regulation is ligand-induced  
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receptor internalization followed by endosomal trafficking, and subsequent 
degradation in lysosomes 
54.  The question is whether HDAC6 affects any of these 
processes, for example internalization, or whether it influences the post-endocytic 
trafficking of EGFR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. HDAC6 regulates ligand-induced EGFR degradation. 
(A) A549 cells were transfected with an EGFP vector as control, FLAG-HDAC6 wild type or FLAG-
HDAC6 H216A/H611A. Cells were then serum starved for 16 hours and pre-treated with 
cycloheximide. Subsequently, they were stimulated with EGF for the durations shown. Cell lysates 
were run on SDS-PAGE and blots probed with EGFR antibody to follow its degradation. Control 
probes were done to show the efficiency of knockdown and equal loading. EGFR signals from the 
several Western blots were quantified with ImageJ® and plotted, taking EGFR level before stimulation 
as 100% Cells were serum-starved and ligand induced EGFR degradation monitored as in.  (B) A549 
cells were transfected with an EGFP vector as control, FLAG-HDAC6 wild type or FLAG-HDAC6 
DelHEBD. EGFR degradation was monitored as above. (C) Parental A549 and HDAC6 stable 
knockdown cells were serum starved and ligand-induced EGFR monitored essentially as in (A). 
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3.4.1 HDAC6 has no effect on EGFR internalization 
 
To answer these questions, first a receptor internalization assay was done by labelling 
surface EGFR with radioactive iodine (
125I)-conjugated EGF. Interestingly, no 
remarkable difference in the rate of receptor internalization was observed in cells 
overexpressing wild type or a deacetylase-deficient mutant of HDAC6 relative to 
control cells (Fig. 16A). It is thus possible that HDAC6 might influence the post-
endocytic trafficking and sorting of the receptor along the endocytic. 
 
3.4.2 Knockdown of HDAC6 accelerates the delivery of EGF late endosomes 
 
In order to further dissect the spatio-temporal influence of HDAC6 on the kinetics of 
EGFR trafficking in vivo, a pulse-chase experiment using Alexa488-labelled EGF as a 
ligand was performed. Parental A549 cells or cells expressing shRNA against 
HDAC6 were pulsed with Alexa488-EGF for 30 seconds and chased for various 
periods of time. The endocytic marker proteins EEA1 (early endosomal marker 1) and 
LAMP1 (late endosomal marker 1) were visualized by immunostaining (Fig. 16B). 
Four-channel laser confocal microscopy images were acquired from at least 10 fields 
per experimental setup with an average of 10 cells per field to get adequate numbers 
for statistical analyses. Images were then analysed by MotionTracker software. This 
algorithm was developed to identify vesicular structures by analysing their 
localization in respect to other structures, size and intensity in three axes, much like 
human motion tracking algorithms being developed for security purposes
61.  Once 
vesicles marked with Alexa488-EGF, EEA1 or LAMP1 were identified, various 
parameters such as endosome number, size, intensity and co-localizations between the 
different markers were quantified. Comparing the results to known endocytic kinetic 
measurements validated the experimental setup.   
First, measurement of the colocalization of EGF with EEA1 (as a proxy for 
internalization) showed that EGF is very rapidly taken into cells peaking after 15 
minutes of starting the chase. Interestingly, as in the radioactive iodine based assay, 
no difference in internalization of EGF was noted between control and HDAC6 
knockdown cells (Fig 17A). Additionally, as reported before by Rink et al
61, 
increasing the chase time  to an hour resulted in progressive increase of the size of 
endosomes (Fig. 17B). Down-regulation of HDAC6 expression markedly accelerated   
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Figure 16. Dynamics of EGFR trafficking. (A) No influence of HDAC6 expression on  the rate of 
internalization of EGFR. CHO cells were transfected with EGFR and EGFP, wild type HDAC6 or 
deacetylase-dead HDAC6- H216A/H611A (DD). After 16 h of serum starvation, cells were stimulated 
with 50 ng/ml EGF for the durations shown. The amount of radioactive EGF/EGFR complex left at the 
cell surface was measured quantified by ligand labelling, normalized to the amount of EGFR at time 
point 0. (B) Representative images for EGFR trafficking dynamic measurment. Parental and HDAC6 
knockdown cells were pulsed for 45sec with EGF-Alexa488, and chased for the shown durations. 
Fixed cells were immunostained with EEA1 and LAMP1 antibodies and DAPI.A minimum of 100 
cells were imaged for every experimental time point and condition. Images analysed later with 
MotionTracker®. 
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the delivery of EGF into LAMP1 positive late endosomes, as visualized by increased 
co-localization of EGF with LAMP1 (Fig. 18A). Furthermore, the distance between 
the EGF-containing endosomes and the nucleus decreased much faster in the 
knockdown cells indicating an increase in velocity of travel towards the centre of the 
cell (Fig. 18B).  
These observations are consistent with the accelerated degradation of EGFR in 
HDAC6 knockdown cells by Western blotting (Fig. 15C). In addition, the integral 
vesicular intensity of EEA1 positive vesicles was increased in knockdown cells, 
demonstrating the accumulation of more content in these endosomes (Fig. 18C). Prior 
observations have shown that early endosomes progressively increase in size, 
concentrate cargo destined for degradation and adopt a more central location in cells 
prior to conversion into late endosomes and before fusing with lysosomes 
61. In 
conclusion, the increased co-localization of EGFR with LAMP1, decrease in 
endosome-nucleus distance and the increased content of endosomes in HDAC6 
knockdown cells is consistent with a model of faster transport of EGFR carrying 
endosomes towards the peri-nuclear area where receptor degradation is known to 
occur 
54, 71.  
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Validation of EGF Alexa488 pulse-chase experimental setup by measuring previously 
described parameters. Images from Fig. 16B were analyzed by MotionTracker. (A)  The 
colocalization of vesicles staining positive for both EGF and EEA1 was quantified as a function of 
time. A rapid increase with gradual decrease shows the entry and exit of  EGF in early endosomes. (B) 
The progression in the  mean size of EGF positive vesicles over one hour of EGF stimulation. 
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3.5 Acetylation and receptor trafficking  
 
How is HDAC6 able to modulate the trafficking of EGFR and endosomes? As the 
stabilization of EGFR required HDAC6 deacetylase activity (Fig. 15A), EGF induced 
acetylation/deacetylation of the receptor itself or a certain protein involved in 
trafficking might be involved. In order to test this hypothesis, it was important to 
identify an acetylated protein that is deacetylated by HDAC6 in the endocytic  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Downregulation of HDAC6 accelerates intracellular trafficking of EGFR. (A) EGF 
delivery to late endosomes is accelerated in HDAC6 knockdown cells. Serum starved A549 cells were 
pulsed with EGF-Alexa488 and chased for the indicated times. Following immunostaining with EEA1 
and LAMP1 antibodies, images as in Fig. 16 were quantified. Graph shows percent of EGF co-
localized with LAMP1 positive vesicles versus time for parental (black) and HDAC6 knockdown cells 
(red). (B) Internalized EGF approached the perinuclear area rapidly in HDAC6 knockdown cells. Data 
generated in EGF pulse-chase experiment were analysed to quantify distance of EGF positive vesicles 
from the nucleus in units of nuclear size in both parental (black) and HDAC6 knockdown cells (red). 
(C) The mean integral intensity of EEA1 vesicles was measured and plotted. This measurement 
corresponds to the content of endosomes. 
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machinery. Hence, a systematic search was done by immunoprecipitating major 
regulators of EGFR trafficking (including c-Cbl, CIN85, HRS, STAM, epsin, EPS15) 
and probing by acetyllysine specific antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Searching for a target: (A) Clathrin heavy chain (CHC) is acetylated but is not a substrate 
of HDAC6. Cell lysaes from TSA treated cells were probed with acetyllysine antibody (left panel). 
Lysates from EGF stimulated cells were IPed with clathrin heavy chain antibody (CHC) and probed 
with acetyllysine antibody (right panel). (B) Acetylation of tubulin increases in response to EGF 
stimulation. Mass spectrometric determination of Lys40 acetylation of tubulin after EGF stimulation. 
HeLa cells were serum-starved for 16 hours and stimulated with EGF. Lysates were subjected to 
immunoprecipitation with tubulin antibody. Samples were run on SDS-PAGE, tubulin bands were cut 
out, proteolytically digested and analysed by mass spectrometry. Graph shows ratio of peptide 
abundance from each sample with EGF stimulation compared with peptides from non-stimulated cells. 
DK*TIGGGD denotes the peptide containing the acetylated Lys40.  The peptides analysed are 1- 
DGQMPSDKTIGGGD,  2-  DKTIGGG,  3-  DKTIGGGD,  4-
DKTIGGGDDSFNTFFSETGAGKHVPRAVFV, 5- DLEPTVI, 6- DCAFMVDNEAIY, 7-  DICRRNL, 
8- DK*TIGGGD  
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Additionally, immunoprecipitated EGFR and associated protein complex was 
subjected to mass spectrometry to identify acetylated peptides. However, no lysine 
acetylation of EGFR could be demonstrated.  Of the established regulators of 
endocytosis, only clathrin heavy chain was identified to be acetylated on a single 
lysine residue, K456. However, to our dismay, this acetylation is not at all modulated 
by HDAC6 or EGF stimulation. Inhibition of HDAC6 by TSA (Fig. 19A left panel) 
or stimulation with EGF for various durations (Fig. 19A right panel) has no effect on 
the acetylation of CHC, effectively ruling out clathrin as a potential mediator of 
HDAC6 function. 
In this search for potential targets we also included HSP90. HSP90 is a known   
substrate of HDAC6 that is involved in maturation of various signaling molecules 
146. 
HSP90 affects maturation of ErbB family members such as ErbB2. Importantly, 
however, wild type or mature EGFR is not influenced by HSP90 activity 
205-207. In 
order to unequivocally rule out that HSP90 does not play a role in our system, we 
have tested its significance in regulating ligand induced EGFR degradation. Serum 
starved A549 cells were cycloheximide treated to inhibit new protein synthesis, then 
left untreated or treated with HSP90 inhibitor geldanamycin for four hours.  After 
addition of EGF for different durations cells were lysed and levels of EGFR were 
detected. Inhibition of HSP90 had no remarkable effect on the normal ligand induced 
degradation of EGFR (data not shown).  In conclusion, it is highly unlikely that the 
effect of HDAC6 on trafficking of the mature and signaling competent membrane 
located receptor could be explained by its action on HSP90. 
 
3.5.2 Acetylation of -tubulin is increased upon EGF stimulation 
 
In stark contrast to the above results, the mass spectrometric (MS) analyses detected 
an increase in the acetylation of  -tubulin on lysine residue 40 (Lys40) following 
EGF stimulation (Fig. 19B). This was done by immunoprecipitating  -tubulin with 
stringent washing and subjecting a band cut from an SDS-PAGE to MS. The intensity 
of the peptide containing acetylated Lys40 (labelled 8) was 2.3-fold higher in EGF-
stimulated cells as compared to the basal level of acetylation of  -tubulin in non-
stimulated cells. The abundance of alternative non-modified peptides was also 
compared between the two samples. As shown in Fig. 19B, the ratio of the EGF  
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stimulated versus non-stimulated intensities of these control peptides (labelled 1 to 7) 
is approximately one, indicating equivalent amounts of total  -tubulin analysed.  
 
3.5.3 Acetylation of -tubulin Lys40 is important for efficient motility of 
endosomes 
At this point, an important question is whether  -tubulin acetylation plays any 
regulatory role in intracellular trafficking.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Acetylation of tubulin on lysine 40 is important for efficient motility of endosomes. 
Fast live cell imaging and individual endosome tracking was performed in A431-GFP-Rab5 cells 
overexpressing wt and K40A-mutant mCherry-tubulin. Imaging parameters include image sequences (4 
images per Z stack, 2 stacks/second) with observation time of 5 minutes and were rendered by 
maximum projection of GFP-Rab5 endosome dynamics in mCherry-tubulin expressing cells.(A) Snap 
shots from video microscopy showing endosomes identified (green circles) and being tracked during 
their motility (green line) (B).The speed of GFP positive early endosomes was computed and depicted 
in the graph. GFP-Rab5 endosomes moved slowly in cells expressing the dominant negative Lys40Ala 
tubulin. Student’s t-test for statistical significance performed, with p<0.05. (C) Efficient processive 
movement of endosomes depends on Lys40 of tubulin. Similar to (B) K40A mutation led to impaired 
processive movement of endosomes. 
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Two recent reports have shown that acetylation of Lys40 in  -tubulin enhances the 
interaction between microtubules and the motor proteins kinesin and dynein, thus 
accelerating the transport of cargo proteins in the secretory pathway 
170, 171.  
To test whether acetylation of  -tubulin Lys40 similarly affects movement of early 
endosomes along microtubules, live cell imaging by spinning disc microscopy was 
performed. This microscope, together with the associated high-speed camera, is suited 
for imaging fluorescently tagged intracellular vesicular structures with reduced photo 
bleaching compared to conventional confocal microscopy. mCherry- -tubulin and a 
mCherry- -tubulin-Lys40Ala were expressed in A431 cells stably transfected with 
low amount of GFP-Rab5. Expression of either mCherry -wild type or Lys40Ala  -
tubulin constructs is known to lead to an adequate incorporation of  -tubulin in 
microtubules 
171. Additionally, it has been demonstrated that Lys40Ala acts in a 
dominant negative manner to reduce acetylation of endogenous microtubules 
208. 
Again, using the MotionTracker software, single GFP-Rab5 endosomes were 
identified and tracked for five minutes (Fig. 20A). The speed and number of 
processive movements of these individual endosomes were calculated. Cells 
expressing  -tubulin- Lys40Ala mutant displayed a statistically significant reduction 
in speed (Fig. 20B) and processivity of Rab5 endosomes (Fig. 20C), as compared to 
cells expressing wild-type  -tubulin. Taken together these results show that an 
increased acetylation of tubulin, which can be induced by EGFR activation, is 
important in regulating the kinetics of trafficking of the receptor via early endosomes 
to late endosomes.  
 
3.6 Phosphorylation of HDAC6 modulates enzymatic activity 
 
3.6.1 HDAC6 is phosphorylated on serine and tyrosine residues 
 
The next important question is how EGFR activation leads to the increase in 
acetylation of  -tubulin. Acetylation is a result of the interplay between 
acetyltransferases and deacetylases. Hence, an increase in acetylation denotes either 
increase in activity of acetyltransferase or decrease in deacetylase activity.  However, 
the molecular identity of tubulin acetyltransferase is so far unclear. Hence, a focus on 
this activity at this juncture is impractical. On the other hand, there is a high basal  
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activity of HDAC6 in cells and several members of the HDAC family are regulated 
by phosphorylation 
209-211, therefore it is reasonable to hypothesize that 
phosphorylation of HDAC6 could also be an important regulatory mechanism.  
To study this, a comprehensive mass spectrometric analysis of HDAC6 was 
performed. Following tryptic digestion of HDAC6, two phosphorylated peptides were 
identified. One contains Tyr570 and the other comprises of three serines, Ser563, 
Ser564, and Ser568 (any one of them can be phosphorylated, but not all).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. HDAC6 is phosphorylated by EGFR. (A) HDAC6 is tyrosine phosphorylated following 
EGF stimulalation. Serum starved HeLa cells were pretreated with sodium orthovanadate and EGF 
stimulated for indicated durations. After IP with HDAC6 antibody and stringent washes, blots were 
probed with anti-phospho-tyrosine and HDAC6 antibodies. (B)  Acetylation of -tubulin lysine 40 
progressively increased after EGF stimulation.Total cell lysates from EGF stimulated HeLa cells as in 
(A) were subjected to Western blotting and probed with anti-acetyllysine 40 tubulin and anti-tubulin 
antibodies. (C) EGFR kinase domain is able to phosphorylate HDAC6. In vitro kinase assay was set up 
with purified recombinant HDAC6 (4μM) and GST-EGFR kinase domain protein (2, 10 and 20 nM) 
with and without ATP. Reaction mix was loaded on SDS-PAGE and blots were probed with 
phosphotyrosine, HDAC6, and EGFR antibodies. 
 
To determine which of these phosphorylation sites is indeed modulated by EGFR 
activation, HeLa cells were serum starved and subsequently stimulated for various 
time points with the EGF ligand. HDAC6 was immunoprecipitated, washed in RIPA  
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buffer and blots were probed with phosphoserine or phosphotyrosine antibodies. A 
marked increase in phosphotyrosine signal that progressed over time was detected, 
suggesting HDAC6 Tyr570 is modulated by EGFR activation (Fig 21A). Probing 
with phosphoserine antibodies was inconclusive due to poor quality of antibodies. 
 
3.6.2 Phosphorylation of HDAC6 by EGFR inhibits deacetylase activity 
 Interestingly, probing lysates from EGF stimulated HeLa cells for acetylation of -
tubulin on Lys40 showed a gradual increase in acetylation that correspond to increase 
in HDAC6 tyrosine phosphorylation. This indicates that phosphorylation might 
indeed have an inhibitory role on the activity of HDAC6 (Fig. 21B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Phosphorylation of HDAC6 on Tyr570 abolished its deacetylase activity. (A) An EGFP 
vector, FLAG-HDAC6 wt, FLAG-HDAC6 Tyr570Glu and FLAG-HDAC6 Tyr570Phe and FLAG-
HDAC6 His216/611Ala plasmids were transfected in HEK293T cells. Cell lysates were probed with 
acetyl Lys-40-tubulin, FLAG and tubulin antibodies. (B) FLAG-HDAC6 S568E and FLAG-HDAC6 
S568A and indicated constructs were transfected in HEK293T cells basically as in (A). (C) 
Dephosphorylation of HDAC6 increased its deacetylase activity. Purified and polymerized 
microtubules were incubated with empty agarose beads (lane 1), immunopurified HDAC6 (lane 2), or 
HDAC6 treated with calf intestinal phosphatase, CIP, (lane 3). Blots were probed for tubulin acetylated 
on Lys40, total tubulin and FLAG-HDAC6.  
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Importantly, HDAC6 was tested whether it can be a substrate for EGFR kinase 
activity using in vitro kinase assay. It was found that purified recombinant HDAC6 
was phosphorylated by EGFR in a concentration dependent manner by purified GST-
EGFR kinase domain, only in the presence of ATP (Fig. 21C). To directly show that 
HDAC6 Tyr570 plays a crucial role by regulating its enzymatic activity, a phospho-
mimicking mutant, Tyr570Glu and a non-phosphorylatable mutant, Tyr570Phe were 
created. In an in vivo deacetylase assay using acetylation of -tubulin on Ly40 as 
readout, phospho-mimicking abolished enzymatic activity dramatically whereas the 
corresponding non-phosphorylatable mutant maintained comparable activity to wild 
type HDAC6 (Fig. 22A). The serine residues that were identified to be 
phosphorylated, i.e. Ser563, 564 and 568 were also mutated to Glu and Ala to mimic 
and abolish phosphorylation respectively. Testing the mutants in in vivo deacetylase 
assay revealed that Ser568Glu is enzymatically dead whereas Ser568Ala remained 
active (Fig. 22B). This shows that Ser568 is the serine that is phosphorylated in the 
peptide and similar to Tyr570 has an important regulatory role on deacetylase activity. 
To further corroborate these findings, an in vitro deacetylase assay was done. 
Immunopurified HDAC6 was incubated with purified brain-derived microtubules in 
the presence and absence of calf intestinal phosphatase (CIP). CIP induced 
dephosphorylation of HDAC6 resulted in a more potent activity than wild-type 
HDAC6 (Fig. 22C). Taken together, phosphorylation of HDAC6 on Tyr570 by EGFR 
inhibits its deacetylase activity and is at least one of the reasons for the increased 
acetylation of  -tubulin following EGF stimulation 
 
3.7 Effects of HDAC6 on EGFR mediated cellular responses 
 
3.7.1 Downregulation of HDAC6 alters Akt and ERK signalling pathways 
PI3K/Akt and ERK pathways constitute two of the most important downstream 
effecter pathways activated by EGFR. Could the changes in kinetics of EGFR induced 
by HDAC6 have any effect on these signalling pathways? To address this, control or 
HDAC6 knockdown A549 cells were stimulated with EGF and cell lysates were 
probed for pERK 42/44, pSer473Akt, pSer9 GSK3, pSer380 PTEN. HDAC6 
depleted cells have slightly reduced ERK2 phosphorylation in response to EGF. In  
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contrast, Akt and its downstream target GSK3 have markedly increased 
phosphorylation (Fig 23).  This apparent differential effect on the activation of the 
two signalling pathways might relate to their distinct mode of activation.  
 
3.7.2 HDAC6 knockdown cells have stunted response to EGF stimulation 
EGF stimulation can lead to either cell spreading or contraction very rapidly. On the 
other hand, prolonged stimulation can induce or inhibit cellular proliferation in a cell 
line dependent fashion
212-214. In order to study the possible effects of HDAC6 on these 
processes, a real time cell analyzer (xCelligence) was used.  
 
 
 
 
 
 
 
Figure 23. EGFR downstream signaling in HDAC6 knockdown cells. A549 control and HDAC6 
knockdown cells were serum starved and stimulated with EGF for up to two hours. Cell lysates from 
these cells were immunoblotted with pERK2, pSer473Akt, pSer9 GSK3, pSer380 PTEN and acetylated 
tubulin antibodies. Stripped blots were later probed with ERk2 and  Akt   to confirm comparable 
loading of samples (left panel). pSer473 and pERK2 bands were quantified and plotted on the right. 
 
In this system, the bottom of the cell culture dish is covered with a microelectrode 
array that senses local ionic perturbations caused by attachment of cells. More cells, 
or more tightly attached cells, mean more impedance to the flow of electric current. 
This impedance is quantified by the device and plotted as “cell index”. The primary 
advantage of this system is that measurement of cell spreading and cell proliferation is 
done continuously in real time without any chemical or antibody labelling. A549 
control or HDAC6 knockdown cells grown in such dishes were serum starved and  
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stimulated with EGF. Impedance measurements were done for up to 72 hours post-
EGF stimulation. Within a few minutes of applying EGF (peak 20 minutes), control 
cells contracted by almost 50% of total cell surface. This is in accordance with a 
previous report where cells were visualized by scanning electron microscopy
212. 
Interestingly, this EGF induced cell rounding is very much reduced and slowed in 
HDAC6 knockdown cells (Fig 24A). Monitoring of the cells for the next few days 
revealed that EGF stimulation had the expected effect of inducing growth arrest on 
control cells. Importantly, HDAC6 knockdown cells continued to grow with minimal 
response to EGF (Fig. 24B). In summary, HDAC6 knockdown cells have markedly 
attenuated responses to EGF, which could be at least partially explained by their 
lower receptor level, both at steady state and following ligand stimulation.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. The response of HDAC6 knockdown cells to EGF is markedly attenuated. Serum 
starved A549 control and knockdown cells were stimulated with EGF and continuously monitored 
using xCelligence® cell analyzer. Upper panel shows the rapid drop in reading of cell index (the 
measurement of cell surface adhering to the surface of cell culture dish) in control cells, compared to 
less pronounced and delayed response in knockdown cells. Longer follow-up shows continued 
proliferation of knockdown cells whereas control cells are barely growing (lower panel).  shows 
addition of EGF to growth medium.  
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4. DISCUSSION 
 
4.1 MYTH screen 
 
This study describes the utilization of split ubiquitin based membrane yeast two-
hybrid screen for the identification of novel interacting partners of ligand unoccupied 
and inactive EGF receptor. Since its initial discovery, EGFR has received a lot of 
attention by the cell signalling community. This is due to the fact that it is a founding 
member of RTKs, the ready availability of tools for its study, its dramatic influences 
on downstream signalling pathways, remarkable growth promoting effects and its 
association with cancer development. To top this, the recent development of 
successful blockbuster therapeutics targeting EGFR in the treatment of a variety of 
cancers has added fuel to this interest. Various biochemical, cell biological and 
genetic tools have been used to study EGFR. The first proteomic approaches used to 
investigate EGFR include the application of the conventional yeast two-hybrid system 
to seek interacting partners of its cytoplasmic domains. Interaction studies have led to 
the identification of a number of key downstream effectors of EGFR
197, 215. Due to 
technical limitations, these studies addressed only fragments of the protein 
(cytoplasmic domains) and not the full-length membrane localized receptor. Mass 
spectrometry based studies, spearheaded by the lab of Mathias Mann, coupled with 
the use of stable isotope labelling by amino acids in cell culture (SILAC) have 
identified more proteins in complex with the activated receptor
195. Another impressive 
work was done by Jones et al who purified all the SH2 and PTP domains in the 
human genome and constructed a protein microarray which was used to study 
interactions to multiple peptides from EGFR and other ErbB family members
196. 
While the above-mentioned methods have contributed immensely to our 
understanding of the set of proteins that bind to EGFR, they have major limitations. 
These are due to the fact that the studies focused either on the proteome recruited to 
EGFR upon ligand binding or used only the cytoplasmic part of the receptor. To the 
best of our knowledge, no comprehensive study of proteins that bind to the ligand-
unoccupied and membrane-inserted full-length receptor has been reported.   
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Hence, an important question is how one can search for interactors of receptors while 
they are still in the membrane environment. Technology drives science and the recent 
availability of the membrane based yeast-two hybrid system with its ability to detect 
interacting partners of cell surface receptors proved to be useful in addressing this 
question
188. Since its inception, MYTH has been used to search for binding partners 
of several receptors with promising results. Further modification of bait expressing 
vectors and availability of high-quality prey libraries have been instrumental in this 
success
189, 190.  
However, a well-validated screen of a single transmembrane protein like a receptor 
tyrosine kinase is so far not reported. The major hindrance has been the instability and 
auto-activation of the bait-transcription factor fusion protein. The degradation might 
be due to misfolding of the heterologous protein and improper insertion into the yeast 
membrane. In the present work, degradation was avoided by replacing the signal 
peptide of EGFR (amino acids 1-24) with the membrane targeting N-terminus of the 
S.cerevisae mating factor  protein. Extensive characterization of the bait fusion 
protein revealed that it was indeed properly inserted into the yeast membrane. The 
large-scale transformation of human fetal brain library and analyses identified close to 
three hundred positive clones, corresponding to 87 proteins.  
Comparison of the MYTH result with two of the most extensive proteomic studies on 
EGFR showed a strikingly minimal overlap. Both Jones et al and Blagoev et al 
reported primarily phosphotyrosine binding proteins that are recruited upon ligand 
association. Hence, the absence of SH2 and PTB domain containing proteins in the 
MYTH did not come as a big surprise. About 10% of MYTH clones were previously 
shown to bind to EGFR experimentally. These were annotated to various protein 
function classes like metabolic enzymes (GAPDH) and cytoskeletal components such 
as gelsolin or cofilin. Of utmost interest was the discovery of 16 transmembrane 
proteins in the screen. This is important in that it validates the ability of the screen to 
fish out transmembrane proteins as binding partners to other membrane proteins, 
furthermore it gave us a list of cell surface proteins that directly interact with EGFR.  
Bioinformatic analyses were particularly helpful in addressing the specificity of many 
of the putative interactors. The results of such computations should be taken with 
certain scepticism unless supported by experimental evidences. Nevertheless one such 
analysis, computation of the domain-domain co-occurrence between interacting  
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proteins, points towards an interesting observation that the domains that occurred in at 
least half of the MYTH clones also occur in other EGFR binding proteins. The 
statistical significance of this analysis show that this is not due to mere chance but can 
have real functional importance.  
The overall success of this MYTH screen has prompted our collaborators and us to 
perform additional screens with other RTKs including the other members of ErbB 
family. As these studies will be presented in other reports, no detailed description is 
given here. It suffices to say that the results from these studies are also very 
encouraging. 
 
4.2 HDAC6 is a novel EGFR interactor 
 
One of the interesting proteins identified in the MYTH screen was HDAC6. At first 
glance, it might be puzzling that a “histone deacetylase” is bound to a cell surface 
receptor. However, HDAC6 is known to be localized primarily to the cytoplasm, with 
minimal nuclear staining on immunofluoresence studies
156. Intriguingly, Zhang   et al 
have reported that HDAC6 can partially translocate to the cell periphery, bind and 
deacetylate cortactin following EGF stimulation of 3T3 cells
147. All the evidence 
accumulated so far convincingly show that HDAC6 is not a histone deacetylase but 
rather is a cytoplasmic lysine deacetylase.  
This study has shown that HDAC6 interacts with endogenous EGFR, irrespective of 
ligand stimulation. The additional finding that HDAC6 can bind to a kinase dead 
mutant of EGFR, K721A, expressed in cells that have minimal amount of endogenous 
EGFR provide additional evidence for the fact that the interaction between the two 
proteins is not dependent on the activation status of the receptor. The constitutive 
interaction between the two proteins is also evident in imaging studies where HDAC6 
is seen to traffic with the receptor from the cell surface to intracellular endosomes. 
This is an intriguing result, however its importance is still not fully clear. Most 
proteins that bind to EGFR are recruited upon phosphorylation of tyrosine residues 
via SH2 or PTP domains
5, 17. The exceptions include the zinc finger containing 
protein, ZPR1 and chaperones that bind to the immature receptor. ZPR1 binds to 
EGFR in the absence of ligand stimulation but dissociates rapidly upon receptor 
activation and translocates to the nucleus to be involved in yet unclear processes
197.   
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Deletion analyses indicate that HDAC6 binds EGFR through its HEBD domain (for 
what I call the HDAC6 EGFR binding domain). This is a stretch of about 40 amino 
acids between the second deacetylase domain and the ubiquitin binding zinc finger at 
the C-terminus. So far, no other protein is known to bind to this region of HDAC6. 
The surface of EGFR that binds to HDAC6 is mapped to the juxtamembrane region 
(JM). The JM region of EGFR is known to be important in proper receptor sorting
216.  
Additionally, the JM region of ErbB family members activates the kinase domain. 
This is distinct from other receptor tyrosine kinases where the JM region is 
inhibitory
217. Interestingly, a recent structural study indicates that the JM region of 
EGFR is vital in creating an asymmetric dimer and kinase activation
13. Unfortunately, 
we do not have structural data of the EGFR-HDAC6 complex and hence is difficult to 
imagine how it is organized. The constitutive interaction of HDAC6 and EGFR raises 
a number of questions regarding the role of HDAC6 in the regulation of EGFR. 
 
4.3 HDAC6 stabilizes ligand-induced degradation of EGFR 
 
Overexpression and RNAi mediated downregulation of HDAC6 coupled to 
pharmacologic intervention has clearly identified HDAC6 as an important negative 
regulator of EGFR degradation. It is important to note that the effect of 
overexpression of HDAC6 is much lower than the knockdown of endogenous 
HDAC6. This is very likely due to the high endogenous expression of HDAC6. In this 
case, subtraction would have a more pronounced effect compared to addition as the 
other protein complexes needed for HDAC6 activity would be saturated. The 
stabilization of EGFR by HDAC6 also depends on the deacetylase activity and the 
binding through HEBD domain. Again, the effects of these mutations of HDAC6 are 
subtler than downregulation of the endogenous protein. 
As abolishing of deacetylase activity or binding ability separately leads to partial 
effects, it is tempting to assume that HDAC6 acts by two independent mechanisms. 
One may be by deacetylating a certain “target” and the other by acting as an adaptor 
protein linking EGFR to an unknown third protein. Hence, removing only one activity  
(catalytic site mutation, binding site deletion or inhibitor treatment) can partially 
compromise its function, whereas shRNA mediated knockdown of the protein can 
totally abrogate all the functions of the protein. Many of EGFR signalling principles  
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have been found to be applicable to other RTKs as well. Therefore, an interesting 
question is whether HDAC6 affects other RTKs similarly. In this regard, recent 
reports provide some evidence this might indeed be the case. Kamemura et al showed 
that stable knockdown of HDAC6 leads to decreased steady-state expression of not 
only EGFR but also platelet-derived growth factor  (PDGF)
218. Additionally, drug 
inhibition of HDAC6 reduced expression of vascular endothelial growth factor 
receptors 1 and 2 (VEGFR1 and 2)
219. Therefore, it seems likely that HDAC6 acts as 
a regulator of a broad group of RTKs. 
 
4.4 HDAC6 plays a pivotal role in the post-endocytic trafficking of EGFR 
 
What accounts for the profoundly accelerated degradation of EGFR in HDAC6 
knockdown cells? Interestingly, HDAC6 does not influence ligand-induced 
internalization of EGFR to any marked extent suggesting rather the post-endocytic 
trafficking is affected. The major HDAC6-dependent effect we have observed so far 
is on the kinetics of EGFR degradation. The challenge was to devise experiments 
where reliable quantitative measurements could be achieved to dissect the temporal 
and spatial effects of HDAC6. 
These investigations were made possible by a combination of confocal 
immunofluorescene microscopy to follow the fate of labelled EGF along the 
endocytic pathway coupled to identification and computational characterization of 
intracellular vesicles. The algorithm used for identifying and tracking these vesicles, 
MotionTracker, was developed primarily by Yannis Kalaidzidis (from the Max-
Planck-Institute for Molecular Cell Biology and Genetics in Dresden). Computer 
based tracking of objects has its origin in the aerospace and military industries where 
satellites and airplanes are tracked based on data from sources like radar. Recent 
investigational street surveillance tools that follow individuals have expanded the 
reach of tracking programs. Algorithms developed for one area of application are 
difficult to modify for utilization in another setup because of fundamental differences 
in the propensity to change shape (e.g. compare an aircraft with an endosome), known 
physical limitations in movement and in the case of intracellular imaging the high 
level of background noise. This has prompted development of several intracellular 
tracking programs
220. Currently, the convergence of improved microscopy,  
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fluorescent tagging of intracellular “entities” and development of tracking algorithms 
is having a profound effect on our understanding of the highly dynamic events in 
cells
61. Intracellular trafficking of endocytosed receptors is a highly dynamic process 
that requires a suitable tracking program for reliable analysis. The major problem in 
automatic identification of vesicles staining positive for EGF or any of endocytic 
markers (in this case EEA1 and LAMP1) is establishing an appropriate cut-off point 
for “true” vesicles. This is due to the low signal-to-noise ratio in these samples 
generated mostly as a result of free fluorescence in non-vesicular structures and auto-
fluorescence of biological samples.  
Therefore, prior validation of the overall experimental setup by comparing results to 
previously well-established phenomena was essential. The entry of ligand-loaded 
EGFR into clathrin-coated vesicles and then into Rab5 or EEA1 positive early 
endosomes is a rapid process that peaks within minutes. Additionally, as endosomes 
undergo homo- and hetero-typic fusion and mature to late endosomes, they increase in 
size concomitant with accumulation of more cargo and organizing proteins
61. 
Importantly, we can see all these changes happening in early endosomes carrying 
EGF in the results presented here. 
 The key finding of the present study, however, is the rapid trafficking of EGF to peri-
nuclear late endosomes in HDAC6 knockdown cells compared to control cells.   
Additionally, changes in intensity of the marker EEA1 show accumulation of more 
content, possibly representing increased fusion of vesicles in knockdown cells. These 
observations are central to explaining the role of HDAC6 in this process. The absence 
of HDAC6 is somehow accelerating the motility of these endosomes. Early 
endosomes are known to travel along microtubules towards the cell centre while 
undergoing maturation to late endosomes. Late endosomes eventually fuse with 
lysosomes to degrade their cargo in the peri-nuclear area of the cell where the 
microtubule-organizing center (MTOC) is located
173-175. The accelerated transport of 
EGF is thus consistent with the faster degradation of EGFR seen in lysates of HDAC6 
knockdown cells.  
These events are highly reminiscent of the effects of another protein, KIF16B, a 
member of the kinesin family of motor proteins. This kinesin is a plus-end directed 
motor protein that binds to PtdIns(3)P and drives the motility of early endosomes. 
Overexpression of KIF16B caused an imbalance in plus- and minus-end (dynein- 
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dependent) movements that finally resulted in translocation of early endosomes to the 
cell cortex. Importantly, this inhibited ligand induced degradation of EGFR. In 
contrast, depletion of KIF16B by siRNAs led to faster translocation of early 
endosomes to the peri-nuclear degradative region and accelerated degradation of 
EGFR
221. Another cytoskeleton-associated protein regulating endocytic transport is 
the Huntingtin associated protein 40 (HAP40). HAP40 is an effector of the small 
GTPase, Rab5, which is a vital endocytic regulator. Overexpression of HAP40 
disrupts endosomal motility by displacing early endosomes from microtubules and 
relocating them to actin filaments. Furthermore, HAP40 is upregulated in brain tissue 
of patients suffering from Huntington’s disease where defective trafficking of brain-
derived neurotrophic factor is implicated in the pathogenesis
222.  
Another example of perturbation in trafficking of EGFR containing vesicles is seen 
when PI3K activity is disrupted.  Class I PI3K gets activated upon growth factors 
stimulation and phosphorylates PtdIns (4,5) to generate PtdIns (3,4,5) that acts as a 
docking platform for various PH and FYVE domain containing proteins. Many 
endocytic regulators (e.g. EEA1, Rabex-5, Rabenosyn) are recruited jointly through 
interaction with PtdIns (3,4,5) and Rab5. Due to its intricate involvement in 
generation of competent endosomes, the inhibition of PI3K by the fungal metabolite 
wortmannin or the synthetic inhibitor LY294002 leads to inhibition of homotypic 
fusion and slows EGFR trafficking and degradation
223, 224.  
In contrast, a constitutively active mutant of Rab5, Q79L, acts in an opposite fashion. 
Rab5 Q79L lacks GTPase activity and is locked in active mode. It enhances 
homotypic fusion of early endosomes leading to massively enlarged “giant 
endosomes” depending on its expression level
204. Upon EGF stimulation of cells 
expressing endogenous EGFR and Rab5 Q79L, the receptor is internalized normally 
but is accumulated in the large endosomes
225.  In summary, there are several proteins 
that slow degradation of EGFR acting on distinct post-endocytic trafficking stages 
without influencing the internalization event and HDAC6 appears to be the newest 
member of this group of modulators. 
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4.5 EGF induces acetylation of -tubulin  
 
After analysis of the influence of HDAC6 on EGFR trafficking, the mechanism 
behind it was addressed. The initial working hypothesis was that there is/are some 
target/s of HDAC6 acting on the trafficking of the receptor. Acetylation as a post-
translational modification is commonly associated with nuclear gene expression 
regulation. This is not surprising, as the vast majority of known acetylated residues 
are found in histones, transcription factors and other proteins involved in gene 
expression. However, there is an increasing amount of evidence showing it is by no 
means a nuclear-only phenomenon.  
With such background, we have tried to seek for acetylated proteins in the endocytic 
apparatus. The approach used, i.e., inhibition of deacetylase activity by TSA, 
followed by immunoprecipitating and probing with acetyllysine antibodies is shown 
to be sensitive for detecting acetylation in the so-far reported target proteins like 
histones, transcription factors, tubulin, HSP90 and cortactin. However, it is likely that 
it has limitations as an initial screening strategy.  
The only lysine-acetylated proteins that came out of this study were clathrin heavy 
chain (CHC) and the already known -tubulin. The major criteria set were that the 
acetylation should be dependent on HDAC6 (hence up regulated upon TSA treatment) 
and potentially responsive to growth factor treatment. Acetylation of CHC fulfilled 
neither criteria in that there was no change upon TSA or EGF addition. On the other 
hand the acetylation of -tubulin on K40 was quite dynamic, increasing markedly 
either upon downmodulation of HDAC6 or activation of EGFR. This was clearly 
demonstrated by mass spectrometry based analysis and by immunoblotting.  
At this juncture, it is worthwhile to mention a recently published report from the 
group of Mathias Mann. The authors applied SILAC to differentially labelled control 
cells and cells treated with two different HDAC inhibitors, suberoylanilide 
hydroxamic acid and MS-275
226. Proteins were digested with trypsin and the resulting 
peptides were immunoprecipitated using acetyllysine specific antibody. This was 
coupled to a high resolution Orbi-trap mass spectrometer that delivered the most 
comprehensive list of acetylated peptides so far. A total of 3600 lysine acetylation 
sites on 1750 proteins were identified. Of particular interest to us was the acetylation 
pattern of endocytic proteins. Proteins like c-Cbl, vps4b and several actin-binding  
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proteins were found to be acetylated. However, acetylation of these proteins was not 
at all modified by treatment with the HDAC inhibitors used. These findings are in line 
with our results, showing even this comprehensive approach did not reveal additional 
proteins that could be targets of HDAC6 in the endocytic apparatus. It is possible that 
acetylation of these proteins does not have a regulatory role (hence not dynamic) or 
there are yet unknown deacetylases that are not inhibited with the above HDAC 
inhibitors.  
Taken together, the evidence provided here shows that acetylation of -tubulin 
undergoes dynamic changes upon activation of EGFR. While our study did not 
identify other acetylated proteins that behave similarly and are targets of HDAC6, 
their existence cannot be conclusively ruled out.  
 
4.6 Acetylation of -tubulin modulates motility of endosomes 
 
Two reports have shed light on the possible roles of acetylation of microtubules (MT) 
in intracellular MT dependent transport. Dompierre et al demonstrated that 
hyperacetylated MTs recruit and bind the motor proteins dynein and kinesin-1 more 
efficiently than MTs with normal acetylation in vitro. Importantly, inhibition of 
HDAC6 activity in neurons accelerated exocytic secretion of brain derived 
neurotrophic factor (BDNF) in a strictly MT acetylation dependent fashion. 
Furthermore, postmortem examination of brains of Huntington disease patients 
revealed a striking reduction in acetylation of MTs
171. All this is of paramount 
importance as one of the hypotheses for the origin of Huntington’s disease is 
defective intracellular trafficking and associated neurotoxicity
227, 228.  
In another report, Reed et al showed that kinesin-1 preferentially recognizes MTs with 
acetylated K40. This recognition is important for the delivery of its cargo protein 
JNK-interacting protein 1 (JIP1) to select neurites in neurons. Furthermore, forced 
upregulation of MT acetylation by treatment of cells with the inhibitor TSA resulted 
in increased and non-selective transport of the cargo into all neurites
170. In summary, 
acetylation of -tubulin is an emerging regulatory mechanism for controlling the 
kinetics of intracellular trafficking.  
So, does K40 acetylation of tubulin play any role in trafficking by early endosomes? 
In order to confirm the involvement of K40 tubulin acetylation in EGF trafficking,  
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live cell imaging of fluorescent-tagged early endosomes were conducted. The 
endosomes used for the study (in A431 cells expressing GFP-Rab5) were not enlarged 
and showed no changes in kinetics of transferrin trafficking and are thus assumed to 
faithfully represent endogenous endosomes. The two important parameters measured 
by MotionTracker were the speed of movement and the processivity of these 
motilities.  
Endosomes are generally found in three states of motion, a short-range non-linear, a 
long-range linear (processive) movement and a transient immobile state. Additionally, 
early endosomes have a net directional flow towards the center of the cell (centripetal 
motion) even though single endosomes move bidirectionally. It is thought that true 
displacement of endosome is caused by processive movement
229, 230. Both the speed 
and processive movement of endosomes in cells expressing a mutant of -tubulin 
(K40A) that acts in a dominant negative fashion on acetylation of MTs were 
significantly lower than control cells. These results are in harmony with the studies 
discussed above, whereby reduced acetylation of MTs leads to a general slowness in 
endosomal motility. Unfortunately, a crucial experiment i.e. dynamic measurement 
after EGF stimulation and direct follow up of EGF/EGFR complex by live cell 
imaging was not successful. This was primarily due to the unacceptably high 
photobleaching of the small vesicles that carry EGF/EGFR immediately after 
internalization. Further optimization of experimental conditions is needed to make 
such direct measurements possible. 
 
4.7 Phosphorylation of HDAC6 by EGFR modulates its deacetylase activity  
 
Following EGF stimulation, acetylation of -tubulin is progressively increased. Based 
on the present work, this is primarily due to the inactivation of HDAC6 by EGFR 
mediated phosphorylation of a key tyrosine residue. This regulation, by 
phosphorylation, of HDAC6 is conceivable when compared to the regulation of other 
HDACs. 
The best-known means of regulating nuclear HDACs is by controlling the formation 
of multi-protein complexes, as most of these HDACs are inactive when alone. In vitro 
reconstitution assays showed that individual HDACs of the NuRD complex have 
severely depressed activity compared to the holo-complex
231. SIR2 group of HDAC  
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are regulated by availability of metabolic cofactors like NAD
+  and by proteolytic 
cleavage of the inactive precursor as in the case of the human SIRT3
 232. Sumoylation 
also plays a role by regulating intracellular localization. However, phosphorylation is 
the most prevalent regulatory modification with diverse effects. HDAC1 is 
phosphorylated on two serine residues and mutation of these to alanine abrogated 
enzymatic activity
209. On the other hand inhibition of phosphatases by okadaic acid 
and hyperphosphorylation of HDAC1 and HDAC2 disrupted association of the 
complex they normally function in
233. Phosphorylation of HDAC8 on Ser39 by 
protein kinase A (PKA) abolished its enzymatic activity almost completely in vivo 
and in vitro
234. On the contrary HDAC4 is associated with ERK1/2 and 
phosphorylation does not influence catalytic activity per se but changes its sub-
cellular localization
235. 
Here, based on initial mass spectrometry, HDAC6 is shown to be phosphorylated on 
serine and tyrosine residues. The effect of Y570 was studied intensively in vitro as 
well as in vivo. The lack of good phosphoserine antibodies hampered the effort to 
study the phosphorylation of S568 further. Based on mutagenesis assays, phospho- 
mimicry of Y570 and S568 abolished enzymatic activity. HDAC6 is involved in a 
variety of cellular processes at different localizations; hence it would not be surprising 
if it were regulated by different kinases. At the plasma membrane it can be 
phosphorylated by EGFR and probably also by other RTKs. At other subcellular sites, 
HDAC6 can be phosphorylated by serine kinases. It is highly likely that 
phosphorylation at these residues leads to conformational changes that is propagated 
to the active site. However, elucidation of the exact mechanism will have to await the 
determination of the high-resolution structure of the protein. 
In summary, a simplified model of the interplay between EGFR and HDAC6 is 
presented (Figure 25). HDAC6 is enzymatically active prior to and some time after 
EGFR activation. During this time, HDAC6 slows the transport of the receptor by 
favoring a state of deacetylated MTs. However, once a critical amount of HDAC6 is 
phosphorylated and inactivated by EGFR, the acetylation of MTs increases. This 
suppression of a negative regulator facilitates trafficking of EGFR-carrying 
endosomes towards signal termination and degradation. 
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Figure 25. Regulation of EGFR trafficking by HDAC6. 
HDAC6 has high basal deacetylase activity that keeps acetylation of microtubules (MT) relatively low. 
This results in slower trafficking of EGFR along MTs in the initial minutes of ligand binding and 
activation. However, later on,  HDAC6 gets progressively phosphorylated by EGFR and looses its 
deacetylase activity. The resulting build up of acetylated MTs enhance trafficking of EGFR for 
degradation in lysosomes.  
 
 
4.8 HDAC6 depletion results in perturbations in cellular physiology  
 
EGF stimulation of A549 cells result in activation of certain downstream pathways 
like the PI3K/Akt and MAP kinase cascades. The depletion of HDAC6 in these cells 
resulted in marginally reduced ERK2 activation but markedly accentuated activation 
of Akt and its substrate GSK3. This apparently conflicting observation can be 
explained by the different mode of activation of ERk1/2 and Akt. 
ERK1/2 phosphorylation and activation is known to require, at least partially, 
localization in early endosomes
236, 237. In HDAC6 knockdown cells, there is a rapid 
transit of the receptor complex into late endosomes with relatively less time spent in 
early endosomes (Fig. 18A and B). These late endosomes are not competent for 
ERK1/2 signalling and thus led to the moderately lowered phosphorylation observed.  
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On the other hand, activation of Akt is primarily driven by its recruitment to the 
plasma membrane through its lipid binding PH domain and internalization is not at all 
required for its signalling
237, 238. Additionally, the transport of cytosolic Akt to the 
plasma membrane has been reported to be microtubule dependent
239, 240. Hence, it is 
tempting to speculate that the increased acetylation induced by HDAC6 knockdown 
also facilitates Akt transport to the plasma membrane and its subsequent activation. 
However, this needs to be addressed further by detailed analyses, for instance, by 
studying localization of Akt in response to microtubule acetylation. 
The other important observation seen was the lack of EGF induced cell rounding and 
growth arrest in HDAC6 depleted A549 cells compared to parental cells. In A431 and 
A549 cells, which express relatively high amount of EGFR, EGF stimulation results 
in massive contraction of the plasma membrane from the edges of cells facilitated by 
cortical actin polymerization
212, 241. These cells also respond to EGF by arresting 
cellular growth and proliferation when grown in serum-lacking media that is 
supplemented with EGF. This is postulated to occur by the induction of cell cycle 
inhibitors like p21
213. HDAC6 knockdown cells express reduced amount of EGFR at 
the cell surface. Hence, it is likely that their stunted response to EGF is due to this 
“downregulated receptor level” much like the lack of response of cells to hormones 
when subjected to sustained exposure (desensitization). This is a phenomenon widely 
seen in biological systems that reduce their responses to persistent stimuli in order to 
adequately respond to new stimuli
242. 
The complex regulatory mechanisms put in place to modulate signalling is astounding 
and the sheer amount of recent publications addressing these issues is not surprising. 
These regulatory mechanisms are not only numerous in number but also appear to be 
organized in different levels. In EGFR signalling for example, these levels can be 
envisioned as receptor level such as dephosphorylation by phosphatases (first level), 
internalization (second level), trafficking (third level) and degradation (fourth level).  
This is a rather simplistic categorization but nonetheless provide a framework of 
thought. Each of these levels is regulated by many players that are able to 
communicate with other levels. The resulting redundancy would be expected to 
impart robustness to the system.  
It is thus helpful to think of HDAC6 in this context, a fine-tuner among many. 
Recently, mice lacking HDAC6 have been created by targeted gene disruption. The  
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mice are viable, fertile and lack gross defects. In all the tissues examined, the level of 
acetylation of -tubulin is profoundly increased proving HDAC6 as the bona-fide 
tubulin deacetylase. The only defects observed in these mice were reduced antibody 
generation in response to stimuli and slightly increased cancellous bone mineral 
density
165. It is unclear how much detailed analyses were done on different organ 
systems. As a regulator of EGFR signalling, which plays essential roles in 
development; the lack of HDAC6 might be expected to have severe consequences. 
However, the redundant nature of regulation of EGFR signalling can result in 
activation of compensatory mechanisms that lead to acceptable level of signal output 
and normal development of the organism.  
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5. SUMMARY and FUTURE OUTLOOKS 
 
The present study has demonstrated the power of the membrane-based yeast two-
hybrid screening technique to identify novel interacting partners of a receptor tyrosine 
kinase. Several detailed investigations have provided compelling evidences for the 
specificity of the interactions identified. Functional analysis of one of the novel 
interactors, HDAC6, has identified it as a novel regulator of EGFR trafficking. 
HDAC6 interacts with EGFR in a constitutive fashion and traffics with EGFR after 
internalization. Gain-of-function and loss-of-function studies indicated that HDAC6 
stabilizes the receptor from ligand-induced degradation. Imaging studies show that 
HDAC6 primarily affects the post-endocytic trafficking of the receptor. HDAC6 is 
able to achieve this feat by deacetylating -tubulin. Acetylation of -tubulin is 
demonstrated to be important for proper kinetics of early endosome motility. Hence, 
deacetylation of -tubulin results in slower transport of cargo proteins carried by 
these endosomes. In a remarkable turn of events, a negative feedback loop was also 
discovered. Activation of EGFR leads to a progressively increasing phosphorylation 
of HDAC6 on Y570, which inactivates the deacetylase activity. Thus, the inhibition 
of an inhibitor results in activation of the pathway, which in this case leads to increase 
in acetylation of -tubulin that facilitates transport of EGFR to its final degradative 
destination. 
While these findings are interesting, they also raise a number of questions that need to 
be addressed to get a clearer picture of the whole process. One of the most important 
issues is a better understanding of the molecular mechanisms behind acetylation of 
microtubule dependent regulation of trafficking in vivo. The increase in acetylation of 
-tubulin following EGF stimulation is clearly demonstrated, however its in vivo 
significance is still not understood. A complementation experiment where endogenous 
tubulin is depleted and replaced with wt or relevant mutants (a non-acetylable K40A, 
charge-retaining K40R and an acetylation mimicking K40Q) would yield crucial 
information on the relevance of acetylation of -tubulin in vivo. The presence of 
many genes and gene products for -tubulin in mammalian cells made the use of 
RNAi mediated knockdown impractical. An ideal model organism for this study is the 
ciliate  Tetrahymena thermophila that encodes -tubulin as a single gene.  
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Replacement of wt -tubulin with mutants has already been successfully 
accomplished in this organism and can be replicated to study the role of acetylation in 
vesicular trafficking
243.  
Acetylation of -tubulin occurs progressively after EGFR activation. Hence, 
investigation of the temporal and spatial organization of this acetylation in 
mammalian cells would be an important part of future studies. This acetylation can 
occur as a selective “wave of acetylation” along microtubules that carry EGFR-
containing endosomes or as a global change in all microtubules. To distinguish 
between these two scenarios, an acetylation sensing “biosensor” can be constructed. 
This is based on the principle of FRET (fluorescent resonance energy transfer) where 
non-radiative energy is transferred from a photo-excited donor to an acceptor 
fluorescent protein found in close proximity (<10nm)
244. In biosensors, FRET is 
induced/abolished by a biological event that results in conformational change of the 
biosensor. It has been used for study of dynamic signal transduction events such as 
activation of kinases, proteases and GTPases
245, 246.  
A microtubule acetylation sensor can hypothetically be constructed by fusing FRET 
pairs (e.g. CFP and YFP-cyan and yellow fluorescent proteins) at opposite ends of a 
chimeric protein that responds to acetylation. This chimera would consist of -tubulin 
(for localization to microtubules), a peptide containing K40 (to be acetylated) and a 
bromodomain (that interacts with acetylated lysines) connected by flexible linker 
sequences. In the absence of acetylation, K40 is not bound to the bromodomain, the 
FRET pairs are not brought close together and hence no FRET signal is generated 
(Fig. 26 upper panel). Once acetylation occurs on K40, the bromodomain recognizes 
and interacts with it. This results in internal conformational changes of the sensor that 
will generate a measurable FRET signal (Fig. 26 lower panel). This, of course, is only 
one of many designs that can be deployed and need to be empirically tested. Potential 
problems that could arise include lack of localization of the biosensor to microtubules, 
absence of bromodomain and acetylated K40 interaction or a conformational change 
that is incompatible with generation of FRET signal.  
Another major question to answer is whether the effect of HDAC6 on EGFR is an 
isolated event or part of a generalized mechanism whereby HDAC6 and acetylation of 
-tubulin regulate other RTKs. As expression levels of VEGFR and PDGFR have  
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been observed to be affected by HDAC6 depletion, it would be worthwhile to study 
the interaction of HDAC6 with different RTKs. It is also important to investigate  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26.  Proposed design of a microtubule acetylation biosensor. 
This hypothetical sensor utilizes the principle of FRET (fluorescent resonance energy transfer) between 
CFP and YFP fused to a chimera that responds to acetylation. The chimera is composed of  -tubulin, 
K40 containing peptide and acetylated lysine binding bromodomain. In the absence of acetylation of 
K40, bromodomain and the associated YFP are not interacting with K40 and no FRET is produced 
(upper panel). Once acetylation of K40 occured on  -tubulin and K40 peptide, bromodomain binds to 
Ack40 leading to conformational changes that generate FRET signal (lower panel).  
 
whether other RTKs can phosphorylate and inactivate the deacetylase activity of 
HDAC6. Another tantalizing question, with far reaching implications, is whether 
acetylation of -tubulin also influences other intracellular vesicular trafficking 
pathways. To answer this, the dynamics of vesicular trafficking between the ER and 
Golgi complex, other organelles’ movements and their correlation with the acetylation 
status of microtubules should be studied. 
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Abbreviations 

ATP Adenosine  5`-triphosphate 
BDNF  Brain derived neurotrophic factor 
C-terminus  Carboxy terminal end 
CCP  Clathrin coated pits 
CCV  Clathrin coated vesicles 
CIE  Clathrin independent endocytosis 
CIP Calf  intestinal  phosphatase 
CLIC  Clathrin and dynamin independent vesicles 
CME  Clathrin mediated endocytosis 
Cub  Carboxy terminal end of ubiquitin (amino acids 35-76) 
DABCO  1,4 diazabicyclo (2,2,2)dextran 
DAG Diacylglycerol 
DAPI 4,6-diamidino-2-phenylindole  dihydrochloride 
DER  Drosophila melangogaster EGF-like ligand receptor 
EDTA  Ethylenediamine tetracetic acid 
EE Early  endosome 
EEA1  Early endosomal antigen 1 
EGF  Epidermal growth factor 
EGFR  Epidermal growth factor receptor 
EPOR Erythropoietin  receptor 
ErbB Erythroblastosis  oncogene  B 
ERK  Extracellular signal regulated kinase 
ESCRT  Endosomal sorting complex required for transport 
GAPDH Glyceraldehyde-3-  dehydrogenase 
GDP Guanine  5`-diphosphosphate 
GEEC  glycosyl-phosphatidylinositol–anchored protein enriched early 
endosomal compartments 
GEF  Guanine nucleotide exchange factor 
GFP  Green fluorescent protein 
GHR  Growth hormone receptor 
GPI Glycosylphosphatidyl  inositol 
GPI-AP  Glycosylphosphatidyl inositol-anchored protein 
GST Glutathione-s-transferase 
GTP Guanosine  5`-triphosphosphate 
HDAC Histone  deacetylase 
HRS  Hepatocyte growth factor regulated tyrosine kinase substrate 
HSP90  Heat shock protein 90 
ILV Intraluminal  vesicles 
IP Immunoprecipitation 
KDa Kilodalton 
LAMP1  Lysosome associated membrane protein 1 
LDLR  Low density lipoprotein receptor 
LBPA Lysophosphatidic  acid 
MAPK  Mitogen activated protein kinase 
MF Mating  factor   
MHC  Major histocompatibility complex  
Abbreviations
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MS Mass  spectrometry 
MT Microtubules 
MTOC  Microtubule organizing center 
MVB Multivesicular  body 
MYTH  Membrane based yeast two-hybrid 
N-terminus  Amino terminal end 
NGF  Nerve growth factor 
NSCLC  Non-small cell lung cancer 
Nub  Amino terminal end of ubiquitin (amino acids 1-34) 
PDGFR  Platelet derived growth factor receptor 
PFA Paraformaldehyde 
PH   Plekstrin homology  
PI3K Phosphoinositide-3  kinase 
PKC  Protein kinase C 
PLC Phospholipase  C 
PTB Phosphotyrosine  binding   
PtdIns Phosphatidyl  inositol 
PTP  Protein tyrosine phosphatase 
RIPA Radioimmunoprecipitation  assay 
RTK  Receptor tyrosine kinase 
SDS-PAGE  Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SH2 Src-homology  2 
shRNA  Short hair pin ribonucleic acid 
STAT  Signal transduction and activators of transcription 
TCL  Total cell lysates 
TF Transcription  factor 
TGF  Transforming growth factor 
TSA Trichostatin  A 
UIM  Ubiquitin interacting  motif 
VEGFR  Vascular endothelial growth factor receptor 
WB Western  blot 
YTH Yeast  two-hybrid 
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